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The effect of chronic and periodic peaks of un-ionised ammonia (UIA-N) exposure on growth 
and eye health in juvenile Atlantic halibut, Hippoglossus hippoglossus, were examined. Fish 
with mean initial weight 51.7 g (SD, 13.2) were exposed to five treatments consisting of 
control group, three groups (ChronicLow, ChronicMedium and ChronicHigh,) chronically 
exposed with UIA-N ranging from 0.06, 0.12 to 0.17 mg l-1 respectivly for 62 days at 11.9ºC, 
pH 8.0 and salinity 34‰ and one group (HighPulse) exposed to the same high levels as above 
for a short daily period. The fish were reared under these treatments for 62 days. Growth was 
significantly reduced at UIA-N concentrations above 0.12 to 0.17 mg l-1.  
Mean weights and growth rates were significantly lower in groups exposed to chronically 
high ambient ammonia concentrations compared to corresponding control group throughout 
the period with ammonia treatments. Chronically low ammonia concentration did not have 
significant effect on weight and growth rate (NOEC= no observable effect concentration 0.06 
mg l-1 UIA-N). The subsequent period of the experimental study (until day 100) no ammonia 
was added and water quality was normalized. However, weight differences were still present 
at day 100, although adaptive growth rates were observed in the previous chronic ammonia 
groups.  
The simulated postprandial peak (HighPulse) did not have any significantly effects on either 
weight or growth rate in the present study, and the threshold limits for these peaks are yet to 
be determined. Minor differences were found in blood physiology between treatments.  
No significant cataract formation was observed between the treatments. Previously unreported 
free amino acid composition in juvenile Atlantic halibut is presented in the study. 
Significantly difference in the imidiazole anserine was found in the group exposed to high 
ammonia (ChronicHigh). The eye histidine status differed significantly at day 62, and also 








The Atlantic halibut (Hippoglossus hippoglossus, L.) is an increasingly important and 
promising species in Norwegian aquaculture. In 2008 the sale of round weight of farmed 
Atlantic halibut was 1587 tons (Statistisk Sentralbyrå, 2009; Norwegian Directorate of 
Fisheries 2009).  Development of successful juvenile production has been prolonged due to 
the highly specific environmental and nutritional requirements of halibut rearing (Shields, 
2001). Most flatfish cultured in aquaculture are grown in land-based facilities and are stocked 
at high densities per unit of water volume or bottom area (Jeon et al., 1993; Björnsson, 1994; 
King et al., 1998; Irwin et al., 1999; Bengtson et al., 2003), and nearly all hatcheries 
producing Atlantic halibut juveniles are held in indoor facilities. Because of high construction 
and running cost of intensive rearing facilities, an effective utilization of water is required, 
especially in the juvenile phase where heated water is often used. In order to reduce the water 
spent, the fish may be kept at high densities and the water can be reused or recirculated. This 
is also being done in order to save energy. An important aspect of land-based production is 
thus to obtain strict water-quality control, which may be critical in order to maximize 
production as well as to maintain the well being of the fish. Poor welfare is known to cause 
many production related problems reducing both the capacity and efficiency of any 
production site. High stocking densities generally require high water exchange rates to supply 
the oxygen needs and to carry out the metabolic byproducts (Lawson, 1995). If oxygen needs 
can be satisfied by aeration or oxygenation devices, the next major water quality concerns are 
the nitrogenous metabolic byproducts excreted by the fish, especially ammonia (Colt and 
Armstrong, 1981; Handy and Poxton, 1993; Tanaka and Kadowaki, 1995).  
1.1 Ammonia 
Ammonia is one of the most critical water quality parameters for optimal performance in 
intensive raring facilities. In high density reuse or recirculation systems, the ammonia 
concentration may build up as a consequence of ammonia excretion, and exert toxic effects. 
Total ammonia nitrogen (TA-N) excretion rates are directly related to dietary nitrogen and 
protein intake in fish (Liao and Mayo, 1974; Rychly, 1980; Beamish and Thomas, 1984; 
Handy and Poxton, 1993; Haskell, 1995; Wagner et al., 1995, Leung et al., 1999).  In high 
density culture systems this may cause constant high levels or periodical peaks of ambient un-
ionised ammonia depending on feeding regime and flow rate, resulting in periodical peaks or 
constant high levels of ambient un-ionized water ammonia which can be detrimental to the 
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fish. Also operational disturbances may periodically cause similar irregularities, e.g. from 
reduced efficiency in farms using recirculation systems, which may result in increased levels 
of ammonia in the system (Lyssenko and Wheaton, 2006).  In addition to ammonia, fish can 
excrete metabolic nitrogen urea (Randall and Wright, 1987). Usually urea is reported to be 
non-toxic to fish (Dosdat et al., 1996), however it can be hydrolyzed rapidly to ammonia and 
carbon dioxide in culture systems if urea hydrolyzing bacteria are present, as often is the case 
in aquaculture systems (Colt and Armstrong, 1981; Pedersen et al., 1993).   
 
Most teleost fish are ammoniotelic and are highly sensitive to ammonia toxicity (Haywood, 
1983; Handy and Poxton, 1993). Due to a favourable blood to water concentration gradient, 
ammonia is rapidly excreted over the gills (Wilkie, 2002) and an internal build up is avoided. 
Ammonia is the main nitrogen excretion product of teleosts, formed primarily as a result of 
amino acid catabolism (Mommsen and Walsh, 1992). It can be extremely toxic to fish if 
allowed to accumulate in the body (Randall and Wrigth, 1987).  In solution, ammonia exists 
in both ionized (IA, NH4
+) and un-ionized (UIA, NH3) forms. Total ammonia (TA, 
NH3+NH4
+) is the sum of these two. The two forms can be interconverted by the equilibrium 
equation: 
 
NH3 + nH20 ↔ NH4
+ + OH- + (n-1)H20      (pK ~9.8) 
 
The toxicity of ammonia to fish and other aquatic organisms is primarily attributed to the un-
ionized form because of its high ability to pass through biomembranes (Haywood, 1983). NH3 
is the most toxic form, among others, due to its high membrane permeability, and its toxicity 
increases with reduced temperature. In flow through systems, concentrations of TA-N is low 
(Rosten et al., 2007, Åtland et al., 2007) but can be significant in recirculation and closed 
transport systems. Most authors therefore present either UIA or UIA-N (NH3-N, unionized 
ammonia-nitrogen) values when describing the ambient ammonia concentration. Ammonia 
excretion is directly related to protein intake and time after feeding (Handy and Poxton, 1993; 
Leung et al., 1999), and in intensive high-density systems or recirculation systems, the 
ammonia concentrations may build up as a consequence of ammonia excretion and increase to 
levels that can cause reduced growth or even death (Person-Le Ruyet et al., 1997). The 
proportions of the two forms in water are highly dependent on pH, but also on other factors, 
such as temperature and ionic strength. The amount of dissolved solids may influence the 
equilibrium constant (pK) and thereby influence the relative proportions (Bower and Bidwell, 
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1978). The pK-value of the system is used to calculate the fraction of UIA in the system 
(Khoo et al., 1977; see also the Materials and methods in this paper for more details).   
 
Acute toxicity of ammonia has been investigated in a number of species (U.S EPA, 1984, 
1989). Typical responses to short-term exposure to elevated ammonia in fish include 
increased gill ventilation, erratic movements, loss of equilibrium, and lack of foraging and 
even mortality (Meade, 1985; Russo and Thurston, 1991). Chronic exposure may typical 
result in gill hyperplasia (Thurston et al., 1981), changes in mucous production, muscle 
depolarization (Beaumont et al., 2000), reduced growth and stamina (Lang et al., 1987), but 
may also act directly on the central nervous system, causing hyperventilation (McKenzie et 
al., 1993), hyperexcitability, coma, convulsions and finally death (Ip et al., 2001). Chronic 
exposure of to sublethal concentrations of ammonia have been found to reduce growth and 
cause physiological disturbance in Atlantic cod (Gadus morhua; Foss et. al, 2004), turbot 
(Scophthalmus maximus; Person-Le Ruyet et al., 2003; Rasmussen and Korsgaard, 1998) and 
spotted wolffish (Anarhichas minor; Foss et al., 2003) juveniles. Concentrations of 25 µg to 
300 µg NH
3
 l-1 have been reported to cause mortality in salmonid fishes, and 10 µg NH
3 l
-1 to 
cause negative gill interaction (Hjeltnes et al., 2008). In order to optimize rearing conditions, 
and thus prevent water quality from acting as a limiting factor for optimal growth and welfare 
of the fish, detailed knowledge on threshold levels for optimal growth is needed in order to 
exploit intensive rearing systems effectively.  
 
Most cultured fish are presumably transported twice during their lifetime; once from the 
hatchery to the on-growing site and secondly from on-growing site to the slaughter house. 
Larval and juvenile stages of Atlantic halibut are often farmed on the same sites, whilst 
juveniles (30-350 g) are transported by truck, boat and plane (Iceland) to sea sites or marine 
tank facilities. Until now, slaughter fish have been killed and bled at site prior to transport and 
to packing and distribution facilities for markets and well boats are rarely used (Hjeltnes et al., 
2008). 
 
During closed transport, limiting factors for survival of the fish include maintaining optimum 
levels of oxygen, carbon dioxide and TA-N. While elevated carbon dioxide often is a first 
limiting factor in the transport water, it can be degassed by increased dimensions of water 
treatment system. There is, however, a risk that the gained improvement in water quality is 
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used for optimising transport biomass, and thereby risks for elevated TA-N and pH, and 
eventually toxic concentrations of un-ionised ammonia. According to Portz et al., (2006), 
however, there are many water quality information sources for long term and intensive culture 
of fishes (Pickering 1981; Adams 2002), but limited information related to short term holding 
of fish in confinement. Temperature, dissolved oxygen, ammonia, nitrite, nitrate, salinity, pH, 
carbon dioxide, alkalinity and hardness in relation to aluminium and iron species are the most 
common water quality parameters affecting physiological stress (Stefansson et al., 2007). In 
the future Atlantic halibut may be transported live to slaughter houses, and with respect to 
water quality, it is essential to keep an optimal water quality in transport tanks during the 
whole transport to reduce the stress response, thereby optimizing the wellbeing of the fish and 
increasing survival and growth after release (Rosten et al., 2006). The Atlantic halibut 
response to chronic exposure and periodic ammonia peaks is however currently unknown.  
1.2 Eye health and cataract in fish  
Fish growth and eye health clearly depend on water quality parameters (Waagbø et al., 2008).  
The eye health has been highlighted as a major issue in halibut production (Williams et al., 
1995). Occurrence of cataract is usually a symptom of poor husbandry such as deteriorated 
water quality. The term cataract describes a condition with loss of transparency of the normal 
clear lens tissue leading to visual disturbance or blindness in farmed fish leading to decreased 
feed uptake. Cataracts have been commonly reported as a problem in salmon aquaculture 
(Bjerkås et. al 1996) and may cause severe production losses for the fish farmer (Williams et 
al., 1995). Development of cataracts is described as a production disease that may potentially 
affects any intensive farming of fish (Waagbø, 2008). Fish lens are sensitive to different types 
of stressors, which may result in reversible or irreversible opacification of the lens (Hargis 
1991; Breck, 2004). This can be observed directly in the fish lens making it a useful 
diagnostic tool. Damage to cornea as a result of eye snatching, friction in high stocking 
density and handling may lead to cornea infection and cataract as a result of this, depending 
on the severity of the cornea damage (Breck et al., 2003). Halibut may be particularly exposed 
for this due to the protruding position of the eyes. In modern fish farming, cataract may be 
considered a multifunctional production-related disease, with several nutritional and 
environmental factors being able to induce the same final lesions (Treasurer et al., 2007). 
Cataract formation can be influenced by water temperature (Bjerkås et al., 2001), salinity 
changes (Bjerkås et al., 1998), nutritional imbalance (Hargis, 1991, Bjerkås et al., 2006), 
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exposures to UV light (Cullen et al., 1994), and toxins and parasites (Valtonen and 
Koskivaara, 1994).  
 
Histidine deficiency as a nutritional factor have been reported as a causative factor in cataract 
formation for Atlantic salmon, probably due to removal of blood meal in the diet in the 1990s 
(Breck et al., 2003; Bjerkås and Sveier, 2006). The development of cataracts has also been 
related to rapid growth in salmon (Bjerkås et al., 1996; Waagbø et al., 1998) and lipid levels 
in the diet (Waagbø et al., 2003). Although these nutritional factors have been demonstrated 
in cataract formation, these can be interlinked with a range of husbandry and environmental 
factors (Bjerkås et al., 2006).   
 
Histidine has been linked to several physiological processes in the fish lens. A diet with 
surplus histidine may reduce cataract development in almonds (Breck et al., 2005b). Histidine 
deficiency compromises lens homeostasis, leading to water uptake, swelling of the lens and 
finally rupture of the lens capsule (Treasurer et al., 2007).  In salmon, free histidine in the lens 
is rapidly converted to N-acetyl histidine (NAH), which seems to have a possible 
osmoregulatory role in the fish lens (Breck et al., 2005a). This was demonstrated by a lower 
cataract score in salmon fed a diet with elevated histidine levels. The role of His and NAH in 
lens osmoregulation includes the ability of rapid osmolyte efflux to equalize any osmotic 
disturbances, since the lens easily endures in hyper- and hypo-osmotic environments by 
shrinking and swelling, respectively (Breck, 2004). Consequently, any physiological state that 
impact lens osmoregulation or put osmoregulatory stresses to the lens may be 
cataractogenous, while elevated dietary His may counteract such osmotic disturbances. Since 
His and His related compounds (imidazoles) also take part in the cellular integrated 
antioxidant system, muscle pH buffering system, and function as anti-glycating agents, the 
role of His in cataract prevention in salmon is not completely understood.  
 
Histidine and histidine derivates may also act as important antioxidants (Wade and Tucker, 
1998) and has been characterized as important buffers in muscular tissue of different fish 
species (Hiroshi and Murai, 1994, Munakata et al., 2000). Existing literature is mainly based 
studies with salmonids, and up to now no systematic experimental studies have been 
conducted on the eye status of Atlantic halibut in culture. The recording of the eye status is a 
selected indicator for stress. Analyses of the eye status as a welfare indicator includes 
inspection for cataract and cornea damage as well as analysis of lens histidine compounds. 
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1.3 Objectives 
This experiment was carried out with Atlantic halibut juveniles in the size interval 13.4-104.8 
g to determine the tolerance limits at which the fish experience physiological disturbance and 
reduced growth from being exposed to chronic high levels of ambient un-ionized ammonia. 
The experiment also included short daily peaks of un-ionized ammonia to determine if this 
could cause the halibut physiological disturbance and reduced growth.  
Measurements of growth and blood physiology are presented. Monitoring blood physiological 
response was included to investigate if, and to what extent the hydromineral and acid base 
status (sodium, potassium, pH, CO2, bicarbonate) of halibut were affected by different levels 
of un-ionized ammonia (chronic and short peaks). Water quality may have an influence on 
eye health and cataract in juvenile Atlantic halibut, and therefore random fish from each 
group were screened for cataract to see if ammonia could have an effect on cataract score. 
Samples were also taken to uncover possible differences in muscle buffering capacity 
(measured as free amino acids and histidine compounds) between treatment groups. To 
further analyse the ammonia potential affect on eye health; lenses were sampled for analysis 
of histidine status and the imidiazole NAH. The free amino acid compositions in juvenile 
Atlantic halibut muscle and lens tissues have previously not been reported.  
 
The experiment was based on the following alternative hypotheses: 
HA1: Ammonia toxicity leads to reduced growth and altered physiology of juvenile Atlantic
 halibut at high concentrations. 
HA2: Periodic exposure to high ammonia levels has the same effect on juvenile 
 Atlantic halibut as chronic high concentrations. 
HA3: Measured blood parameters will differ between the treatments.  
HA4: Muscle buffering capacity (measured as free amino acids) will differ between the
 treatments.  
HA5: Observed cataract formation will differ between treatments. 
HA6: The eye histidine status will be different between treatments. 
HA7: Osmotic differences (measured as N-acetyl histidine) in the lens will occur between 
treatments.  
 
where H0 being that different exposures to unionized ammonia has no significant effect on the 
above mentioned parameters. 
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2 Materials and methods  
2.1 Fish stock, rearing conditions and experimental facilities 
The Atlantic halibut juveniles used in the present study were delivered by a commercial 
hatchery, Aga Marin AS, Norway. They originated from a common pooled egg batch. During 
and after first feeding the larvae and juveniles were reared under a natural light regime at an 
average temperature of around 11.5 °C. On the 10 of October 2008, 823 Atlantic halibut 
juveniles arrived at the Bergen High-Technology Centre Ltd. (BHTC, in Akvahall 2), and 
were placed in four holding tanks with a continuous light and temperature of 11.9±0.2 ºC. 
They were fed a commercial formulated feed from Skretting AS in excess by automatic 
feeders for 1 week prior to the start of the experiment (Skretting Topaz Respons 3mm 
extruded sinking pellet, Averøy, Norway AS). The diet contained 52 % protein from fishmeal, 
soy meal and fish protein concentrate and 18 % fat from fish oil. This diet was used 
throughout the whole experimental period. It also contained vitamin and mineral premix and 
is sold as a health diet for marine fish with Makroguard ®. 
 
Table 2.1: Two samples of the diet were analyzed for total amino acids after acid hydrolysis according to an 
accredited HPLC method at NIFES. The data represents mean values and % deviation from mean. (Amino acid 








%    
deviation
Hypro 3.8 3.9 3.9 1.5
His 11.5 11.6 11.6 0.8
Tau 4.3 4.3 4.3 1.8
Ser 22.6 23.0 22.8 1.4
Arg 34.2 34.4 34.3 0.5
Gly 29.7 29.8 29.8 0.4
Asp 45.1 44.8 44.9 0.8
Glu 79.0 78.8 78.9 0.3
Thr 21.3 21.5 21.4 0.6
Ala 30.6 30.4 30.5 0.5
Pro 27.3 27.3 27.3 0.2
Lys 34.9 34.3 34.6 1.7
Tyr 15.5 15.5 15.5 0.4
Met 13.2 13.3 13.2 0.4
Val 26.0 25.6 25.8 1.5
Ile 21.4 21.0 21.2 1.9
Leu 38.2 38.1 38.2 0.3
Phe 22.3 22.4 22.4 0.7  
 
On the 13 of October 299 juvenile halibut were anaesthetized with metacain (0.05 g l-1) and 
tagged intraperitoneally with Trovan® Passive Integrated Transponder tags (Trovan Ltd) to 
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be able to observe growth performance of individual fish. On the 17 of October, two days 
before the experimental start-up, tagged and untagged fish (n=823) were distributed evenly 
and randomly into ten grey square fibreglass tanks with rounded corners (1 m x 1 m) and a 
rearing volume of 400 litres, with a bottom outlet and covered with a lid tanks. The tagged 
fish was reared together with additional untagged fish (~55 untagged and 30 tagged fish). The 
mean weight of tagged fish was 51.7 g ±13.2 (Mean ± SD) and did not differ significantly 
between tanks. A circular automatic feeder and a fluorescent spotlight (30 W) were built into 
the lid. The juveniles where exposed with continuous light, with a light intensity at 60 % of 
30W on full light (tank centre: 6.5 µmol-1 m2). Incoming seawater was pumped from 95 
meters depth of the Bergen city fjord, run through particle- and UV filters, and aerated before 
entering the header tanks. Each header tank supplied two tanks with seawater, and thus five 
different treatments were possible in the ten tank facility. Initial seawater flow rate was 5 l 
min-1, which was increased to 8 l min-1 at 13 of November 2008 to sustain adequate oxygen 
levels in the tanks (80 % saturation).   
 
Table 2.2 Overview of the experimental conditions. Means of ammonia concentration (TA-N, calculated UIA-
N), O2 saturation, temperature (ºC) and pH ±SD are presented in the Table (see Table I-IV, Appendix III for 
further details on descriptive statistics). N is the number of fish used per treatment at start-up, and the density is 
the total mass of fish kg m-2 at the start (day 0) and at the end (day 100) of the experiment. Asterisk: values are 
presented in Table 2.3.  
Treatment N TA-N (mg l
-1
) UIA-N (mg l
-1
) O2 saturation (%) Temp. (ºC) pH Salinity Density (kg m
-2
)
T0 Means±SD Means±SD Means±SD Means±SD (‰) T0-T4
Control 167 0.2 ± 0.1 0.002 ± 0.001 81 ± 3.0 11.9 ± 0.1 8.0 34 4.39 - 8.64
ChronicLow 162 5.3 ± 0.70 0.06 ± 0.01 81 ± 2.5 11.9 ± 0.2 8.0 34 4.14 - 6.09
ChronicMedium 165 10.5 ± 1.43 0.12 ± 0.02 80 ± 2.2 11.9 ± 0.2 8.0 34 4.18 - 5.94
ChronicHigh 164 14.9 ± 1.43 0.17 ± 0.03 83 ± 3.2 11.9 ± 0.2 8.0 34 4.39 - 5.87
HighPulse 165 * * 81 ± 3.0 11.9 ± 0.2 8.0 34 4.36 - 7.69
Total 823  
2.2 Experimental design  
The experimental period took place between 21 October 2008 and 29 January 2009. 
The experiment consisted of five different experimental conditions. The treatments consisted 
of a Control group, three groups (ChronicLow, ChronicMedium and ChronicHigh) 
chronically exposed to ammonia [TA-N (total ammonia nitrogen) levels of 5.0, 10.0 and 15.0 
mg l-1] an one group (HighPulse) exposed to ammonia for a short period (high TA-N level 2-3 
h day-1 with a peak of 15 mg l-1) simulating a postprandial increase of un-ionised ammonia in 
the tanks. All treatment groups were carried out in two replicate tanks. The experiment 
consisted of two parts: The first period (from day 0 to day 62) ammonia treatments were 
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performed, while the second period (from day 63 to day 100) the ammonia treatments were 
stopped. The last period was included in the present study in order to observe if any 
compensatory growth occurred in the groups experiencing the highest ammonia treatments. 
 
The water temperature was set to approximately 12 ºC (11.9±0.2 ºC) and the pH and salinity 
of the incoming water were stable at 8.0 and 34 ‰, respectively (monitored by the technical 
staff at BHTC). The desired ammonia concentrations were obtained by pumping a solution of 
NH4Cl (100 gram l
-1 fresh water; VWR International AS, Oslo) by four electromagnetic 
metering dosage pumps into the header tanks (Iwaki electromagnetic metering pump, model 
EW-F10VC-20EPF2, Iwaki Co. Ltd, Tokyo, Japan) supplying the respective tanks with water. 
There where no ammonia added to the water in the control tanks. In the periodical exposed 
group, the dosage into the header tank was controlled manually. The pumps started daily at 
09:00 and were active for half an hour.  
 
TA-N in a 100 ml sample of water from the rearing tanks was measured once daily in the 
chronic treatment groups using an ammonia gas sensing combination electrode (Thermo 
Orion, Model 95-12) connected to an expandable ion analyzer (Thermo Orion, EATM920). A 
two-point calibration procedure was performed before measurements. Samples were 
continuously stirred while added 3 ml strong basic solution (ISA), to elevate the pH in order 
to convert all ammonia to the un-ionised, gaseous, form. Samples were analyzed immediately 
to avoid the gaseous NH3 from escaping the samples before measurements. The ammonia 
electrode was kept in the sample until the meter presented a stable value of ammonia 
concentration. In the periodically exposed group TA-N levels were measured at 15 min after 
pump start-up and then after 30 min, 45 min 1 h, 1.5 h, 2 h and 3 h. 
 
Percentage UIA-N (un-ionised ammonia nitrogen) was calculated using the equation of 
Johansson and Wedborg (1980), which gives the UIA-N/TA-N ratio as a function of pH, 
temperature and salinity. Corrections for pH measurements performed with low-ionic strength 
buffers e.g. conversion of the Hansson scale, where performed according to Whitfield (1974).  
The formulas are listed under ‘Calculation of UIA-N concentrations’ later in this chapter.  
In total the experiment lasted 100 days and all the fish was slaughtered 1 week after the end of 
the experiment.  
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2.3 Daily measurements and feeding  
Temperature and oxygen saturation were measured directly in the outflow using portable 
instruments; OxyGuard® and OxyGuard Handy Gamma® (OxyGuard International AS, 
Denmark), respectively. Feed was provided in excess from automatic feeders for 2 hours 
twice daily (from 8:00 to 10:00 and from 14:00 to 16:00) except in weekends (fed once from 
8:00 to 10:00). The dry weight fed per day was noted for each tank. The tanks were flushed 
and the uneaten pellets were collected in a sieve in the outflow 30 min after feeding in the 
morning and afternoon and counted immediately in order to measure feed intake. The fish 
were not fed the day before or during sampling. The tanks where checked for dead fish daily.  
 
Table 2.3 Experimental measurements of TAN and calculated UIA-N in the HighPulse group. Dosage pumps 
were on for 0.5 h starting from 9:00 to 9:30. Table showing levels at given times during the day with the highest 
concentration at 9:30.  
Time TA-N (mg l
-1




08:00 0.2 ± 0.1 0.002 ± 0.001
09:15 7.6 ± 1.25 0.09 ± 0.01
09:30 15.0 ± 1.32 0.18 ± 0.02
09:45 13.9 ± 1.06 0.16 ± 0.01
10:00 10.5 ± 1.38 0.12 ± 0.02
10:15 8.2 ± 0.58 0.10 ± 0.01
10:30 6.3 ± 0.64 0.07 ± 0.01
10:45 4.9 ± 0.61 0.06 ± 0.01
11:00 3.7 ± 0.56 0.04 ± 0.01
11:15 3.2 ± 0.55 0.04 ± 0.01
11:30 2.2 ± 0.43 0.03 ± 0.00
11:45 2.1 ± 0.34 0.02 ± 0.00
12:00 1.4 ± 0.18 0.02 ± 0.00
12:15 1.3 ± 0.19 0.01 ± 0.00
12:30 1.2 ± 0.13 0.01 ± 0.00  
2.4 Sample procedures 
Growth data and blood samples were collected five times: at experimental start up (21 
October, T0), and approximately every third week during the experiment (T1, T2, T3 and T4). 
The fish were anesthetized (Metacain, 0.05 g l-1) and weights and lengths of all tagged 
specimens were measured to the nearest 0.1 cm and 0.1 g at each sampling point, whereas 
only the weight was measured for the untagged fish.  
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Blood samples were collected at the start of the experiment (T0) and at the same days as the 
length and weight measurements, after a 24 h fasting period. Blood samples were collected 
from the caudal vessels of eight fish from each experimental group (4 per tank) and analyzed 
using an i-STAT Portable Clinical Analyzer (Emergo Europe, The Netherlands). The analyzer 
was used with EC8+ disposable cartridges, measuring whole blood sodium and potassium 
concentrations, glucose, partial gas pressure of CO2 (pCO2), hematocrit and pH level, and 
displaying calculated values of blood bicarbonate, total carbon dioxide and haemoglobin 
concentrations. As the instrument is optimised for analyzing human blood at 37 ºC, 
temperature corrections of the measured blood pH and pCO2 were needed (see Temperature 
corrections of blood analysis under Calculations).  
 
In addition to the growth measurements, 4 random untagged fish were removed from each 
tank (40 fish per sampling) on 22 December (T3) and 29 January (T4) for blood samples, lens 
and muscle tissue samples. This was also done initially on 21 October (T0) with 20 random 
fish. Sampled fish were anaesthetized (metacain 0.05 g l-1) and then killed with a blow to the 
head. 
2.5 Cataract screening 
Initially 20 fish were examined for lens opacities by use of a slit lamp (Kowa SL-14 with 16 x 
magnification, Kowa, Japan) under darkened conditions and after anaesthesia. Examined fish 
included 8 fish from each treatment, e.g. a total of 40 untagged fish on each of the sample 
days. Cataracteous changes per eye were scored on a scale from no changes (score 0) to 
complete cataracts (score 4), in accordance with the scoring method described by Wall and 
Bjerkås (1999). Cataract scores in individual fish are given as the sum score of both eyes (e.g. 
ranging from 0 to 8 per fish). Prevalence of fish with cataracteous changes and sum of scores 
of all examined individuals within the experimental groups are reported.  
2.6 Muscle and lens sampling for analysis of free amino acid   
Skin free muscle tissue was sampled from the random sampled fish (20 fish at T0, and 40 fish 
at T3 and T4). From the same individuals, both eye lenses were dissected by removing the 
cornea. Attached aqueous humour was removed by gently rolling the lenses on a clean filter 
paper. The samples and lenses were immediately frozen on dry ice and later stored at -80 ºC. 
Muscle samples were analyzed for free amino acids by use of a Biochrom 20 Plus Amino 
Acid Analyser (Amersham, Cambridge, UK), according to a standardized procedure from the 
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manufacturer (Biochrom AAAFAQ08; Breck et al., 2005a). The muscle tissue was 
homogenized in 10 % sulfosalicylicacid and centrifuged for 15 min at 8000 rpm (g). The 
supernatant was thereafter mixed with running buffer (Lithium Citrate Loading Buffer, 80-
2038-10, Biochrom Ltd., Cambridge, UK) and an internal standard was added. The samples 
were transferred using a syringe, and filtered through a membrane filter (0.45 µm, Millex® 
Syringe filter unit, Millipore Corp, USA) into vials. The amino acid concentration was then 
analyzed by use of a Biochrom 20 Plus Amino Acid Analyser (Biochrom Limited) based on 
low pressure ion-exchange chromatography. After post column ninhydrin derivatization, 
colorimetric detection was done at 570 nm and 440 nm (Waters 486, Waters Corporation) and 
the individual amino acid peaks compared to the external and internal standards. 
 
Individual lenses (n=4 per tank) were analyzed for His an N-acetyl histidine (NAH) by the 
use of reversed-phase HPLC (High Performance Liquid Chromatography) according to the 
method by O’Dowd et al., (1990) with modifications by Breck et al., (2005b). The lenses 
were placed in 80 % ethanol and homogenized on a mill for 5 min at frequency 30 and later 
centrifuged at 3000 rpm for 30 min. The supernatants were concentrated to dryness by use of 
a Termaks incubator (40°C, normal atmosphere) (Termaks, Bergen, Norway) over night, 
dissolved in phosphate buffer (pH 2.0) and filtered through a membrane filter (0.45 µm, 
Millex® Syringe filter unit, Millipore Corp, USA). An isocratic reverse phase HPLC was 
performed, using a 4.6 mm ID x 250 mm column with as silica-based packing (ZORBAX SB-
C18, Agilent Technologies AS, Norway) and a Waters 600 E pump (Waters Corporation, 
Milford, Massachusetts, USA). A 0.1 M Phosphate buffer (pH 2) was used as eluting solvent, 
with a flow rate of 0.6 ml min-1. NAH and His were detected by UV absorbance (Waters 486 
– Tuneable Absorbance Detector, Waters Corporation) at 210 nm, using external standards. A 
diet sample was analyzed by for total amino acids after acid hydrolysis according to an 
accredited HPLC method at NIFES (MET.NÆR.01-17, NIFES, Bergen, Norway). 
2.7 Calculations 
All growth estimates in the present study are based on individually tagged fish, whereas the 
feed conversion efficiency, feed consumption and daily feeding rate are based on the pooled 




Specific growth rate (SGR) 
The specific growth rate (% weight gain per day) was calculated by using the formula given 
by Houde and Schekter (1981):  
SGR = (eg-1)*100  
The instantaneous growth coefficient g is:  
g= (lnW2-lnW1) (t2-t1)
-1,  
W2 and W1 are mean wet weights for individually tagged fish in g at days t2 and t1. 
 
Temperature corrections of blood analyses  
The i-STAT analyzer is optimized for analyzing human blood samples, holding 37 ºC. The 
blood collected from the fish held a temperature if approximately 12 ºC. To correct the 
present pH and pCO2 values for temperature we used the formulas supplied by the i-STAT 





where the t is the actual blood temperature, and pH and pCO2 are the values given by the  
i-STAT analyzer. Values corrected for temperature are denoted tp.  
 
Calculation of UIA-N concentrations  
The measured ammonia concentrations (TA-N, mg l-1 NH3) where converted to total ammonia 
nitrogen concentrations (TA-N, mg l-1 N) by the conversion factor given by Haywood (1983):  
NH3 (mg l
-1) = 0.8224 NH3-N (mg l
-1)  
 
In order to find the concentration of UIA-N, the pK of ammonia system was calculated using 
the equation given by Khoo et al., (1977): 
pK=0.09018+2727.9(T+273.1)+(0.1552+0.0003142T)I, 
 
where pK= -log(Keq), Keq=[NH3][H
+]/[NH4
+] (all species in mol kg-1), T=temperature (ºC) , 
and I=ionic strength (M). The Keq and pH (converted to the Hansson scale, according to 
Whitfied, 1974) was then used to find the fraction of UIA-N out of TA-N using the following 
expression (Khoo et al., 1977): 
 
UIA-N/TA-N= Keq/10
-pH+ Keq  
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NAH (Na-Acetyl-L-Histidine) determination using HPLC: 
Calculations of NAH and His levels in lenses were done by using an external standard 
method. 
 
Standards: External standard method input in to Empower software (Waters Corporation, 
Milford, Massachusetts, USA) with the values: 
0.25 mM NAH-0.25 mM His standard level 1 and 
0.50 mM NAH-0.50 mM His standard level 2 
Calibrate the standards against each other. Calculate samples after existing calibration curve. 
Sample weight=weight sample*200 µl volume sample/600 µl volume added.  
 
Muscle free amino acid determination - ninhydrin detection: 
The method and the calculations are found in the NIFES quality assurance handbook. The 
method is considered robust (personal comment, Anita Birkenes, NIFES).  
The concentrations of all the components in the standards are set as µmol/ml, and for the 
internal standard in sample are set as µmol/ml also. Dilution set as 0.6 ml. Sample weight is 
given as the measured amount g. 
 
The results are calculated by using Empower software in the following way: 
The areal under each top is measured both for standard and samples. The response is 
considering of the response of the internal standard.  
 
R= Areal (aa) * C(is) 
 Areal (is) 
With the help of linear regression the Empower programme calculates a standard curve for 
each amino acid. 
y=ax+b , where 
b=0, the curve is forced through, Origo 
y=R 
x=C2 
a=response factor for each component in the standard.  
 





R=corrected response for aa, mM 
Areal (aa)= Respons for aa (areal in AU) 
C(is)=concentration of internal standard (is), mg/ml 
C1=concentration in the sample material, mg/g sample 
C2=concentration of injected sample, mg/ml 
V=dilution, ml 
w=weighted amount, g 




-1  x 131.2 mg mol-1 x 150 ml) x 2.51 =0.1640 mg ml-1  
  (0.750 ml x 1000 ml l-1) 
1=Dilution of the sample before adding IS 
2.8 Statistical analyses 
All statistical analyses were done in STATISTICA 8.0 (Statsoft, Inc., 2007) except for the 
Chi- square test for differences in mortality that was done manually by using Control as the 
internal control group (Zar, 1984). To assess normality of distributions a Kolmogorov-
Smirnov test (Zar, 1984) was applied and homogenity of variance was evaluated by a 
Levene´s F test. Effects of ammonia on growth, blood parameters muscle free amino acids, 
and lens histidine and NAH were tested using a two way nested Analysis of Variance 
(ANOVA) (Zar, 1984). Replicates were nested in treatment factor in the analysis. Significant 
values for blood parameters were followed up by a two way Analysis of Covariance 
(ANCOVA) where weight was set as co-varying factor (Zar, 1984). Significant ANOVAs and 
ANCOVAs were followed by a multiple comparison test (Student-Newman-Keuls test; Zar, 
1984). Student-Newman-Keuls test will be abbreviated SNK test in the following sections. A 
significance level of α=0.05 was used if not otherwise stated. 
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3 Results 
3.1 Total mortality  
Mortality occurred in all fish tanks during this experimental period and total mortality varied 
from 19.0-35.8 % (29-50 fish) between treatment groups (Table 3.1).  
The day after the second sampling (T2=11 November) 27 fish were found dead in one of the 
tanks (ChronicLow replicate a). This was due to an experimental accident during sampling. In 
the first period (days 0-21) the ChronicLow group had a significantly lower total mortality 
than the Control group (χ2 >5.44, p<0.05, Table 3.1) and the HighPulse group had 
significantly higher mortality than the Control group (χ2 >5.44, p<0.05, Table 3.1).  
 
In the second period (days 22-42) the ChronicMedium and ChronicHigh group displayed 
significantly higher mortality than the Control group (χ2 >6.00, χ2 >8.17 respectively, p<0.05, 
Table 3.1). In the third period (days 43-62) significantly higher mortalities observed in all 
groups compared to Control group (ChronicLow: χ2 >208.33, p<0.05, ChronicMedium: χ2 
>16.33, p<0.05, ChronicHigh: χ2 >12.00, p<0.05, HighPulse: χ2 >8.33, p<0.05, Table 3.1).  
During the last period (no treatment, days 63-100) only the HighPulse group had significantly 
higher mortality than the Control group (χ2 >7.36, p<0.05, Table 3.1).  
 
Table 3.1: Total mortality (N dead, number of dead fish) and percent dead of total number (% dead) of fish per 
treatment. ●=lower mortality than in control group, ■=higher mortality than in control group.  
Days 0-21 Days 22-42 Days 43-62 Days 63-100 Total
N dead % dead N dead % dead N dead % dead N dead % dead N Dead % dead
Control 9 5.4 6 3.8 3 2.0 11 7.9 29 19.0
ChronicLow   2● 1.2 10 6.3     28■ 19.2 10 9.0 50 35.8
ChronicMedium 9 5.4   12■ 7.7    10■ 6.9 14 11.4 45 31.4
ChronicHigh 4 2.4   13■ 8.1   9■ 6.1    20■ 16.7 46 33.4
HighPulse  16■ 9.6 10 6.8   8■ 5.8 8 6.7 42 28.9  
 
3.2 Effect of ammonia on growth 
All growth information reported here is based on those individually tagged fish, and sampled 
at the same time as for the lens and muscle tissue samples (at T0, T3 and T4) for comparison. 
Average initial weight ranged from 51.4 - 54.1 g and there where no significant differences in 
initial weights between treatment groups (Figure 3.1; Table V; Two-way nested ANOVA p 
>0.35, Appendix III for details). The average weight ranged from 73.5-89.5 g after 62 days. 
At the end of the second growth period (day 100), the average weight ranged from 100.8 to 
134.9 g. At day 62 (22 of December 2008) the ChronicHigh group displayed significantly 
lower mean weight (65.9 g) compared to Control, ChronicLow and HighPulse group (89.6, 
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80.0 and 88.5 g, Figure 3.1, Table CXI, SNK-test p<0.05; Table CCX, Appendix III) but not 
to the ChronicMedium group (73.6 g, Figure 3.1, Table CXI, SNK-test p<0.05; Table CCX, 
Appendix III). The ChronicMedium group showed no significant difference in mean weight 
when compared to ChronicLow and ChronicHigh groups, but to the HighPulse and Control it 
did. 
 
At termination of the experiment (day 100), the ChronicHigh treatment group still displayed a 
significantly lower mean weight (100.0 g) than the Control and HighPulse group (138.4 and 
128.1 g, Figure 3.1, Table CXII, SNK-test p<0.05; TABLE CCXI, Appendix III) but not to 
the ChronicMedium and no longer to the ChronicLow group (109.5 and 120.7 g respectively, 
Figure 3.1, Table CXII; SNK-test p<0.05; Table CCXI, Appendix III). The ChronicMedium 
group also had a lower significant mean weight than the Control group (Figure 3.1, Table 






































Figure 3.1: Weight data (group means ± SE, see Table V, Appendix III). The groups are separated by colour, 
line type and shape of marker: Control, ChronicLow, ChronicMedium, ChronicHigh and HighPulse. Means 
sharing a common letter are significantly different (SNK test, p<0.05, Table CCX to CCXI, Appendix III)  
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Mean individual specific growth rates (SGR) for the whole experimental period ranged from 
0.28 to 1.00 % day-1 (Figure 3.2, Table VI, Appendix III). The first period presented here 
represent the whole period with the different ammonia treatments. The effect of the ammonia 
were significant and pronounced in the ChronicHigh group as this group had a significantly 
lower SGR compared to the other groups (Figure 3.2, SNK-test p<0.001, Table CXIII, 
Appendix III). The ChronicMedium group also had a significant lower SGR compared to 
Control, HighPulse and ChronicLow but also significantly different from ChronicHigh. In the 
last period there were no significant differences in SGR between any groups (Figure 3.2, 
SNK-test p>0.001,Table CXIV, Appendix III). For the calculated SGR Overall only the 
ChronicMedium and ChronicHigh groups had  significantly lower SGR’s compared to the 
other groups (SNK-test p<0.001, Table CXV).  
 
0-62 xzvzxv 63-100 gdd Overall












































Figure 3.2: Mean individual specific growth rates (% day-1, group means + SE, see TABLE VI, APPENDIX 
III). Colour pattern of the columns indicate the level of ammonia concentration. Means not sharing a common 
letter are significantly different (SNK test, p<0.05, Table CXIII-CXV, Appendix III).  
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Measured average Na+ concentrations in blood samples were in the range 157-170 (mmol l-1) 
during this experiment (Table 3.2). No significant differences were found between the groups 
at any times (Table 3.2, Two-way crossed ANCOVA p>0.05; Table CXCIX and CC, 





Mean measured K+ concentrations ranged from 3.52 to 5.65 (mmol 1-1) in the blood samples 
from this experiment (Table 3.2). No significant differences in K+ were found between 
treatments on day 62. However on day 100 there were a significant difference in the 
ChronicLow group compared to the other groups (Table 3.2, Two-way crossed ANCOVA 
p<0.05, Table CCII, SNK-test p<0.05, see Table CCXVII, Appendix III).  
 
Blood pH  
The average measured mean and temperature corrected pH was in the range of 7.20-7.34 
(Table 3.2) in the blood samples taken in this experiment. The ammonia treatments had no 
significant effects on blood pH at day 62 and day 100 (Table CCXIX to CCXX, Appendix 
III).  
 
Blood CO2 partial pressure  
The average values of blood CO2 partial pressure (pCO2) were in the range 4.33 – 6.67 mmHg 
(Table 3.2). On day 62 the ChronicHigh group a significantly lower pCO2 mean compared to 
Control, ChronicLow, HighPulse group, but not significantly lower compared to 
ChronicMedium (SNK-test p<0.05, Table CCXXI, Appendix III). On day 100 the 
ChronicLow group had significantly higher pCO2 compared to Control, ChronicHigh and 
HighPulse, but not compared to the ChronicMedium group (SNK-test p<0.05, Table CCXXII, 










Mean measured values of blood HCO3
- concentrations ranged from 3.20-3.84 (mmol 1-1) 
during the experiment (Table 3.2). Significantly higher HCO3
- concentrations were found for 
the ChronicHigh group at day 62 compared to the Control, but not significantly different from 






Table 3.2: Blood parameters. Measured and temperature corrected (tp) blood parameters for juvenile Atlantic halibut exposed to five water ammonia treatments at three 
different sample dates. (Treatments being Control, ChronicLow, ChronicMedium, ChronicHigh and HighPulse, or Control, CL, CM, CH and HP respectively). Values are 
given as mean and standard deviation (SD). Means not sharing a common letter, at the same sampling date, are significantly different (SNK-test p<0.05).  
Blood parameters
Day 0 Day 62 Day 100
Control Control CL CM CH HP Control CL CM CH HP
Na
+ 157 168 170 169 168 167 170 171 168 170 169
(mmol 1
-1
) (3.6) (5.77) (3.78) (2.78) (3.96) (3.77) (4.63) (4.53) (3.96) (4.99) (2.39)
K
+ 3.52 4.26 4.31 4.19 4.40 4.33 4.83 a 5.65 b 4.51 a 4.71 a 4.43 a
(mmol 1
-1
) (0.34) (0.22) (0.47) (0.20) (0.42) (0.49) (0.55) (0.96) (0.59) (0.45) (0.25)
pH tp 7.34 7.31 7.29 7.29 7.33 7.31 7.25 7.20 7.23 7.27 7.26
(0.08) (0.09) (0.04) (0.06) (0.09) (0.06) (0.06) (0.07) (0.04) (0.05) (0.05)
pCO2 tp 4.77 5.79 a 5.25 a 4.92 ab 4.33 b 5.32 a 5.67 a 6.67 b 6.15 ab 5.55 a 5.64 a
(mmHg) (0.97) (0.44) (0.39) (0.64) (1.02) (0.39) (0.49) (0.93) (0.73) (0.40) (0.31)
HCO3
- 3.56 4.14 a 3.61 ab 3.40 ab 3.20 b 3.79 ab 3.56 3.84 3.74 3.66 3.69
(mmol 1
-1







3.4 Effect of ammonia on cataract 
At start of the experiment, 10 % of mild cataract was found in the examined fish (Table 3.3), 
where no cataract were found in examined fish at the end of the first period (day 62) where 
the fish had been exposed to ammonia. After the following weeks with normalized water 
quality at the end of the experiment 10 % of mild cataract was observed. The number of fish 
affected had only a cataract score for one of the two eyes.  
 
Table 3.3 Cataract development in groups of juvenile Atlantic halibut exposed to different ammonia regimes for 




Treatment Control CL CM CH HP % affected
Start
Sum scores 1 20
# affected 1 10
day 62
Sum scores 0 0 0 0 0 40
# affected 0 0 0 0 0 0
day 100
Sum scores 1 1 1 1 0 40
# affected 1 1 1 1 0 10  
Individual fish were examined by use of a slit-lamp biomicroscope and scored from 0 (no cataract) to 4 
(complete cataract) per eye, e.g. score 0 to 8 per fish. Due to low prevalence of mild cataracts, data is given as 
sum of individual scores and (#) of affected fish observed per experimental treatment. 
 
3.5 Effect of ammonia on muscle and lens free amino acids 
Mean values of the free amino acids found in the white muscle tissue samples from all five 
experimental groups are given in Table 3.2. Muscle samples taken at day 62 only showed 
significant differences in Glu, Gln, Ala and Aaiba. The ChonicLow group had a significant 
higher level of Glu compared to the other groups (0.87 (µmol g-1) versus 0.60 µmol g-1 in the 
Control group). The ChronicMedium and ChronicHigh groups had significantly higher levels 
of Gln compared to the others. Lower mean values of Ala where found in the ChronicHigh 
and HighPulse groups, and ChronicMedium group displayed lower levels of Aaiba compared 
to the other groups.   
 
At the end of the experiment, after a 6 week period of normalized water quality (no ammonia 
added), differences were found in Urea, Asn, Glu, Gln, Aaba, Cysth2, Orn and Ans.  
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The ChronicHigh group had a significantly lower measured mean value of Urea compared to 
the other groups, with ChronicMedium and HighPulse having significantly higher value 
compared to ChronicHigh. Significantly higher values of Asn were found in the ChronicHigh 
group compared to the all the other groups and significantly higher value of Glu were found 
in ChronicLow compared to all the other groups. The ChronicMedium had a significantly 
higher Gln concentration than the other treatment groups. For the free amino acid Aaba, the 
HighPulse group had a significantly lower value compared to the rest, while the ChronicHigh 
group had the significantly higher value compared to the HighPulse group. A similar pattern 
was found for the free amino acid Cysth2. The ChronicLow group displayed significantly 
higher value of Orn compared to the other groups, except from the Control group. Ans were 
found at a significantly higher concentration in the HighPulse group compared to the other 
groups (SNK-tests p<0.05, see Tables CCXXVIII to CCXCVII, Appendix III).   
 
Muscle levels of Urea and Amm ranged between 5.25 to 7.67 µmol g-1 and 3.24 to 3.96 µmol 
g-1, respectively. No significant differences in muscle levels of Urea between treatments were 
found in this experiment, however some differences were found in muscle Amm as described 
above. Measured levels of the imidiazole His ranged between 0.37 to 0.97 µmol g-1 in the 
muscle tissue of juvenile Atlantic halibut in this experiment, although no significant 
differences were found between the treatment groups. The imidiazole Ans levels ranged 
between 0.37 to 0.97 µmol g-1. The imidiazole Car were not detected in muscle tissue of 
juvenile Atlantic halibut.  
 
Muscle levels of Tau ranged between 9.35 and 14.5 µmol g-1 in juvenile Atlantic halibut, and 
Tau was the free amino acid that was found in high levels. White fish normally have a higher 
content of Tau, and the muscle tissue samples had to be analyzed using a different method 
which was adapted to higher levels of Tau (different channel in the HPLC Empower 
software). Measured total free amino acid ranged between 40.41 to 47.34 µmol g-1, and when 
Tau values were not included the values ranged between 31.0 to 35.4 µmol g-1. There were no 
significant differences found in measured total free amino acid.  
 




Table 3.4: Mean values (µmol g-1) of free amino acids (FAA) found in juvenile Atlantic halibut muscle tissue exposed to five water ammonia treatments at three sampling dates. (Treatments being 
Control, ChronicLow, ChronicMedium, ChronicHigh and HighPulse, abbreviated Control, CL, CM, CH and HP respectively). Values are given as mean and standard deviation (SD). Means not 
sharing a common letter, at the same sampling date, are significantly different (SNK-test, p<0.05). 
T0 T3 T4
Control CL CM CH HP Control CL CM CH HP
Free Amino 
Acid
Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D
Phser 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00
Tau 9.35 2.50 12.29 2.88 10.93 1.98 11.36 3.12 11.13 2.72 12.11 2.86 13.40 1.27 13.12 1.73 13.15 2.44 12.50 2.38 14.49 1.90
Pea 0.09 0.03 0.08 0.01 0.08 0.01 0.08 0.01 0.07 0.02 0.07 0.02 0.08 0.01 0.09 0.02 0.09 0.02 0.08 0.01 0.08 0.02
Urea 5.40 1.16 7.67 1.19 7.07 1.11 6.90 1.02 7.11 1.42 7.16 1.10 6.38 0.50 abc 6.29 1.02 abc 6.27 0.88 b 5.25 0.58 c 6.81 1.36 b
Asp 0.53 0.20 0.58 0.22 0.60 0.13 0.54 0.14 0.57 0.11 0.66 0.20 0.66 0.14 0.67 0.14 0.57 0.14 0.54 0.15 0.60 0.12
Hypro 0.56 0.54 0.44 0.22 0.54 0.29 0.46 0.43 0.31 0.23 0.49 0.37 0.63 0.23 0.82 0.32 0.64 0.29 0.77 0.29 0.52 0.23
Thr 1.13 0.36 1.46 0.39 1.35 0.43 1.19 0.49 1.03 0.29 1.31 0.48 1.62 0.52 1.73 0.34 1.50 0.25 1.95 0.23 1.48 0.28
Ser 1.73 0.42 1.71 0.48 1.91 0.38 1.25 0.48 1.56 0.29 1.50 0.63 1.00 0.15 1.12 0.20 1.20 0.40 1.04 0.24 1.04 0.26
Asn 0.64 0.58 0.67 0.54 0.33 0.14 0.94 0.76 0.71 0.29 0.49 0.31 0.71 0.90 a 0.45 0.34 a 1.19 0.64 a 1.82 0.62 b 0.52 0.39 a
Glu 0.69 0.25 0.60 0.17 a 0.87 0.19 b 0.64 0.14 a 0.59 0.07 a 0.67 0.07 a 0.65 0.19 ab 0.75 0.12 b 0.62 0.13 ab 0.49 0.10 a 0.61 0.10 ab
Gln 0.83 0.20 0.85 0.19 abc 0.80 0.16 ab 1.05 0.23 c 1.04 0.17 c 0.71 0.16 b 1.00 0.28 ab 0.93 0.20 ab 1.12 0.13 b 0.91 0.21 ab 0.73 0.23 a
Sarc 0.04 0.01 0.04 0.02 0.03 0.01 0.03 0.01 0.03 0.01 0.03 0.01 0.03 0.01 0.04 0.02 0.04 0.02 0.03 0.01 0.04 0.01
Pro 0.87 0.96 1.32 0.91 1.76 1.09 1.53 1.48 0.93 0.65 1.28 0.76 2.30 0.97 1.76 1.09 1.71 0.91 2.46 0.88 0.96 0.30
Gly 7.58 0.54 7.13 0.67 7.36 0.30 6.70 1.11 7.71 0.52 7.44 0.78 5.94 0.50 5.90 0.85 6.04 0.63 5.82 0.68 5.96 1.05
Ala 4.28 0.49 4.06 0.53 abc 4.53 0.71 abc 4.88 0.89 b 3.69 0.51 bc 3.69 0.58 c 3.88 0.57 3.86 0.53 4.04 0.42 3.69 0.54 3.65 0.42
Citr 0.05 0.04 0.08 0.07 0.08 0.07 0.06 0.06 0.05 0.04 0.12 0.09 0.14 0.08 0.16 0.07 0.13 0.05 0.09 0.04 0.11 0.04
Aaba 0.06 0.02 0.06 0.01 0.06 0.02 0.06 0.03 0.05 0.02 0.06 0.02 0.07 0.02 abc 0.07 0.02 abc 0.07 0.02 abc 0.08 0.02 b 0.05 0.01 c
Val 0.09 0.03 0.07 0.03 0.07 0.03 0.09 0.03 0.09 0.03 0.08 0.04 0.05 0.01 0.05 0.02 0.05 0.01 0.05 0.02 0.06 0.02
Met 0.05 0.02 0.04 0.01 0.04 0.01 0.05 0.02 0.05 0.02 0.05 0.03 0.04 0.01 0.03 0.01 0.03 0.01 0.03 0.01 0.04 0.01
Cysth2 0.38 0.16 0.96 0.26 0.88 0.36 0.78 0.55 0.69 0.37 0.77 0.41 0.77 0.14 abc 0.80 0.28 abc 0.83 0.12 abc 0.93 0.17 b 0.60 0.16 c
Ile 0.06 0.02 0.04 0.02 0.04 0.02 0.05 0.02 0.06 0.02 0.05 0.03 0.03 0.01 0.03 0.01 0.02 0.01 0.02 0.01 0.03 0.01
Leu 0.12 0.04 0.07 0.04 0.08 0.03 0.11 0.03 0.12 0.04 0.10 0.05 0.06 0.02 0.07 0.03 0.06 0.03 0.05 0.02 0.07 0.02
Tyr 0.05 0.01 0.06 0.01 0.05 0.01 0.04 0.02 0.05 0.02 0.07 0.02 0.05 0.01 0.05 0.02 0.05 0.01 0.05 0.02 0.05 0.01
Phe 0.04 0.01 0.04 0.01 0.03 0.01 0.03 0.01 0.04 0.02 0.04 0.01 0.04 0.01 0.04 0.01 0.03 0.01 0.03 0.01 0.04 0.00
Aaiba 0.06 0.02 0.03 0.01 a 0.03 0.01 a 0.01 0.01 b 0.03 0.01 a 0.03 0.01 a 0.04 0.01 0.05 0.01 0.05 0.01 0.04 0.01 0.04 0.01
Ethanolamine 0.02 0.01 0.04 0.01 0.03 0.00 0.03 0.01 0.03 0.01 0.02 0.01 0.01 0.00 0.02 0.01 0.03 0.02
Amm 3.87 0.34 3.78 0.35 3.96 0.26 3.91 0.21 4.16 0.27 3.79 0.29 3.44 0.45 3.57 0.10 3.30 0.12 3.24 0.25 3.51 0.13
Hylys1 0.05 0.05 0.07 0.03 0.06 0.02 0.06 0.03 0.05 0.02 0.05 0.02 0.13 0.03 0.12 0.04 0.13 0.07 0.14 0.04 0.10 0.04
Hylys2 0.02 0.01 0.05 0.01 0.03 0.02 0.04 0.03 0.05 0.02 0.05 0.02 0.03 0.01 0.03 0.02 0.03 0.01 0.03 0.01 0.03 0.01
Orn 0.02 0.01 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.03 0.02 0.03 0.01 ab 0.04 0.01 b 0.02 0.00 a 0.02 0.00 a 0.03 0.01 a
Lys 0.53 0.24 0.60 0.21 0.63 0.10 0.65 0.23 0.60 0.12 0.44 0.15 0.54 0.13 0.49 0.14 0.49 0.13 0.57 0.18 0.48 0.10
His 0.84 0.58 1.44 0.58 1.24 0.55 1.07 0.68 1.07 0.60 1.32 0.66 1.66 0.16 1.72 0.13 1.50 0.38 1.72 0.23 1.62 0.26
Ans 0.37 0.13 0.82 0.08 0.72 0.07 0.75 0.12 0.67 0.15 0.72 0.14 0.84 0.08 a 0.84 0.11 a 0.81 0.09 a 0.92 0.07 ab 0.97 0.08 b
Arg 0.09 0.05 0.15 0.07 0.12 0.04 0.11 0.03 0.11 0.03 0.11 0.04 0.15 0.05 0.14 0.03 0.14 0.06 0.17 0.09 0.12 0.03
SUM Free 
AA(exl. Tau) 
31.06 0.79 35.05 0.17 35.40 1.16 34.09 2.79 34.07 0.51 33.40 1.32 33.01 1.84 32.73 1.39 32.79 0.29 33.05 0.05 31.00 1.33
SUM Free AA 40.41 3.29 47.34 3.05 46.33 3.14 45.45 5.91 45.20 3.23 45.51 4.18 46.42 3.11 45.85 3.12 45.93 2.73 45.55 2.44 45.49 3.23  
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Mean lens His ranged from 0.95-1.44 µmol g-1 in samples taken during this experiment 
(Figure 3.8). At day 62 no significant differences were found between Control and the 
HighChronic and HighPulse groups, but significant lower lens His were found in the 
ChronicLow, and ChronicMedium groups than in the Control. Still there were no significant 
differences between ChronicMedium and ChronicHigh groups. At the end of the experiment 
after 6 weeks of no treatments (normal water quality) no significant differences were found 
between groups (see Tables CCXXV to CCXXVI, Appendix III).  
0 svfsg 62 100







































Figure 3.3: Histidine concentration in the lenses of Atlantic halibut (µmol g-1 sample, group means + SE, Table 
XIII, Appendix III). Colour and pattern indicate the water concentration of ammonia: Control, ChronicLow, 
ChronicMedium, ChronicHigh, and High Pulse. Means not sharing a common letter are significantly different 
(SNK test, p<0.05, see Table CCXXV-CCXXVI, Appendix III).  
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During this experiment the mean value of NAH ranged from 7.30-12.8 µmol g-1 in the lens 
samples taken in this experiment (Figure 3.9). Significantly lower values were found after the 
9 week exposure to the different ammonia treatments in ChronicLow, ChronicMedium and 
ChronicHigh groups compared to the Control and HighPulse groups. Sample taken at the end 
of this experiment showed no significant differences (See Tables CCXXVII to CCXXVIII, 
Appendix III).  
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Figure 3.4: NAH concentration in the lenses of Atlantic halibut juveniles (µmol g-1 sample, group means + SE, 
see Table XIV, APPENDIX III). Colour and pattern of the columns indicate the level of ammonia concentration: 
Control, ChronicLow, ChronicMedium, ChronicHigh and HighPulse. Means not sharing a common letter are 




4.1 Effect of ammonia on growth 
In the present experiment, juvenile Atlantic halibut were exposed to ambient UIA 
concentrations ranging from 0.06-0.17 mg l-1 for 62 days. In the subsequent period (days 63 -
100) ammonia treatment was terminated and water quality normalized to examine if the 
groups previously exposed to high levels experienced any compensatory growth. Condition 
factor (CF), feed conversion efficiency (FCE), daily feeding rate (F %) calculations are not 
presented in the results, as they were part of another study (Paust, 2010).  
 
Mean weight and growth rates for the juvenile Atlantic halibut were significantly lower in 
groups exposed to chronically high ambient ammonia concentrations compared to 
corresponding control group, throughout the period with ammonia treatments. Chronically 
low ammonia concentrations did not have significant effect on growth and SGR.  
 
In the present study significant differences in mean weights between the experimental groups 
were seen at day 62, and these differences were still present at day 100. In contrast to what 
seen during the ammonia treatment no significant differences were found in growth rates 
between groups during this period. The groups previously exposed to high levels of ammonia 
were not able to catch up with the control group during a relatively fast growing period. If 
there were any indications of compensatory growth the previously exposed groups would 
have grown remarkably during these weeks and better than growth in control groups, and this 
did not happen. Compensatory growth (CG) in fish is commonly described as a phase of 
unusually rapid growth following a period of reduced feeding (Ali et al., 2003), or suboptimal 
growing conditions (Foss and Imsland, 2002). Application of this growth spurt mechanism 
has been suggested (Quinton and Blake, 1990; Jobling et al., 1994) as appropriate exploitation 
may result in increased growth and higher food conversion efficiency (Wang et al., 2000; 
Foss and Imsland, 2002). This has been applied with cyclic starvation/re-feeding regimes to 
induce CG. Short term starvation (2-5 weeks) and subsequent recommencement of feeding in 
juvenile (200-400g) Atlantic halibut resulted in partial growth compensation, and a tendency 
of increased feed conversion efficiency (Heide et al., 2006).  
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Studies aiming at determining the effect of both acute and chronic ammonia exposure and 
identifying threshold levels, have been performed for several marine fish species such as 
Atlantic cod (Foss et al., 2004; Remen et al., 2008), Dover sole (Solea solea) (Alderson, 
1979), European seabass (Dicentrarchus labrax) (Dosdat et al., 2003; Lemarié et al., 2004) 
and giltheaded seabream (Sparus aurata) (Wasjbrot et al., 1993). The threshold limit for 
reduced growth (NOEC=no observable effect) observed in the current study with halibut 
juvenile (0.06 mg UIA-N l-1)  is similar compared to what has been juvenile Atlantic cod 
(Foss et al., 2004) and the same low levels were found in juvenile Dover sole (0.066 mg UIA-
N l-1) (Alderson, 1979).  Threshold limits have found to be higher for turbot juveniles (11 – 
0.18 mg UIA-N l-1) (Rasmussen and Korsgaard, 1996; Person-Le Ruyet et al., 1997) for 
juvenile giltheaded seabream (0.27 mg UIA-N l-1) (Wajsbrot et al., 1993) and Lemarié et al., 
(2004) identified a safe limit of 0.26 mg UIA-N l-1 for optimal growth of juvenile seabass.  
 
Most previous studies have investigated chronic exposure of ammonia, but as pointed out by 
Colt (2006), determining threshold levels by chronic exposure will rarely or ever reflect a true 
culture situation, whereas postprandial peaks is a reality under culture conditions for halibut 
as well as for other fish species. Results from studies with chronic exposure levels are thus 
not directly applicable and more realistic trials are necessary, at least if the aquaculture 
industry shall benefit from the research done. Postprandial ammonia peaks have been reported 
to occur 4 to 12 h after feeding in the Japanese flounder (Paralichthys olivaceus), the 
giltheaded seabream, striped seabream (Lithognathus mormyrus), aerolated grouper 
(Epinephelus areolatus) and Mangrove snapper (Lutjanus argentimaculatus), with peak rates 
of exretion being several times higher than fasting rates (Klumpp and von Westerhagen, 1986; 
Cockcroft and Du-Preez, 1990; Kikuchi, et al., 1991; Leung et al., 1999).Surprisingly, the 
short daily peaks resulted in no equivalent growth reductions as seen in the chronically high 
ammonia exposed groups. In our experiment the high ammonia peak group showed no 
significant difference in mean weights or SGR compared to the Control group. The high 
ammonia peak group (HighPulse) was used as an experimental condition which intended to 
mimic postprandial ammonia peaks. In a study by Yigit et al., (2005) ammonia exretion rates 
was measured in Black Sea turbot (Scophthalmus maeoticus) at 12 ºC under natural light 
conditions. They observed that the rates were 2-3 times higher immidiately after feeding than 
in starved fish, reaching a peak 3-6 hours after feeding and declining afterwards. The effect of 
short daily peaks on growth performance has not been previously investigated in juvenile 
Atlantic halibut, however this experiment did not meet the threshold ammonia peak to 
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observe the same affect that chronic high levels had on growth performance. Studies done on 
turbot (Foss et al., 2007; Foss et al., 2009) demonstrated that chronic exposure to increased 
TA-N levels (6.5 and 12.3 mg l-1) resulted in reduced growth, and short exposure (3-4 hours a 
day) may result in almost the same growth reduction (~15 % compared to the control) as 
chronic levels. With this in knowledge it will be of outmost importance to make sure that the 
threshold levels determined are not exceeded at any time of the day. Measurements of TA-N 
levels in the rearing systems should be performed at various times during the day, and 
especially following the time of day where feed intake are expected to be at its highest. Foss 
et al., (2009) demonstrated that short daily ammonia peaks may result in negative effects on 
growth, equivalent to that found under chronic exposure in juvenile turbot. Comparing 
measured TA-N and calculated UIA-N levels for the experimental group HighPulse with 
levels used in Foss et al., 2009 it is clear that levels in the HighPulse group is ~LowPulse 
levels in the Foss et al., 2009 trial. Although a 5 % growth reduction was found in their 
LowPulse group when compared to their Control. 
 
Table 4.1: Measured total ammonia nitrogen TA-N (mg l-1) and calculated values of un-ionised ammonia (UIA-
N) in the experimental group HighPulse compared to values from experimental groups LowPulse and HighPulse 
in Foss et al., 2009.  
Treatment TA-N UIA-N
T0.5 h T1h T1.5 T3 h T0.5 h T1h T1.5 T3 h
LowPulse 5.26 6.41 5.1 1.3 0.11 0.13 0.1 0.03 Foss et al., 2009
HighPulse 10.63 13.06 9.72 2.24 0.22 0.27 0.2 0.05 Foss et al., 2009
HighPulse 15 6.3 3.7 1.4 0.18 0.07 0.04 0.02  
 
In summary, chronic high levels of 0.17 mg l-1 UIA-N resulted in significantly reduced 
overall growth in juvenile Atlantic halibut in this experiment and threshold limits of UIA-N 
for growth reduction is between 0.12-0.17 mg l-1 UIA-N (SGR between 0.06% day-1 and 0.12 
% day-1). Further trials need to be conducted in relation of identifying the threshold limits of 
postprandial peaks of ammonia. When considering the various threshold limits that exist for 
different species and also the different life stages of species, it becomes clear that 
comprehensive studies are necessary in order to assist safe rearing practises in intensive 
aquaculture facilities. Studies like these provides the farmer with information to which TA-N 
levels that should be avoided generally by increasing water flow, reducing biomass, changing 
feeeding regime or increasing biofilter capacity (if rearing in recirculation systems). It has 
also been demonstrated that ammonia interacts with several other environmental factors, e.g. 
dissolved oxygen, (Wajsbrot et al., 1991; Foss et al., 2003), pH (Thurston et al., 1981), 
salinity (Alabaster et al., 1979; Sampaio et al., 2002) and carbon dioxide (Randall and Wright, 
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1989). Tolerance in variations in such parameters is species and age specific and needs to be 
identified in order to balance the use of water with water quality requirements of the species 
and life-stage in question. Significant efforts is still needed in mapping the species tolerance 
to important water quality parameters using a multifactorial approach, that might reflect 
“true” culture situation, whereas several parameters interact to affect fish performance 
simultaneously.  
4.2 Effects of ammonia on physiological status 
Measured parameters were mostly within the range of what has previously been reported from 
studies on halibut and other marine species (Jonassen et al., 1999; Staurnes, 2001; Imsland et 
al., 2008a, 2008b; Magnussen et al., 2008). With few exceptions blood parameters were not 
affected by either chronic levels or periodic peaks. Measurement of blood parameters did not 
indicate any major physiological disturbances induced by our treatments, but some values 
indicated physiological disturbances of the juvenile Atlantic halibut. At day 62 differences 
were found in pCO2 and HCO3
- in ChronicHigh group, and at day 100 differences were found 
in K+ and pCO2 in the ChronicLow group. Minor variations in blood Na
+ and K+  levels were 
seen throughout the experiment, indicating that the hydromineral balance was maintained. 
Blood  pCO2 and HCO3
- showed significant difference in the ChronicHigh compared to the 
Control group. According to the Henderson Hasselbach equation of acid-base regulation, a 
higher concentration of bicarbonate as a proportion of CO2 will result in higher pH 
(Claiborne, 1998). No significant differences were found in blood pH values between 
treatments in samples taken during the experiment, which according to the Henderson 
Hasselbach equation means that the levels are equivalent which is in agreement with the 
present data (ChronicHigh vs. Control). Person-Le Ruyet et al (2003) found an increase in 
electrolytes and total Ca+ concentrations in blood in juvenile turbot reared above 0.34 mg l-1 
UIA-N so it is possible that the ammonia levels in the present study (max 0.17 mg l-1 UIA-N ) 
were too low to cause disruptions in homeostasis in juvenile Atlantic halibut.  
 
All together, measurements of blood parameters do not give any clear evidence that the 
halibut exposed to the different chronic and periodic exposure of UIA-N in this study were 




4.3 Effect of ammonia on cataract 
During sampling the anesthetized fish were screened for cataract using a slit-lamp 
biomicroscope. The slit-lamp biomicroscope has proven to be useful for clinical 
characterisation and classifiction of cataracts and is more applicable under practical field 
conditions , together with a scoring system for the extension of changes in the lens (Wall et 
al., 1999; Bjerkås et al., 2006) The changes are graded as seen straight trough the pupil. Each 
eye is scored seperately as follows: 0: normal lens, 1: opacity affecting lens less than 10 % of 
the lens, 2: 10-15 % opacity, 3: 50-75 % opacity, and 4: complete cataract (>75 %). The 
results from the eyescreening in the present study showed that observed cataract did not differ 
significantly between treatments. At day 62 no cataract was observed, and cataracts graded as 
1, were found in four fishes (one eye) in four out of the five treatments (Table 3.3) at day 100. 
This result should however be regarded with caution because of the small number of fish per 
treatment in this experiment (n=8).  
 
Pankhurst and Montgomery (1994) found that growth of the eye is maintained at the expense 
of low somatic growth during suboprimal rearing conditions. A diet sample was analyzed by 
for total amino acids after acid hydrolysis and found a mean His level to be 11.6 ± 0.8 mg g-1 
sample (mean±SD, Table 2.1). Breck et al (2005b), found that Atlantic salmon lens under rich 
supply of dietary His accumulated high levels of NAH (five times free His concentrations) 
and that high lens NAH concentration was positively correlated with low cataract scores. 
Further they found that in fish fed lower His levels, cataract scores were higher in fish that 
have been exposed to fluctuation in water salinity and elevation of water temperature than in 
fish maintained in stable environment. The diet used in this study was sold and marketed as a 
health diet with added His to reduce stress during rearing e.g. handling of fish. By using this 
diet in our experiment we most likely masked some of the effect our UIA-N treatments had on 
free amino acid composition in muscle and lenses. Although the same food was given to all 
experimental groups it would have been interesting to see if a more “normal” halibut diet 






4.4 Effect of ammonia on muscle and lens free amino acids 
In most fish skeletal muscle constitutes of more than 50 % of the whole body mass. Muscles 
concetrates of the largest pools of free amino acids (Smutna et al., 2002).  
No significant differences were found in the total free amino acid content in sampled juvenile 
Atlantic halibut between different ammonia treatments. Total free amino acids content in 
juvenile Atlantic halibut ranged between 40.4 to 47.4 µmol g-1 in this experiment.  
Sum of free amino acid found in salmon fed either control og high His diets ranged from 24.1 
to 28.3 µmol g-1 (Breck et al., 2005a) and compared to the results found in this experiment the 
Atlantic halibut muscle tissue contains almost double levels of free amino acids.  
 
Muscle Urea ranged from 5.25 to 7.67 µmol g-1 in this experiment and differences were found 
at day 100 with significant lower levels of Urea found in the ChronighHigh group. Muscle 
Amm ranged from 3.24 to 3.96 µmol g-1, though no differences were found.  
 
White fish often contain higher levels of taurine (Tau). And reported levels of Tau in this 
experiment ranged from 9.4 to 14.5 µmol g-1, and was the free amino acid reported in largest 
quanta in the total amount of free amino acids. Tau is synthesized from methionine (Met) via 
cysteine (Cys) and is known to play a physiological role in osmoregulation in fish an other 
animals (Schaffer et al., 2000; Buentello and Gatlin 2002). The physiological role of Tau is 
not completely clear within species or across species. Tissue Tau levels have been 
demonstrated to be responsive to osmotic pressure, and Tau is thought to serve some 
antioxidiative capacity. Japanese flounder have been reported to require Tau in the diet, at 
least at the juvenile stages, to maximise growth rates (Takeuchi, 2001) 
Breck et al, 2005a reported levels of Tau in salmon fed different His diets at range of 0.93 to 
2.25 µmol g-1. 
 
Van Waarde (1988) classified of imidiazole-related compounds (histidine and anserine) in 
skeletal muscle of fish and reported that very low levels (< 1 µmol g-1) of imidiazole related 
compounds are found in the families of Pleuronectidae (flounders).  
No significant differences were found in muscle His (0.84 to 1.72 µmol g-1) in muscle tissue 
of the fish in the present experiment. As a His dipeptide, muscle anserine (Ans) constitute a 
major marker of His status in salmonids, probably important for its strong buffering capacity 
at physiological pH (Hiroshi and Murai, 1994). Metabolic stress due to the ammonia 
treatment could eventually lead to increased susceptibility for cataract development. Elevated 
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muscle Ans were only observed in the ChronicHigh group. The reduction in muscle non-
essential amino acids following increased levels of imidiazole compounds has been described 
in masu salmon (Oncorhynchus masou) as well as in yellowtail (Seriola quinqueradiata) 
Ogata et al., (1998) suggested a physiological mechanism by white muscle selectivity 
accumulates imidiazole compounds and maintains the total amino acid pool by down-
regulating the level of non-essential amino acids. Both Ans and NAH is believed to keep His 
“trapped” in the respective tissues and prevent this essential amino acid from being 
catabolised or used in protein synthesis. Breck et al., (2005a) found Ans levels in salmon fed 
different His diets to be 9.73-16-07 µmol g-1, and the levels found in this experiment 0.33-
1.82 µmol g-1. The imidiazole carnosine (Car) was not detected in muscle tissue of juvenile 
Atlantic halibut. The imidazole-related compounds have postulated to have numerous 
biological roles such as H+ buffer (Abe and Okuma, 1991; Sewell et al., 1992), a divalent ion 
regulator (Baran, 2000), a neurotransmitter (Petroff et al., 2001), a non-enzymatic free radical 
scavenger (Kohen et al., 1988; Guitto et al., 2005), an antioxidant (Boldyrev et al., 2004) and 
a blood glucose regulator (Nagai et al., 2003; Sauerhofer et al., 2007).  
 
In the present study lens His was found in levels within the range of 0.95 to 1.44 µmol g-1. 
Mean lens His was found at different levels between the five treatments at day 62. Lower 
levels of lens His were found in the ChronicLow and ChronicMedium groups. Samples taken 
at the end of this experiment had no significant differences in lens His levels.  
 
Another natural imidiazole-related compound N-α-acetylhistidine (NAH), is found in very 
high concentrations ubiquitously in the central nervous system as well as in the lens and retina 
and occasionally in the hart (Baslow, 1965; Erspramer et al.,1965, Yamada and Furuchi, 
1990). NAH is considered an “imidazole dipeptide”, whose α-amino group C-terminal amino 
acid (histidine) is bound to a carboxylic group of acetate in place of β-alanine or γ-
aminobutyric acid. Yamada et., al (2009) suggested that NAH may play some exlusive role as 
an emergency reservoir for histidine (an essential amino acid) against a long period of food 
deprivation, in skeletal muscle of fish species possessing high levels of muscle NAH. In the 
present study NAH mean values ranged from 7.30-12.97 µmol g-1 in the lens of juvenile 
halibut which is within the critical low levels of imidiazoles <1.0 and 9.1 µmol NAH g-1 lens 
found in Atlantic salmon (Breck, 2004). Significant differences lower levels of measured 
NAH were found in all the chronic exposed groups compared to the Control and HighPulse 
groups. Baslow (1998) suggested that together with other histidine containing derivates; 
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carnosine, anserine and homocarnosine, NAH serves as a molecular water pump regulating 
hydration of lens tissue.  A decrease in lens NAH level has been associated with cataract 
development in Atlantic salmon undergoing parr-smolt transformation (Breck et al., 2005b). 
NAH may be important for water homeostasis in lens (Breck, 2004), as well as a central 
nervous tissue (Baslow, 1998). NAH is synthesized from L-His and acetyltransferase, in the 
brain and lens (Baslow, 1966; Yamada et al., 1995), and hydrolyzed to histidine by the NAH-
degrading enzyme, anserinase in these tissues (Baslow and Lenney, 1967; Lenney et el., 
1978; Yamada et al., 1991; Yamada et al., 1993).  
 
Table 4.2: N-α-acetylhistidine (NAH) in ocular lens of several fish species.  
NAH (µmol g-1)
Species lens Reference 
Perch 4.7 Abe, 1995
(Lateolabrax japonicus )
White croaker 2.83 Abe, 1995
(Argyrosomus argentatus )
Bigeye Tuna 11.4 Abe and Okuma, 1992
(Thunnus obesus )
Japanese Barracuda 3.44 Abe, 1995
(Sphyraena japonica )
Coho salmon 1.68 Abe and Okuma, 1992
(Oncorhynhus kiutch )
Rainbow trout 3.15 Abe and Okuma, 1992
(Oncorhynhus mykiss )
Japanese charr 4.85 Abe and Okuma, 1992
(Salvelinus leucomaenis ) 
Japanese eel 1.98 Espramer et al., 1965
(Anguilla japonica ) 
Conger eel 1.17 Hanson, 1966
(Astroconger myriaster )
Skipjack tuna 22.6 Togashi et al., 1998
(Katsuwonus pelamis )
Atlantic salmon 1.3-12.91 Breck et al., 2005b 
(Salmo salar ) smolt
Atlantic halibut 7.3-132 Author 
(Hippoglossus hippoglossus )
juveniles
1Range depending on dietary level of histidine 




This is the first report on free amino acids in muscle and lens tissue of juvenile Atlantic 
halibut. Most of the work in this field (Waagbø et al., 1998; Breck et al,2005a,b,; Bjerkås and 
Sveier,2006) is conducted on salmonids and may not be fully comparable with findings in 
Atlantic halibut due to salmonids being anadromous fish and Atlantic halibut being merely a 
marine species. Diffences in values of free amino acid when compared to those in salmonids 
are discussed. More systematic trials and research is required to further investigate factors that 
leads to cataract in Atlantic halibut.   
5 Summary and conclusions 
Chronic high levels of ammonia led to lowered mean weights and lower growth rates and 
growth was significantly reduced in ChronicHigh and ChronicMedium groups compared to 
the Control group. Thus HA1 can be accepted.  
 
High periodic peaks was used as an experimental condition to mimic postprandial peaks often 
found in culture systems. In this study the periodic peaks did not have the same effect on 
growth as chronically high exposure had, and  no significant effect on weight or growth rates 
were found, when compared to the Control group. Accordingly  HA2 cannot be accpeted 
 
Measurements of blood parameters did not give any clear evidence that the halibut exposed to 
the different chronic and periodic exposure of UIA-N in this study was subjected to any form 
of physiological stress. Minor differences were found in ChronicHigh group measured pCO2 
and HCO3
-  at day 62, and diffences in K+ and pCO2 in the ChronicLow group at day 100 HA3 
can be accepted.  
 
Minor differences were found in measured free amino acids (FAA) used to explain bufering 
capacity. At day 62 differences were found in Glu, Gln and Aaiba and at day 100 after a 
period of normalised water quality conditions differences were found in more free amino 
acids (Urea, Asn, Glu, Gln, Aaba, Cysth2, Orn and Ans). Although no systematic trend was 
found HA4 is accepted. 
 
The sampled fish was screened for cataract and indications of catract formation was found, 
although the results showed no clear evidence that the treatments contributed to differences 
and H05 cannot be rejected. 
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Differences in eye histidine status were found on samples taken on day 62, with lower levels 
found in ChronicLow and ChronicMedium group. HA6 can be accepted. .  
 
Osmotic differences (measured as NAH) in the lens was found at day 62 in all the chronically 
ammonia exposed groups. The groups had lower levels of NAH compaired to Control group 
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7.1 Discussion of materials and methods 
7.1.1 Total mortality 
Significantly higher total mortality was observed in all treatment groups in the third period of 
the experiment (ChronicLow, ChronicMedium, ChronicHigh and HighPulse) compared to 
Control. The ChronicLow group had massive mortality in this period, and was caused by an 
accident in connection with the sampling or they were sensitive to the sampling procedure. 
From just the one tank 27 fish were found dead the day after the sampling day. The necessity 
to perform a test for bacterial infection was considered, although not committed because there 
were no mortalities in the replicate tank. A reason for the high mortality is most likely due to 
the anaesthesia and wake-up period. During sampling the fish were anesthetised with 
Metacain, and after length and weight measurement the fish were placed in a wake-up tub 
with added oxygen. It is probably a shorter duration of time in the wake-up tub that might 
have caused this to happen. Since Halibut is a flatfish located on the bottom floor of the tank, 
and sometimes stacked on-top of each other, the effect of many fish dying at the same time 
may be substantial. The dead fish will lie upon the live fish and mucus and slime formation 
could suffocate the others and following more fish died. The colour of the water in the tank 
was greyish, and when removing dead fish a lot of mucus was observed.  
The number of fish varied substantially between periods in all groups, the significant 
differences between treatment groups and control group can be explained by coincidence 
rather than treatment effect. Some of these fish also showed signs of physical damage 
(injuries eyes, pectoral fins and tails) and they may have been victims to aggressive behaviour 
by dominant individuals during e.g. feeding as proposed by Greaves and Tuene (2001). 
Growth coefficient (Zar, 1984) was calculated to determine if the dead fish generally were 
smaller than the remaining fish (Table I, Appendix IV), and the growth coefficient were high 
in four treatment groups, but not in the Control. Communication errors lead to all dead fish 
from the last period to be thrown away without weight descriptions. The scanner was 
unavailable the last period and therefore the fish was supposed to be temporarily stored in the 
freezer until the scanner came back, and during this time the fish was thrown away due to 
renovations in the storage freezer. This made comparing weights from dead fish with 
remaining fish impossible.   
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7.1.2 Experimental design 
The experiment consisted of 823 juvenile halibuts at start up and to be able to observe growth 
performance of individual fish, 299 fish were tagged. The tagged fish was randomly chosen. 
The untagged fish was used for blood samples, weight and growth measurements, sampled for 
histidine analysis and chosen randomly. Twenty fish was sampled at start-up and 40 fish (n=2 
per tank, n=4 per treatment) sampled on each sample day. All the fish was weighted at the 
sample days to be able to calculate growth data (specific growth rate) and feed conversion 
ratio.   
 
The fish used in this experiment was poorly sorted by size ranging from 13g to approximately 
104 g. This probably resulted in aggressive behaviour in the tanks when small fish was pooled 
together with larger more dominant fish (see discussion above). An aggressive behaviour also 
observed was eye snatching. Several fish lost one or both eyes, or lost the one good eye (Pers. 
Observation). This is expected to have an influence on the death rate. There will be 
problematic to state that the ammonia treatment cause high death rates if the death rate is the 
same between the groups during or post exposure of ammonia. We found altogether 212 dead 
fish and some of these were even tagged fish. A few of these tagged fish could have died 
because of buccal infections post tagging or by eye snatching. Also noted that the gills of 
some dead fish were slimy and this could be caused by ammonia toxicity. 
 
Some fish exhibited altered behaviour e.g. very active and would not settle at the bottom. This 
was even noticed to be occurring in one control tank. These could well in fact be losers 
selected because they were easy to catch by the farmer. The muscle tissue samples were 
sampled from fish with poor pigmentation. It is shown that albinism causes lower activity of 
some enzymes. 
 
The formulated feed that was used in this experiment was a health diet, with extra added 
histidine, that was supposed to reduce the stress in the juveniles when handling. According to 
the manufacturer this is given to fish normally for a two week period prior to stressful 
handling. (e.g. transportation, vaccination etc). AGA Marin recommended this diet since they 
achieved higher survival by providing this diet to the juvenile halibut.  
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The sampled lenses at the last sample day were sampled in Eppendorf tubes. These were 
supposed to be sampled in Brand tubes as the others since the Eppedorf tubes cracks during 
centrifugation in the laboratory. The lenses had to be transferred over to Brandt tubes and we 
may have lost some of the material that was already weighed in with the Eppondorf tubes. 
They were transferred while frozen at -80 ºC and knocked over to the Brand tube. When they 
started melting the lenses got sticky and where harder to transfer.  This could probably bias 
the results and the calculations when comparing relative lens size. 
 
A daily measurement of pH was not included in the experimental design as the buffer 
capacity of seawater is high and the density of fish in the tank was low.  
Daily measurement of pH would therefore have given a more precise basis for the calculation 
of UIA.  
 
The i-STAT Analyzer is made for analyzing human blood and the blood sample in the i-
STAT cartridge is heated to 37 ºC when inserted to the analyzer. pH and pCO2 are 
temperature-dependent measures, and as the body temperature of the Atlantic halibut 
juveniles was approximately 12 ºC, a temperature correction was made in order to obtain the 
actual pH and pCO2 in the blood samples. We used the temperature correction formulas given 
in the i-STAT Analyzer Manual, although these formulas are more suitable for temperature 
corrections in human blood samples close to 37 ºC than for fish blood holding 12 ºC. As the 
purpose of this study was not to determine the exact pH and pCO2 values, but rather to 
investigate any possible differences in pH/pCO2 in relation to the treatments, this matter was 
not pursued, and calculated values were presented.  
 
Any factors in the room that could affect the fish are considered small, as all tanks were 
covered, with equal lightning, flow and temperature and where subject to the same 
experimental procedures.  
7.1.3 Statistical methods 
Random sampling and independence among observations are requirements needed to be 
fulfilled for statistical testing. In this study fish were randomly distributed into 8 tanks, where 
each tank can be regarded as independent since they were isolated with no contact between 
fish in the different tanks. As the predictor variables (ammonia and replicates) were fixed, 
categorical factors, and the response variables continuous factors, we used ANOVA to 
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distinguish treatment effects from variability due to random error (Zar, 1984). This procedure 
may be defended because of the fish were randomly distributed in the tanks, fish were 
randomly selected for blood, lens and muscle sampling and because there were equal numbers 
of fish in the groups used for analyses (Zar, 1984). The fulfilment of the underlying 
assumptions for ANOVA testing, namely a homogeneity of variances and normally 
distributed sample populations (Zar, 1984), is discussed below.  
 
For growth, feed and blood parameters the Kolmogorov-Smironv test revealed only few 
deviations from normality (Appendix III). The Levene´s F-test for homogenity revealed minor 
deviation from homogenity of measured growth, but some inhomogenity (p<0.05) for a few 
blood parameters, and measured muscle and lens amino acids. However, analysis of variance 
is robust, operating well despite considerable heterogeneity of variances as long as the 
number of observations is equal or approximately equal (Zar, 1984). Hence, the requirements 
were fulfilled and a parametric approach was applied on all measured growth, feed and blood 
parameters. Weight was included as a covarying factor in the ANCOVA (analysis of 
covariance) because ANCOVA neutralizes any size effect, ensuring that any experimental 
effect found are in fact real. All significant ANOVA and ANCOVA´s were followed by a 
































Table I: Abbreviation of free amino acids explained and included in the TABLE.  
Abbreviations        
      fw 
phser O-Phospho-L-serine 185.1 
tau Taurine   125.1 
pea O-Phosphoethanolamine 141.1 
urea Urea   60.1 
asp L-Aspartic acid 133.1 
hypro Hydroxy-L-proline 131.1 
thr L-Threonine   119.1 
ser L-Serine   105.1 
asn L-Aspargine   132.1 
glu L-Glutamic acid 147.1 
gln L-Glutamine   146.1 
sarc L-Sarcosine   89.1 
aaaa L-alfa-Aminoadipic Acid 161.2 
pro L-Proline   115.1 
gly L-glycine   75.1 
ala L-Alanine   89.1 
citr L-Citrulline   175.2 
aaba L-alfa-Amino-n-butyric Acid 103.1 
val L-Valine   117.1 
cystine L-Cystine   240.2 
met L-Methionine   149.2 
cysth1 Cystathionin1   222.2 
cysth2 Cystathionin2   222.2 
ile L-Isoleucine   131.2 
leu L-Leucine   131.2 
nor L-Norleucine   131.2 
tyr L-Tyrosine   181.2 
b-ala b-Alanine   89.1 
phe L-Phenylalanine 165.2 
aaiba DL-beta-Aminoisobutyric Acid 103.1 
gaba Gamma-Amino-n-butyric Acid 103.1 
ethanolamin Ethanolamine   61.08 
amm Ammoniumklorid 18 
hylys1 Hydroxylysin1 162.6 
hylys2 Hydroxylysin2 162.6 
orn L-Ornithine   132.2 
lys L-Lysine   146.2 
1-mhis 1-Methyl-L-histidine 169.2 
his L-Histidine   155.2 
trp L-Trypthofan   204.2 
3-mhis 3-metylhistidin 169.2 
ans anserine   240.2 
car carnosin   226.2 
arg arginine   174.2 
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8.1 Applied chemicals 
8.1.1 Ammonia measurements 
Two NH4Cl standards were used in the calibration of the Thermo Orion 720A meter. These 
were made by adding 100 ml distilled water to 0.3 and 3 ml of 0.1 M NH4Cl (5.348 g NH4Cl 
per liter; VWR International, Oslo), respectively. 
 
In order to measure the concentrations of total ammonia in water samples, the pH in the 
samples was elevated by adding 3 ml of a strong basic solution (ISA). ISA was made of 
100ml methanol, 18.612 g EDTA, 200 g NaOH and enough destilled H20 to make 1 l 
solution. 100 ml methanol was added to 0.8 l destilled H20 in a glass flask (1 l) where the 
solution was continuously stirred. Then 18.612 g EDTA was added, and then NaOH was 
added a little at a time, to avoid overheating. During the addition of NaOH the glass flask was 
placed in a sink with iced slurry to cool down. Enough distilled water was added to get 1 l of 
ISA.  
 
8.1.2 Muscle and lens and free amino acids 




Sulfosalicylic acid (C7H6O6S*2H2O) Sigma, Cat. No. S-0640 
Lithium Citrate Loading buffer, pH 2.2 Biochrom Cat. No. 80-2038-10 
Hydrochloric acid, 37% (HCl) Merck, Cat. No. 1.00317 
Norleucin, DL, Sigma, Cat. No. N-1398 
Fysiological aa standard A/N, Sigma, Cat. No. A-6407 
Fysiological aa. Standard B, Sigma, Cat. No. A-6282 







Running buffers:  
Lithium buffer A, Biochrom, Cat. No. 80-2038-15 
Lithium buffer B. Biochrom, Cat. No. 80-2038-16 
Lithium buffer C II, Biochrom, Cat. No. 80-2099-83 
Lithium buffer D II, Biochrom, Cat. No. 80-2038-18 
Lithiumhydroxide F, Biochrom, Cat. No. 80-20338-20 
Lithium buffer pH 3.55, Biochrom, Cat. No. 80-2037-69 
 
Ultrasolve, Biochrom, Cat. No. 80-2110-75 
MilliQ-water 
 
Solutions and standards: 
10% Sulfursalicylic acid 
Wighted 10 g of Sulfosalicylic acid and transferred it to a graduated flask, and diluted up to 
the mark with water.  
 
Hydrochloric acid, 6M 
Added 500 ml of 37 % hydrochloric acid (HCl) to water in a 1000 ml graduated flask. When 
the solution was chilled enough more water was added up to the mark.  
 
Internal standard I (2.5mM Nor) 
Exactly 0.3280 g of Norleucin was transferred to a 1000 ml graduated flask and dissolved 
with 17 ml 6 M hydrochloric acid, and further diluted with water until the mark.  
 
2.5 mM glutamine 
Exactly 0.0365 g of Glutamin was transferred to a 100 ml graduated cylinder and diluted with 
water up to mark. 
 
Workstandard, 0.625 mM 
Pipetted out accurately and transferred to 4 ml vial 500 µl standard A/N, 500 µl standard B, 
500 µl standard I and 500 µl Loading buffer. Then the solution was mixed well with a 
whirlmixer. Stored at -20 ºC.  
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External standard 0.5 mM 
200 µl of the workstandard was accurately pipetted out and 50 µl glutamine was added and 
mixed well using a whirlmixer.  
 
Ninhydrinereagent 
The Ninhydrine solution was placed in an ultrasound bath for 10 min. Ultrasolve was 
transferred to a lightfiltered flask and placed for stirring using a magnetic stirrer with addition 
of Nitrogen gas for 10 min. (Some of the Ultrasolve was kept to rinse out the flask containing 
Ninhydrine solution). The sonycated Ninhydrine solution was transferred to the Ultrasolve 




Flask 1000ml (Blue cork) 
Reservoarflask with lightfilter 2000 ml (blue cork) 
Graduated cylinders: 250-500-1000 ml 
Graduated flasks: 100-1000-2000 ml 
Chromacol samplevials: 2SV without insert 
Chromacol samplevials: 2SV with insert 
Watch glass 
Brand eppendorftube, 2.0 ml rounded tip: 780550 
Eppendorftube, 1.5 ml 
Micropipette 20-200 µl, 200 µl, 200 µl, 1000 µl and 1000-5000 µl 
Pipette tips, 200-1000-5000 µl microtips 
Cork for Chromacol samplevials: 2SV without insert: 8 mm 8-SC-8RT1 
Cork for Chromacol samplevialss: 2SV with insert: 9 mm 9-SC-8RT1 
Skalpel 
Balls for grinding in the mill 
Mill: Retch MM301 
Analytical balance, 4 decimals 
Centrifuge: Eppendorf centrifuge 54 1 
Filter: Syringefilter 4 mm-0.22 µm, Millex-GV 
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Whirlmixer 
Biochrom 20 Plus 
Coloumn, Biochrom Physological coloumn 200 mm Cat. No. 80-2038-20 
Midas coolray-injector, Spark 
BusSAT/IN Waters 




Flow: 25 ml h-1 for buffer, 20 ml h-1 for Ninhydrin 
Wavelength: 570 nm for Channel 1, 440 nm for Channel 2 
Injection volume: 20 µl  
Midas carusell: 8 ºC 
 
Chemical used in Determination of NAH (Na-Acetyl-l.Histidene) using HPLC 
(MET.NÆR.01-32, NIFES, Bergen, Norway).  
 
Chemicals: 
1. di-Sodiumhydrogen phophate-dihydrate (Na2HPO4*2H20), p.a, Merck, Cat. No. 6580. 
2. Ortho-Phosphoracid , 85 % (H3PO4),p.a Merck, Cat. No. 0573 
3. Ethanol, (Et-OH), rectified, 96 %., Arcus 
4. Na-acetyl-l-Histidine (NAH), F.W.215.21, Aldrich 85,754-8 
5. L-Histidine (HIS), C6H9N3O2, Sigma grade, Cat. No. H-8776 
6. Methanol, Merck, Cat. No. 6018.  
7. Distilled water, MilliQ, Millipore. 
 
Solutions and standards: 
80 % Et-OH: 
Measured up 80.0 ml of 96 % Et-OH in a 100ml measuring cylinder using a 3.3 ml automatic 





Eluent I (0.1 M Sodiumphospatebuffer, pH 2.0):  
Weighted 17.8 g Na2HPO4*2H2O and diluted to the mark with distilled water in a 1000 ml 
graduated flask. Then 13.5 ml was pipetted out and diluted further with distilled water to 2000 
ml. Took out approximately 350 ml of the Na2HPO4-solution and transferred it to a 2000 ml 
beaker and then added the H3PO4-solution to the sodiumphosphatebuffer until the pH 
measuren 2.0.  
 
0.5 mM NAH- 0.5 mM HIS standard:  
These were prepared by the technical staff at NIFES.  
0.0538 g NAH was weighted and added 0.0388 HIS in their own weigh boats. Both were 
transferred into a 100 ml graduated flask. To dissolve them a little sodiumphosphatebuffer 
was added, and diluted with the buffer to the mark. 5.0 ml was taken out and transferred to a 
25 ml graduated flask and diluted with buffer. Small portions of this solution were put in the 
freezer, and can be stored for 3 years. Shake them well before use.  
 
0.25 mM NAH-0.25 mM HIS standard:  
Mixed 0.5 mM NAH and 0.5mM HIS standard with sodiumphosphatebuffer in a 1:1 relation. 
Mix well.  
 
Eluent II: (Methanol and water): 
Mixed Methanol and distilled water 1:1.  
 
Instruments and equipment: 
Analytical balance, 4 decimals 
Vortex Genie2, Scientific instrument 
pH-meter 
Homogenisator, Retsh Mill 
Eppendorftubes, 2 ml Brand 
Graduated cylinders/Erlenmeyer flasks (25, 100, 500, 1000 and 2000 ml) 
Beaker, 2000 ml 
Graduated cylinder, 100 ml 
Chromacol sampletubes, 4 ml, springs and inserts 
Pastaurpipette 
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Micropipette with tips, 200-1000 µl 
Heating cabinet 
Centrifuge, Eppendorf 5415C 
Vibramixer 
Planatery balls 
Syringe filter, 4 mm-22 µl, Millex-GV 
HPLC-system-Waters 
Autosampler: Waters 717+ 
System control/pump: Waters 600E 




Waters 600 Controller/pump module 
Waters 468 Absorbance detector, wavelength 210 nm 
Waters 717 Autosampler 
Coloumn: Zorbax SB250x4.6 mm id, Reversed-phase C18, 5 µm 
Flow: 0.6 ml min-1 (Eluent I) for 10 min, wash, 1.0 ml (Eluent II) for 10 min, condition 
coloumn with Eluent I for 25 min. 









































9.1 Descriptive statistics 
Experimental conditions  
Table I: Descriptive statistics based on daily temperature (ºC) measurements in treatment groups. Means, total 
number of observations (N), standard deviation (SD), and standard error (SE), minimum and maximum are 
included in the TABLE. 
Temperature ºC
Treatment N Mean SD SE
Control 118 11.87 0.14 0.01
ChronicLow 120 11.94 0.17 0.02
ChronicMedium 118 11.91 0.18 0.02
ChronicHigh 115 11.89 0.16 0.01
HighPulse 119 11.90 0.16 0.01  
 
Table II: Descriptive statistics based on daily temperature (ºC) measurements in all tanks. Means, total number 
of observations (N), standard deviation (SD), and standard error (SE), minimum and maximum are included in 
the TABLE. 
Temperature ºC
Treatment Replicate  N Mean SD SE Min Max
Control a 59 11.9 0.13 0.02 11.6 12.2
Control b 59 11.9 0.14 0.02 11.6 12.2
ChronicLow a 60 12.0 0.17 0.02 11.5 12.3
ChronicLow b 60 11.9 0.18 0.02 11.4 12.3
ChronicMedium a 59 11.9 0.18 0.02 11.5 12.2
ChronicMedium b 59 11.9 0.18 0.02 11.5 12.2
ChronicHigh a 57 11.9 0.16 0.02 11.5 12.2
ChronicHigh b 58 11.9 0.16 0.02 11.5 12.3
HighPulse a 60 11.9 0.17 0.02 11.5 12.3
HighPulse b 59 11.9 0.16 0.02 11.5 12.3  
Table III: Descriptive statistics based on daily oxygen measurements in treatment groups, represented here in % 
saturation. Means, total number of observations (N), standard deviation (SD), and standard error (SE), minimum 
and maximum are included in the TABLE. 
Oksygen %
Treatment N Mean SD SE
Control 94 80.81 3.04 0.31
ChronicLow 100 80.70 2.52 0.25
ChronicMedium 97 80.22 2.21 0.22
ChronicHigh 98 83.02 3.16 0.32
HighPulse 99 80.89 2.97 0.30  
 
 67 
Table IV: Descriptive statistics based on daily oxygen measurements in all tanks, presented in % saturation.  
Means, total number of observations (N), standard deviation (SD), and standard error (SE), minimum and 
maximum are included in the TABLE. 
Oksygen %
Treatment Replicate  N Mean SD SE Min Max
Control a 44 80.5 1.99 0.30 77.0 87.1
Control b 50 81.1 3.72 0.53 73.0 89.0
ChronicLow a 51 80.4 2.38 0.33 74.0 86.9
ChronicLow b 49 81.1 2.63 0.38 75.0 86.8
ChronicMedium a 48 80.3 1.98 0.29 74.0 84.8
ChronicMedium b 49 80.1 2.42 0.35 76.0 85.2
ChronicHigh a 49 83.8 3.27 0.47 76.0 90.1
ChronicHigh b 49 82.2 2.85 0.41 74.0 88.0
HighPulse a 50 81.4 2.81 0.40 74.0 88.1
HighPulse b 49 80.4 3.06 0.44 73.0 87.6  
9.2 Response variables 
Table V: Descriptive statistics base don measurements of weights at T0 (day 0), T3 (day 62) and T4(day 100). 
Means, total number of observations (N), standars deviation (SD) and standard error (SE) for each group are 
included in the TABLE . 
Weight T0 Weight T3 Weight T4
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 54.1 59 14.5 1.89 89.6 56 29.7 3.97 138.4 52 47.4 6.58
ChronicLow 49.1 60 11.7 1.51 80.0 45 25.1 3.74 120.7 42 47.1 7.27
ChronicMedium 52.1 60 14.4 1.86 73.6 54 28.3 3.85 109.5 48 43.8 6.32
ChronicHigh 52.2 60 13.3 1.71 65.9 52 20.5 2.84 100.0 40 35.6 5.62
HighPulse 51.4 60 11.7 1.51 88.5 47 25.9 3.78 128.1 41 40.3 6.30  
 
Table VI: Descriptive statistics base don calculated SGR from T0-T3 (day 0-62) and T3-T4 (day 62-100). 
Means, total number of observations (N), standard deviation (SD) and standard error (SE) for each group are 
included in the TABLE. 
SGR1 (T0-T3) SGR2 (T3-T4) SGR Overall
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 0.75 56 0.4 0.05 1.00 52 0.4 0.06 0.87 52 0.3 0.04
ChronicLow 0.68 45 0.3 0.05 0.93 42 0.4 0.06 0.80 42 0.3 0.05
ChronicMedium 0.47 52 0.4 0.05 0.81 48 0.6 0.08 0.65 48 0.3 0.05
ChronicHigh 0.28 52 0.4 0.05 0.80 40 0.5 0.09 0.54 40 0.3 0.05
HighPulse 0.79 47 0.3 0.04 0.89 41 0.4 0.06 0.85 41 0.3 0.04  
 
Table VII: Descriptive statistics based on measurements of blood Na+ at three sampling dates (T0/day 0, T3/day 
62, T4/day 100). Means, total number of observations (N), standard deviation (SD) and standard error (SE) are 
included in the TABLE. 
Blood Na
+
 T0 Blood Na
+
 T3 Blood Na
+
 T4
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 156.5 19 3.60 0.82 167.9 8 5.77 2.04 170.4 8 4.63 1.64
ChronicLow 170.4 8 3.78 1.34 171.4 8 4.53 1.60
ChronicMedium 168.5 8 2.78 0.98 168.4 8 3.96 1.40
ChronicHigh 168.3 8 3.96 1.40 170.0 8 4.99 1.76
HighPulse 166.8 8 3.77 1.33 168.5 8 2.39 0.85  
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Table VIII: Descriptive statistics based on measurements of blood K+ at three sampling dates (T0/day 0, T3/day 
62, T4/day 100). Means, total number of observations (N), standard deviation (SD) and standard error (SE) are 
included in the TABLE. 
Blood K
+
 T0 Blood K
+
 T3 Blood K
+
 T4
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 3.52 19 0.34 0.08 4.26 7 0.22 0.08 4.83 8 0.55 0.20
ChronicLow 4.31 8 0.47 0.17 5.65 8 0.96 0.34
ChronicMedium 4.19 8 0.20 0.07 4.51 8 0.59 0.21
ChronicHigh 4.40 8 0.42 0.15 4.71 7 0.45 0.17
HighPulse 4.33 8 0.49 0.17 4.43 8 0.25 0.09  
 
Table IX: Descriptive statistics based on measurements of blood pH at three sampling dates (T0/day 0, T3/day 
62, T4/day 100). Means, total number of observations (N), standard deviation (SD) and standard error (SE) are 
included in the TABLE. 
 Blood pHtp T0 Blood pHtp T3 Blood pHtp T4
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 7.34 19 0.08 0.02 7.31 7 0.09 0.04 7.25 8 0.06 0.02
ChronicLow 7.29 8 0.04 0.02 7.20 8 0.07 0.02
ChronicMedium 7.29 8 0.06 0.02 7.23 8 0.04 0.01
ChronicHigh 7.33 8 0.09 0.03 7.27 8 0.05 0.02
HighPulse 7.31 8 0.06 0.02 7.26 8 0.05 0.02  
 
Table X: Descriptive statistics based on measurements of blood pCO2 at three sampling dates (T0/day 0, T3/day 
62, T4/day 100). Means, total number of observations (N), standard deviation (SD) and standard error (SE) are 
included in the TABLE. 
Blood pCO2 tp T0 Blood pCO2 tp T3 Blood pCO2 tp T4 
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 4.77 19 0.97 0.22 5.79 7 0.44 0.17 5.67 8 0.49 0.17
ChronicLow 5.25 8 0.39 0.14 6.67 8 0.93 0.33
ChronicMedium 4.92 8 0.64 0.23 6.15 8 0.73 0.26
ChronicHigh 4.33 8 1.02 0.36 5.55 8 0.40 0.14
HighPulse 5.32 8 0.39 0.14 5.64 8 0.31 0.11  
 
Table XI: Descriptive statistics based on measurements of blood HCO3
- at three sampling dates (T0/day 0, 
T3/day 62, T4/day 100). Means, total number of observations (N), standard deviation (SD) and standard error 
(SE) are included in the TABLE. 
Blood HCO3
-
 T0 Blood HCO3
-
 T3 Blood HCO3
-
 T4 
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 3.56 19 0.76 0.18 4.14 7 0.95 0.36 3.56 8 0.47 0.16
ChronicLow 3.61 8 0.51 0.18 3.84 8 0.87 0.31
ChronicMedium 3.40 8 0.44 0.16 3.74 8 0.59 0.21
ChronicHigh 3.20 8 0.84 0.30 3.66 8 0.57 0.20
HighPulse 3.79 8 0.28 0.10 3.69 8 0.53 0.19  
 
Table XII: Descriptive statistics based on analysis of Histidine in the lens at three sampling dates (T0/day 0, 
T3/day 62, T4/day 100). Means, total number of observations (N), standard deviation (SD) and standard error 
(SE) are included in the TABLE. 
Lens His T0 Lens His T3 Lens His T4
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 1.10 20 0.42 0.09 1.27 7 0.09 0.04 1.29 8 0.279 0.10
ChronicLow 0.95 8 0.08 0.03 1.13 8 0.12 0.04
ChronicMedium 1.02 8 0.05 0.02 1.17 8 0.12 0.04
ChronicHigh 1.44 8 0.22 0.08 1.27 8 0.08 0.03
HighPulse 1.33 8 0.23 0.08 1.21 8 0.17 0.06  
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Table XIII: Descriptive statistics based on analysis of NAH in the lens at three sampling dates (T0/day 0, 
T3/day 62, T4/day 100). Means, total number of observations (N), standard deviation (SD) and standard error 
(SE) are included in the TABLE. 
Lens NAH T0 Lens NAH T3 Lens NAH T4
Treatments Means N SD SE Means N SD SE Means N SD SE
Control 12.79 20 2.23 0.50 9.28 7 0.845 0.32 8.78 8 2.111 0.75
ChronicLow 7.30 8 0.71 0.25 8.66 8 1.69 0.60
ChronicMedium 7.65 8 0.87 0.31 9.28 8 1.50 0.53
ChronicHigh 8.25 8 1.41 0.50 8.18 8 1.10 0.39
HighPulse 9.45 8 0.79 0.28 9.79 8 0.55 0.19  
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Table XIV : Descriptive statistics based on analysis of free amino acids (FAA) in the muscle tissue samples at 
T0 (day 0). Means (µmol g-1), total number of observations (N), standard deviation (SD) and standard error (SE) 
are included in the TABLE. Abbriviations explained in Table I, APPENDIX II. 
Free amino acid T0
N Mean SD SE
Phser 20 0.01 0.00 0.00
Tau 20 9.35 2.50 0.56
Pea 20 0.09 0.03 0.01
Urea 20 5.40 1.16 0.26
Asp 20 0.53 0.20 0.05
Hypro 20 0.56 0.54 0.12
Thr 20 1.13 0.36 0.08
Ser 20 1.73 0.42 0.09
Asn 20 0.64 0.58 0.13
Glu 20 0.69 0.25 0.06
Gln 20 0.83 0.20 0.05
Sarc 5 0.04 0.01 0.00
Aaaa 0 n.d
Pro 20 0.87 0.96 0.21
Gly 20 7.58 0.54 0.12
Ala 20 4.28 0.49 0.11
Citr 20 0.05 0.04 0.01
Aaba 20 0.06 0.02 0.00
Val 20 0.09 0.03 0.01
Cystine 0 n.d
Met 20 0.05 0.02 0.00
Cysth1 0 n.d
Cysth2 20 0.38 0.16 0.04
Ile 20 0.06 0.02 0.00
Leu 20 0.12 0.04 0.01
Tyr 20 0.05 0.01 0.00
B-ala 0 n.d
Phe 20 0.04 0.01 0.00
Aaiba 20 0.06 0.02 0.00
Gaba 0 n.d
Ethanolamine 0 n.d
Amm 20 3.87 0.34 0.08
Hylys1 10 0.05 0.05 0.01
Hylys2 20 0.02 0.01 0.00
Orn 20 0.02 0.01 0.00
Lys 20 0.53 0.24 0.05
1-mhis 0 n.d
His 20 0.84 0.58 0.13
Trp 0 n.d
3-mhis 0 n.d
Ans 20 0.37 0.13 0.03
Car 0 n.d
Arg 20 0.09 0.05 0.01








Table XV : Descriptive statistics based on analysis of free amino acids (FAA) in the muscle tissue samples at T3 
(day 62). Means (µmol g-1), total number of observations (N), standard deviation (SD) and standard error (SE) 
are included in the TABLE. Abbriviations explained in Table I, APPENDIX II. 
T3
Control CL CM CH HP
Free Amino Acid N Mean S.D S.E N Mean S.D S.E N Mean S.D S.E N Mean S.D S.E  N Mean S.D S.E
Phser 8 0.01 0.00 0.00 8 0.01 0.00 0.00 8 0.01 0.00 0.00 8 0.01 0.01 0.00 8 0.01 0.01 0.00
Tau 8 12.29 2.88 1.02 8 10.93 1.98 0.70 8 11.36 3.12 1.10 8 11.13 2.72 0.96 8 12.11 2.86 1.01
Pea 8 0.08 0.01 0.00 8 0.08 0.01 0.00 8 0.08 0.01 0.00 8 0.07 0.02 0.01 8 0.07 0.02 0.01
Urea 8 7.67 1.19 0.42 8 7.07 1.11 0.39 8 6.90 1.02 0.36 8 7.11 1.42 0.50 8 7.16 1.10 0.39
Asp 8 0.58 0.22 0.08 8 0.60 0.13 0.04 8 0.54 0.14 0.05 8 0.57 0.11 0.04 8 0.66 0.20 0.07
Hypro 8 0.44 0.22 0.08 8 0.54 0.29 0.10 8 0.46 0.43 0.15 8 0.31 0.23 0.08 8 0.49 0.37 0.13
Thr 8 1.46 0.39 0.14 8 1.35 0.43 0.15 8 1.19 0.49 0.17 8 1.03 0.29 0.10 8 1.31 0.48 0.17
Ser 8 1.71 0.48 0.17 8 1.91 0.38 0.13 8 1.25 0.48 0.17 8 1.56 0.29 0.10 8 1.50 0.63 0.22
Asn 8 0.67 0.54 0.19 8 0.33 0.14 0.05 8 0.94 0.76 0.27 8 0.71 0.29 0.10 8 0.49 0.31 0.11
Glu 8 0.60 0.17 0.06 8 0.87 0.19 0.07 8 0.64 0.14 0.05 8 0.59 0.07 0.03 8 0.67 0.07 0.02
Gln 8 0.85 0.19 0.07 8 0.80 0.16 0.06 8 1.05 0.23 0.08 8 1.04 0.17 0.06 8 0.71 0.16 0.06
Sarc 8 0.04 0.02 0.01 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00
Aaaa 0 n.d 0 n.d 0 n.d 0 n.d 0
Pro 8 1.32 0.91 0.32 8 1.76 1.09 0.39 8 1.53 1.48 0.52 8 0.93 0.65 0.23 8 1.28 0.76 0.27
Gly 8 7.13 0.67 0.24 8 7.36 0.30 0.11 8 6.70 1.11 0.39 8 7.71 0.52 0.18 8 7.44 0.78 0.28
Ala 8 4.06 0.53 0.19 8 4.53 0.71 0.25 8 4.88 0.89 0.31 8 4.44 0.51 0.18 8 3.69 0.58 0.21
Citr 8 0.08 0.07 0.02 8 0.08 0.07 0.02 8 0.06 0.06 0.02 8 0.05 0.04 0.01 8 0.12 0.09 0.03
Aaba 8 0.06 0.01 0.00 8 0.06 0.02 0.01 8 0.06 0.03 0.01 8 0.05 0.02 0.01 8 0.06 0.02 0.01
Val 8 0.07 0.03 0.01 8 0.07 0.03 0.01 8 0.09 0.03 0.01 8 0.09 0.03 0.01 8 0.08 0.04 0.01
Cystine 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Met 8 0.04 0.01 0.00 8 0.04 0.01 0.00 8 0.05 0.02 0.01 8 0.05 0.02 0.01 8 0.05 0.03 0.01
Cysth1 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Cysth2 8 0.96 0.26 0.09 8 0.88 0.36 0.13 8 0.78 0.55 0.19 8 0.69 0.37 0.13 8 0.77 0.41 0.15
Ile 8 0.04 0.02 0.01 8 0.04 0.02 0.01 8 0.05 0.02 0.01 8 0.06 0.02 0.01 8 0.05 0.03 0.01
Leu 8 0.07 0.04 0.01 8 0.08 0.03 0.01 8 0.11 0.03 0.01 8 0.12 0.04 0.02 8 0.10 0.05 0.02
Tyr 8 0.06 0.01 0.00 8 0.05 0.01 0.00 8 0.04 0.02 0.01 8 0.05 0.02 0.01 8 0.07 0.02 0.01
B-ala 1 0.03 1 0.01 2 0.02 0.00 0.00 0 n.d 1 0.02
Phe 8 0.04 0.01 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.04 0.02 0.01 8 0.04 0.01 0.01
Aaiba 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.01 0.01 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00
Gaba 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Ethanolamine 7 0.02 0.01 0.00 3 0.04 0.01 0.01 3 0.03 0.00 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00
Amm 8 3.78 0.35 0.12 8 3.96 0.26 0.09 8 3.91 0.21 0.07 8 4.16 0.27 0.10 8 3.79 0.29 0.10
Hylys1 7 0.07 0.03 0.01 6 0.06 0.02 0.01 6 0.06 0.03 0.01 5 0.05 0.02 0.01 6 0.05 0.02 0.01
Hylys2 8 0.05 0.01 0.00 8 0.03 0.02 0.01 6 0.04 0.03 0.01 6 0.05 0.02 0.01 6 0.05 0.02 0.01
Orn 8 0.03 0.02 0.01 8 0.02 0.01 0.00 8 0.02 0.01 0.00 8 0.01 0.01 0.00 8 0.03 0.02 0.01
Lys 8 0.60 0.21 0.07 8 0.63 0.10 0.03 8 0.65 0.23 0.08 8 0.60 0.12 0.04 8 0.44 0.15 0.05
1-mhis 0 n.d 0 n.d 0 n.d 0 0 n.d
His 8 1.44 0.58 0.21 8 1.24 0.55 0.19 8 1.07 0.68 0.24 8 1.07 0.60 0.21 8 1.32 0.66 0.23
Trp 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
3-mhis 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Ans 8 0.82 0.08 0.03 8 0.72 0.07 0.02 8 0.75 0.12 0.04 8 0.67 0.15 0.05 8 0.72 0.14 0.05
Car 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Arg 8 0.15 0.07 0.02 8 0.12 0.04 0.01 8 0.11 0.03 0.01 8 0.11 0.03 0.01 8 0.11 0.04 0.01











Table XVI : Descriptive statistics based on analysis of free amino acids (FAA) in the muscle tissue samples at 
T4 (day 100). Means (µmol g-1), total number of observations (N), standard deviation (SD) and standard error 
(SE) are included in the TABLE. Abbriviations explained in Table I, APPENDIX II. 
T4
Control CL CM CH HP
N Mean S.D S.E N Mean S.D S.E N Mean S.D S.E N Mean S.D S.E  N Mean S.D S.E
Phser 8 0.01 0.00 0.00 8 0.01 0.00 0.00 8 0.01 0.00 0.00 8 0.01 0.00 0.00 8 0.01 0.00 0.00
Tau 8 13.40 1.27 0.45 8 13.12 1.73 0.61 8 13.15 2.44 0.86 8 12.50 2.38 0.84 8 14.49 1.90 0.67
Pea 8 0.08 0.01 0.00 8 0.09 0.02 0.01 8 0.09 0.02 0.01 8 0.08 0.01 0.01 8 0.08 0.02 0.01
Urea 8 6.38 0.50 0.18 8 6.29 1.02 0.36 8 6.27 0.88 0.31 8 5.25 0.58 0.20 8 6.81 1.36 0.48
Asp 8 0.66 0.14 0.05 8 0.67 0.14 0.05 8 0.57 0.14 0.05 8 0.54 0.15 0.05 8 0.60 0.12 0.04
Hypro 8 0.63 0.23 0.08 8 0.82 0.32 0.11 8 0.64 0.29 0.10 8 0.77 0.29 0.10 8 0.52 0.23 0.08
Thr 8 1.62 0.52 0.18 8 1.73 0.34 0.12 8 1.50 0.25 0.09 8 1.95 0.23 0.08 8 1.48 0.28 0.10
Ser 8 1.00 0.15 0.05 8 1.12 0.20 0.07 8 1.20 0.40 0.14 8 1.04 0.24 0.08 8 1.04 0.26 0.09
Asn 8 0.71 0.90 0.32 8 0.45 0.34 0.12 8 1.19 0.64 0.23 8 1.82 0.62 0.22 8 0.52 0.39 0.14
Glu 8 0.65 0.19 0.07 8 0.75 0.12 0.04 8 0.62 0.13 0.05 8 0.49 0.10 0.03 8 0.61 0.10 0.04
Gln 8 1.00 0.28 0.10 8 0.93 0.20 0.07 8 1.12 0.13 0.05 8 0.91 0.21 0.07 8 0.73 0.23 0.08
Sarc 8 0.03 0.01 0.00 8 0.04 0.02 0.01 8 0.04 0.02 0.01 7 0.03 0.01 0.00 8 0.04 0.01 0.00
Aaaa 3 0.01 0.00 0.00 5 0.02 0.00 0.00 2 0.02 0.00 0.00 0 n.d 0 n.d
Pro 8 2.30 0.97 0.34 8 1.76 1.09 0.39 8 1.71 0.91 0.32 8 2.46 0.88 0.31 8 0.96 0.30 0.11
Gly 8 5.94 0.50 0.18 8 5.90 0.85 0.30 8 6.04 0.63 0.22 8 5.82 0.68 0.24 8 5.96 1.05 0.37
Ala 8 3.88 0.57 0.20 8 3.86 0.53 0.19 8 4.04 0.42 0.15 8 3.69 0.54 0.19 8 3.65 0.42 0.15
Citr 8 0.14 0.08 0.03 8 0.16 0.07 0.02 8 0.13 0.05 0.02 8 0.09 0.04 0.01 8 0.11 0.04 0.01
Aaba 8 0.07 0.02 0.01 8 0.07 0.02 0.01 8 0.07 0.02 0.01 8 0.08 0.02 0.01 8 0.05 0.01 0.00
Val 8 0.05 0.01 0.00 8 0.05 0.02 0.01 8 0.05 0.01 0.00 8 0.05 0.02 0.01 8 0.06 0.02 0.01
Cystine 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Met 8 0.04 0.01 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.04 0.01 0.00
Cysth1 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Cysth2 8 0.77 0.14 0.05 8 0.80 0.28 0.10 8 0.83 0.12 0.04 8 0.93 0.17 0.06 8 0.60 0.16 0.06
Ile 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.02 0.01 0.00 8 0.02 0.01 0.00 8 0.03 0.01 0.00
Leu 8 0.06 0.02 0.01 8 0.07 0.03 0.01 8 0.06 0.03 0.01 8 0.05 0.02 0.01 8 0.07 0.02 0.01
Tyr 8 0.05 0.01 0.00 8 0.05 0.02 0.01 8 0.05 0.01 0.00 8 0.05 0.02 0.01 8 0.05 0.01 0.00
B-ala 0 n.d 0 n.d 1 0.04 0 n.d 0 n.d
Phe 8 0.04 0.01 0.00 8 0.04 0.01 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.04 0.00 0.00
Aaiba 8 0.04 0.01 0.00 8 0.05 0.01 0.00 8 0.05 0.01 0.00 8 0.04 0.01 0.00 8 0.04 0.01 0.00
Gaba 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Ethanolamine 8 0.02 0.01 0.00 6 0.01 0.00 0.00 7 0.02 0.01 0.00 0 n.d 7 0.03 0.02 0.01
Amm 8 3.44 0.45 0.16 8 3.57 0.10 0.04 8 3.30 0.12 0.04 8 3.24 0.25 0.09 8 3.51 0.13 0.05
Hylys1 8 0.13 0.03 0.01 8 0.12 0.04 0.01 8 0.13 0.07 0.02 8 0.14 0.04 0.02 8 0.10 0.04 0.01
Hylys2 8 0.03 0.01 0.00 8 0.03 0.02 0.01 8 0.03 0.01 0.00 8 0.03 0.01 0.00 8 0.03 0.01 0.00
Orn 8 0.03 0.01 0.00 8 0.04 0.01 0.00 8 0.02 0.00 0.00 8 0.02 0.00 0.00 8 0.03 0.01 0.00
Lys 8 0.54 0.13 0.04 8 0.49 0.14 0.05 8 0.49 0.13 0.04 8 0.57 0.18 0.06 8 0.48 0.10 0.03
1-mhis 0 n.d 1 0.01 0 n.d 0 n.d 0 n.d
His 8 1.66 0.16 0.06 8 1.72 0.13 0.04 8 1.50 0.38 0.14 8 1.72 0.23 0.08 8 1.62 0.26 0.09
Trp 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
3-mhis 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Ans 8 0.84 0.08 0.03 8 0.84 0.11 0.04 8 0.81 0.09 0.03 8 0.92 0.07 0.03 8 0.97 0.08 0.03
Car 0 n.d 0 n.d 0 n.d 0 n.d 0 n.d
Arg 8 0.15 0.05 0.02 8 0.14 0.03 0.01 8 0.14 0.06 0.02 8 0.17 0.09 0.03 8 0.12 0.03 0.01










9.3 ANOVA results 
One-way ANOVAs  
Table XVII: Test results from one-way ANOVA on measured weight data from T0 (day 0) 
Weight T0
One way ANOVA 
SS Degr. of MS F p
Intercept 801561.7 1 801561.7 4630.764 <0.001
Treatment 766.1 4 191.5 1.106 0.354
Error 50889.9 294 173.1  
 
Table XVIII: Test results from one-way ANOVA on measured weight data from T3 (day 62) 
Weight T3
One way ANOVA 
SS Degr. of MS F p
Intercept 1594675 1 1594675 2318.804 <0.001
Treatment 21056 4 5264 7.654 <0.001
Error 171241 249 688  
 
Table XIX: Test results from one-way ANOVA on measured weight data from T4 (day 63-100) 
Weight T4
One way ANOVA 
SS Degr. of MS F p
Intercept 3144319 1 3144319 1670.417 <0.001
Treatment 41538 4 10385 5.517 <0.001
Error 410353 218 1882  
 
Table XX: Test results from one-way ANOVA on calculated SGR data from T0-T3 (day 0-62) 
SGR1 (T0-T3)
One way ANOVA 
SS Degr. of MS F p
Intercept 88.96808 1 88.96808 698.9173 <0.001
Treatment 9.30697 4 2.32674 18.2785 <0.001
Error 31.69624 249 0.12729  
 
Table XXI: Test results from one-way ANOVA on calculated SGR data from T3-T4 (day 63-100) 
SGR2 (T3-T4)
One way ANOVA 
SS Degr. of MS F p
Intercept 173.1746 1 173.1746 770.7624 <0.001
Treatment 1.2956 4 0.3239 1.4416 0.221
Error 48.9802 218 0.2247  
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Table XXII: Test results from one-way ANOVA on calculated SGR data from T0-T4 (day 0-100) 
SGR Overall
One way ANOVA 
SS Degr. of MS F p
Intercept 121.2266 1 121.2266 1314.003 <0.001
Treatment 3.6087 4 0.9022 9.779 <0.001
Error 20.1121 218 0.0923  
 





SS Degr. of MS F p
Intercept 1133669 1 1133669 66602.45 <0.001
Treatment 55 4 14 0.81 0.526
Error 596 35 17  
 





SS Degr. of MS F p
Intercept 1152263 1 1152263 65297.24 <0.001
Treatment 52 4 13 0.74 0.570
Error 618 35 18  
 





SS Degr. of MS F p
Intercept 717.8616 1 717.8616 4852.689 <0.001
Treatment 0.2001 4 0.0500 0.338 0.850
Error 5.0296 34 0.1479  
 





SS Degr. of MS F p
Intercept 905.4917 1 905.4917 2418.947 <0.001
Treatment 7.5917 4 1.8979 5.070 0.003









SS Degr. of MS F p
Intercept 2076.603 1 2076.603 400800.5 <0.001
Treatment 0.009 4 0.002 0.4 0.791
Error 0.176 34 0.005  
 




SS Degr. of MS F p
Intercept 2096.548 1 2096.548 686964.9 <0.001
Treatment 0.026 4 0.007 2.1 0.096
Error 0.107 35 0.003  
 
Table XXIX: Test results from one-way ANOVA on measured Blood pCO2 temperature corrected data from T3 
(day 62) 
Blood pCO2 tp T3 
One-way ANOVA
SS Degr. of MS F p
Intercept 1019.999 1 1019.999 2573.852 <0.001
Treatment 8.784 4 2.196 5.541 0.002
Error 13.474 34 0.396  
 
Table XXX: Test results from one-way ANOVA on measured Blood pCO2 temperature corrected data from T4 
(day 100) 
Blood pCO2 tp T4 
One-way ANOVA
SS Degr. of MS F p
Intercept 1408.850 1 1408.850 3737.935 <0.001
Treatment 7.108 4 1.777 4.714 0.004
Error 13.192 35 0.377  
 
Table XXXI: Test results from one-way ANOVA on measured HCO3





SS Degr. of MS F p
Intercept 512.0317 1 512.0317 1233.406 <0.001
Treatment 3.9361 4 0.9840 2.370 0.072
Error 14.1146 34 0.4151  
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Table XXXII: Test results from one-way ANOVA on measured HCO3





SS Degr. of MS F p
Intercept 546.8603 1 546.8603 1425.839 <0.001
Treatment 0.3260 4 0.0815 0.212 0.930
Error 13.4238 35 0.3835  
 
Table XXXIII: Test results from one-way ANOVA on measured Lens His data from T3 (day 62) 
Lens His T3
One-way ANOVA
SS Degr. of MS F p
Intercept 56.19951 1 56.19951 2294.480 <0.001
Treatment 1.40793 4 0.35198 14.371 <0.001
Error 0.83277 34 0.02449  
 
Table XXXIV: Test results from one-way ANOVA on measured Lens His data from T4 (day 100) 
Lens His T4
One-way ANOVA
SS Degr. of MS F p
Intercept 58.83535 1 58.83535 2080.523 <0.001
Treatment 0.14426 4 0.03606 1.275 0.298
Error 0.98977 35 0.02828  
 
Table XXXV: Test results from one-way ANOVA on measured NAH data from T3 (day 62) 
NAH T3
One-way ANOVA
SS Degr. of MS F p
Intercept 2734.696 1 2734.696 2962.472 <0.001
Treatment 28.708 4 7.177 7.775 <0.001
Error 31.386 34 0.923  
 
Table XXXVI: Test results from one-way ANOVA on measured NAH data from T4 (day 100) 
NAH T4
One-way ANOVA
SS Degr. of MS F p
Intercept 3195.353 1 3195.353 1443.388 <0.001
Treatment 12.202 4 3.050 1.378 0.262
Error 77.483 35 2.214  
 
Table XXXVII: Test results from one-way ANOVA on measured Phser data from T3 (day 62) 
Phser  T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.006917 1 0.006917 327.7042 <0.001
Treatment 0.000040 4 0.000010 0.4779 0.752
Error 0.000739 35 0.000021  
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Table XXXVIII: Test results from one-way ANOVA on measured Phser data from T4 (day 100) 
Phser T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.006838 1 0.006838 659.5601 <0.001
Treatment 0.000002 4 0.000000 0.0458 0.996
Error 0.000363 35 0.000010  
 
Table XXXIX: Test results from one-way ANOVA on measured Tau data from T3 (day 62) 
Tau  T3
One-way ANOVA
SS Degr. of MS F p
Intercept 5346.893 1 5346.893 712.1014 <0.001
Treatment 11.672 4 2.918 0.3886 0.815
Error 262.801 35 7.509  
 
Table XL: Test results from one-way ANOVA on measured Tau data from T4 (day 100) 
Tau T4
One-way ANOVA
SS Degr. of MS F p
Intercept 7108.836 1 7108.836 1793.387 <0.001
Treatment 17.034 4 4.259 1.074 0.384
Error 138.737 35 3.964  
 
Table XLI: Test results from one-way ANOVA on measured Pea data from T3 (day 62) 
Pea T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.248535 1 0.248535 1222.741 <0.001
Treatment 0.001040 4 0.000260 1.279 0.297
Error 0.007114 35 0.000203  
 
Table XLII: Test results from one-way ANOVA on measured Pea data from T4 (day 100) 
Pea  T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.297218 1 0.297218 1041.173 <0.001
Treatment 0.001357 4 0.000339 1.189 0.333
Error 0.009991 35 0.000285  
 
Table XLIII: Test results from one-way ANOVA on measured Urea data from T3 (day 62) 
Urea T3
One-way ANOVA
SS Degr. of MS F p
Intercept 2063.604 1 2063.604 1496.623 <0.001
Treatment 2.714 4 0.678 0.492 0.742
Error 48.259 35 1.379  
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Table XLIV: Test results from one-way ANOVA on measured Urea data from T4 (day 100) 
Urea T4
One-way ANOVA
SS Degr. of MS F p
Intercept 1536.323 1 1536.323 1800.656 <0.001
Treatment 10.473 4 2.618 3.069 0.029
Error 29.862 35 0.853  
 
Table XLV: Test results from one-way ANOVA on measured Asp data from T3 (day 62) 
Asp T3
One-way ANOVA
SS Degr. of MS F p
Intercept 13.88509 1 13.88509 510.6066 <0.001
Treatment 0.05937 4 0.01484 0.5458 0.703
Error 0.95177 35 0.02719  
 
Table XLVI: Test results from one-way ANOVA on measured Asp data from T4 (day 100) 
Asp T4
One-way ANOVA
SS Degr. of MS F p
Intercept 14.79142 1 14.79142 749.2163 <0.001
Treatment 0.09903 4 0.02476 1.2540 0.306
Error 0.69099 35 0.01974  
 
Table XLVII: Test results from one-way ANOVA on measured Hypro data from T3 (day 62) 
Hypro T3
One-way ANOVA
SS Degr. of MS F p
Intercept 7.965563 1 7.965563 79.04611 <0.001
Treatment 0.236277 4 0.059069 0.58617 0.675
Error 3.526988 35 0.100771  
 
Table XLVIII: Test results from one-way ANOVA on measured Hypro data from T4 (day 100) 
Hypro T4
One-way ANOVA
SS Degr. of MS F p
Intercept 18.35077 1 18.35077 244.4606 <0.001
Treatment 0.46530 4 0.11632 1.5496 0.209
Error 2.62732 35 0.07507  
 
Table XLIX: Test results from one-way ANOVA on measured Thr data from T3 (day 62) 
Thr T3
One-way ANOVA
SS Degr. of MS F p
Intercept 64.19889 1 64.19889 359.7979 <0.001
Treatment 0.87320 4 0.21830 1.2234 0.319
Error 6.24506 35 0.17843  
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Table L: Test results from one-way ANOVA on measured Thr data from T4 (day 100) 
Thr T4
One-way ANOVA
SS Degr. of MS F p
Intercept 109.4485 1 109.4485 954.9980 <0.001
Treatment 1.1689 4 0.2922 2.5498 0.056
Error 4.0112 35 0.1146  
 
Table LI: Test results from one-way ANOVA on measured Ser data from T3 (day 62) 
Ser T3
One-way ANOVA
SS Degr. of MS F p
Intercept 100.7682 1 100.7682 463.5998 <0.001
Treatment 1.9159 4 0.4790 2.2036 0.089
Error 7.6076 35 0.2174  
 
Table LII: Test results from one-way ANOVA on measured Ser data from T4 (day 100) 
Ser T4
One-way ANOVA
SS Degr. of MS F p
Intercept 46.52002 1 46.52002 670.0178 <0.001
Treatment 0.19750 4 0.04938 0.7112 0.590
Error 2.43009 35 0.06943  
 
Table LIII: Test results from one-way ANOVA on measured Asn data from T3 (day 62) 
Asn T3
One-way ANOVA
SS Degr. of MS F p
Intercept 15.80175 1 15.80175 74.12781 <0.001
Treatment 1.67823 4 0.41956 1.96819 0.121
Error 7.46091 35 0.21317  
 
Table LIV: Test results from one-way ANOVA on measured Asn data from T4 (day 100) 
Asn T4
One-way ANOVA
SS Degr. of MS F p
Intercept 35.29514 1 35.29514 94.51336 <0.001
Treatment 10.39468 4 2.59867 6.95872 <0.001
Error 13.07043 35 0.37344  
 
Table LV: Test results from one-way ANOVA on measured Glu data from T3 (day 62) 
Glu T3
One-way ANOVA
SS Degr. of MS F p
Intercept 18.18048 1 18.18048 981.1229 <0.001
Treatment 0.42648 4 0.10662 5.7538 0.001
Error 0.64856 35 0.01853  
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Table LVI: Test results from one-way ANOVA on measured Glu data from T4 (day 100) 
Glu T4
One-way ANOVA
SS Degr. of MS F p
Intercept 15.68381 1 15.68381 880.9492 <0.001
Treatment 0.28967 4 0.07242 4.0676 0.008
Error 0.62312 35 0.01780  
 
Table LVII: Test results from one-way ANOVA on measured Gln data from T3 (day 62) 
Gln T3
One-way ANOVA
SS Degr. of MS F p
Intercept 31.72317 1 31.72317 939.1252 <0.001
Treatment 0.70969 4 0.17742 5.2524 0.002
Error 1.18228 35 0.03378  
 
Table LVIII: Test results from one-way ANOVA on measured Gln data from T4 (day 100) 
Gln T4
One-way ANOVA
SS Degr. of MS F p
Intercept 35.14875 1 35.14875 743.3242 <0.001
Treatment 0.65429 4 0.16357 3.4592 0.018
Error 1.65501 35 0.04729  
 
Table LIX: Test results from one-way ANOVA on measured Sarc data from T3 (day 62) 
Sarc T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.042055 1 0.042055 227.9107 <0.001
Treatment 0.000857 4 0.000214 1.1616 0.344
Error 0.006458 35 0.000185  
 
Table LX: Test results from one-way ANOVA on measured Sarc data from T4 (day 100) 
Sarc T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.048764 1 0.048764 264.5185 <0.001
Treatment 0.000726 4 0.000181 0.9844 0.429
Error 0.006268 34 0.000184  
 
Table LXI: Test results from one-way ANOVA on measured Pro data from T3 (day 62) 
Pro T3
One-way ANOVA
SS Degr. of MS F p
Intercept 135.1298 1 135.1298 177.2607 <0.001
Treatment 11.0587 4 2.7647 3.6266 0.014
Error 26.6813 35 0.7623  
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Table LXII: Test results from one-way ANOVA on measured Pro data from T4 (day 100) 
Pro T4
One-way ANOVA
SS Degr. of MS F p
Intercept 135.1298 1 135.1298 177.2607 <0.001
Treatment 11.0587 4 2.7647 3.6266 0.014
Error 26.6813 35 0.7623  
 
Table LXIII: Test results from one-way ANOVA on measured Gly data from T3 (day 62) 
Gly T3
One-way ANOVA
SS Degr. of MS F p
Intercept 2112.691 1 2112.691 3967.977 <0.001
Treatment 4.583 4 1.146 2.152 0.095
Error 18.635 35 0.532  
 
Table LXIV: Test results from one-way ANOVA on measured Gly data from T4 (day 100) 
Gly T4
One-way ANOVA
SS Degr. of MS F p
Intercept 1407.486 1 1407.486 2396.511 <0.001
Treatment 0.200 4 0.050 0.085 0.987
Error 20.556 35 0.587  
 
Table LXV: Test results from one-way ANOVA on measured Ala data from T3 (day 62) 
Ala T3
One-way ANOVA
SS Degr. of MS F p
Intercept 746.1159 1 746.1159 1724.095 <0.001
Treatment 6.7262 4 1.6815 3.886 0.010
Error 15.1465 35 0.4328  
 
Table LXVI: Test results from one-way ANOVA on measured Ala data from T4 (day 100) 
Ala T4
One-way ANOVA
SS Degr. of MS F p
Intercept 583.9864 1 583.9864 2313.189 <0.001
Treatment 0.7902 4 0.1975 0.782 0.544
Error 8.8361 35 0.2525  
 
Table LXVII: Test results from one-way ANOVA on measured Citr data from T3 (day 62) 
Citr T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.251857 1 0.251857 57.03696 <0.001
Treatment 0.021428 4 0.005357 1.21320 0.323
Error 0.154549 35 0.004416  
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Table LXVIII: Test results from one-way ANOVA on measured Citr data from T4 (day 100) 
Citr T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.633026 1 0.633026 193.2047 <0.001
Treatment 0.026047 4 0.006512 1.9874 0.118
Error 0.114676 35 0.003276  
 
Table LXIX: Test results from one-way ANOVA on measured Aaba data from T3 (day 62) 
Aaba T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.132365 1 0.132365 349.1132 <0.001
Treatment 0.000516 4 0.000129 0.3401 0.849
Error 0.013270 35 0.000379  
 
Table LXX: Test results from one-way ANOVA on measured Aaba data from T4 (day 100) 
Aaba T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.180096 1 0.180096 619.8617 <0.001
Treatment 0.002971 4 0.000743 2.5561 0.056
Error 0.010169 35 0.000291  
 
Table LXXI: Test results from one-way ANOVA on measured Val data from T3 (day 62) 
Val T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.257282 1 0.257282 233.1339 <0.001
Treatment 0.002759 4 0.000690 0.6250 0.648
Error 0.038625 35 0.001104  
 
Table LXXII: Test results from one-way ANOVA on measured Val data from T4 (day 100) 
Val T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.111725 1 0.111725 383.2852 <0.001
Treatment 0.000741 4 0.000185 0.6354 0.641
Error 0.010202 35 0.000291  
 
Table LXXIII: Test results from one-way ANOVA on measured Met data from T3 (day 62) 
Met T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.084548 1 0.084548 243.6317 <0.001
Treatment 0.000441 4 0.000110 0.3176 0.864
Error 0.012146 35 0.000347  
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Table LXXIV: Test results from one-way ANOVA on measured Met data from T4 (day 100) 
Met T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.046104 1 0.046104 671.1629 <0.001
Treatment 0.000526 4 0.000131 1.9130 0.130
Error 0.002404 35 0.000069  
 
Table LXXV: Test results from one-way ANOVA on measured Cysth2 data from T3 (day 62) 
Cysth2 T3
One-way ANOVA
SS Degr. of MS F p
Intercept 26.78951 1 26.78951 166.1815 <0.001
Treatment 0.35475 4 0.08869 0.5502 0.700
Error 5.64222 35 0.16121  
 
Table LXXVI: Test results from one-way ANOVA on measured Cysth2 data from T4 (day 100) 
Cysth2 T4
One-way ANOVA
SS Degr. of MS F p
Intercept 24.70555 1 24.70555 750.8695 <0.001
Treatment 0.47360 4 0.11840 3.5985 0.015
Error 1.15159 35 0.03290  
 
Table LXXVII: Test results from one-way ANOVA on measured Ile data from T3 (day 62) 
Ile T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.097713 1 0.097713 228.2924 <0.001
Treatment 0.002701 4 0.000675 1.5777 0.202
Error 0.014981 35 0.000428  
 
Table LXXVIII: Test results from one-way ANOVA on measured Ile data from T4 (day 100) 
Ile T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.029322 1 0.029322 212.4634 <0.001
Treatment 0.000744 4 0.000186 1.3484 0.272
Error 0.004830 35 0.000138  
 
Table LXXIX: Test results from one-way ANOVA on measured Leu data from T3 (day 62) 
Leu T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.372683 1 0.372683 235.4002 <0.001
Treatment 0.011086 4 0.002772 1.7506 0.161
Error 0.055412 35 0.001583  
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Table LXXX: Test results from one-way ANOVA on measured Leu data from T4 (day 100) 
Leu T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.145926 1 0.145926 264.0144 <0.001
Treatment 0.003020 4 0.000755 1.3661 0.266
Error 0.019345 35 0.000553  
 
Table LXXXI: Test results from one-way ANOVA on measured Tyr data from T3 (day 62) 
Tyr T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.125776 1 0.125776 381.3506 <0.001
Treatment 0.003163 4 0.000791 2.3976 0.069
Error 0.011544 35 0.000330  
 
Table LXXXII: Test results from one-way ANOVA on measured Tyr data from T4 (day 100) 
Tyr T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.109830 1 0.109830 486.6674 <0.001
Treatment 0.000137 4 0.000034 0.1516 0.961
Error 0.007899 35 0.000226  
 
Table LXXXIII: Test results from one-way ANOVA on measured Phe data from T3 (day 62) 
Phe T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.053876 1 0.053876 395.4380 <0.001
Treatment 0.000664 4 0.000166 1.2182 0.321
Error 0.004769 35 0.000136  
 
Table LXXXIV: Test results from one-way ANOVA on measured Phe data from T4 (day 100) 
Phe T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.050980 1 0.050980 705.2514 <0.001
Treatment 0.000234 4 0.000059 0.8107 0.527
Error 0.002530 35 0.000072  
 
Table LXXXV: Test results from one-way ANOVA on measured Aaiba data from T4 (day 100) 
Aaiba T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.029322 1 0.029322 487.9776 <0.001
Treatment 0.001676 4 0.000419 6.9715 <0.001
Error 0.002103 35 0.000060  
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Table LXXXVI: Test results from one-way ANOVA on measured Aaiba data from T4 (day 100) 
Aaiba T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.078854 1 0.078854 1123.625 <0.001
Treatment 0.000503 4 0.000126 1.793 0.152
Error 0.002456 35 0.000070  
 
Table LXXXVII: Test results from one-way ANOVA on measured Ethanolamine data from T3 (day 62) 
Ethanolamine T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.022611 1 0.022611 205.9627 <0.001
Treatment 0.000810 4 0.000203 1.8446 0.153
Error 0.002635 24 0.000110  
 
Table LXXXVIII: Test results from one-way ANOVA on measured Amm data from T3 (day 62) 
Amm T3
One-way ANOVA
SS Degr. of MS F p
Intercept 614.4208 1 614.4208 7903.417 <0.001
Treatment 0.7834 4 0.1958 2.519 0.059
Error 2.7209 35 0.0777  
 
Table LXXXIX: Test results from one-way ANOVA on measured Amm data from T4 (day 100) 
Amm T4
One-way ANOVA
SS Degr. of MS F p
Intercept 465.8336 1 465.8336 7604.719 <0.001
Treatment 0.5984 4 0.1496 2.442 0.065
Error 2.1440 35 0.0613  
 
Table XC: Test results from one-way ANOVA on measured Hylys1 data from T3 (day 62) 
Hylys1 T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.094772 1 0.094772 136.0083 <0.001
Treatment 0.001300 4 0.000325 0.4664 0.760
Error 0.017420 25 0.000697  
 
Table XCI: Test results from one-way ANOVA on measured Hylys1 data from T4 (day 100) 
Hylys1 T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.606144 1 0.606144 302.0399 <0.001
Treatment 0.006554 4 0.001639 0.8165 0.523
Error 0.070239 35 0.002007  
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Table XCII: Test results from one-way ANOVA on measured Hylys2 data from T3 (day 62) 
Hylys2 T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.063341 1 0.063341 154.4727 <0.001
Treatment 0.001541 4 0.000385 0.9397 0.455
Error 0.011891 29 0.000410  
 
Table XCIII: Test results from one-way ANOVA on measured Hylys2 data from T4 (day 100) 
Hylys2 T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.033074 1 0.033074 259.1812 <0.001
Treatment 0.000201 4 0.000050 0.3936 0.812
Error 0.004466 35 0.000128  
 
Table XCIV: Test results from one-way ANOVA on measured Orn data from T3 (day 62) 
Orn T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.021344 1 0.021344 149.0754 <0.001
Treatment 0.001934 4 0.000484 3.3775 0.019
Error 0.005011 35 0.000143  
 
Table XCV: Test results from one-way ANOVA on measured Orn data from T4 (day 100) 
Orn T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.035046 1 0.035046 592.9300 <0.001
Treatment 0.001251 4 0.000313 5.2906 0.002
Error 0.002069 35 0.000059  
 
Table XCVI: Test results from one-way ANOVA on measured Lys data from T3 (day 62) 
Lys T3
One-way ANOVA
SS Degr. of MS F p
Intercept 13.62239 1 13.62239 479.0907 <0.001
Treatment 0.22374 4 0.05593 1.9672 0.121
Error 0.99518 35 0.02843  
 
Table XCVII: Test results from one-way ANOVA on measured Lys data from T4 (day 100) 
Lys T4
One-way ANOVA
SS Degr. of MS F p
Intercept 10.47655 1 10.47655 573.5021 <0.001
Treatment 0.05135 4 0.01284 0.7028 0.595
Error 0.63937 35 0.01827  
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Table XCVIII: Test results from one-way ANOVA on measured Muscle His data from T3 (day 62) 
Muscle His T3
One-way ANOVA
SS Degr. of MS F p
Intercept 60.31690 1 60.31690 158.8677 <0.001
Treatment 0.83607 4 0.20902 0.5505 0.700
Error 13.28836 35 0.37967  
 
Table XCIX: Test results from one-way ANOVA on measured Muscle His data from T4 (day 100) 
Muscle His T4
One-way ANOVA
SS Degr. of MS F p
Intercept 108.3068 1 108.3068 1759.993 <0.001
Treatment 0.2547 4 0.0637 1.035 0.403
Error 2.1538 35 0.0615  
 
Table C: Test results from one-way ANOVA on measured Ans data from T3 (day 62) 
Ans T3
One-way ANOVA
SS Degr. of MS F p
Intercept 21.60165 1 21.60165 1640.033 <0.001
Treatment 0.09574 4 0.02393 1.817 0.148
Error 0.46100 35 0.01317  
Table CI: Test results from one-way ANOVA on measured Ans data from T4 (day 100) 
Ans T4
One-way ANOVA
SS Degr. of MS F p
Intercept 30.56378 1 30.56378 4102.857 <0.001
Treatment 0.14615 4 0.03654 4.905 0.003
Error 0.26073 35 0.00745  
 
Table CII: Test results from one-way ANOVA on measured Arg data from T3 (day 62) 
Arg T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.581774 1 0.581774 320.8500 <0.001
Treatment 0.009409 4 0.002352 1.2972 0.290
Error 0.063463 35 0.001813  
 
Table CIII: Test results from one-way ANOVA on measured Arg data from T4 (day 100) 
Arg T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.824551 1 0.824551 271.7815 <0.001
Treatment 0.009806 4 0.002452 0.8081 0.528
Error 0.106186 35 0.003034  
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SS Degr. of MS F p
Intercept 84509.50 1 84509.50 5148.388 <0.001
Treatment 24.67 4 6.17 0.376 0.824
Error 574.52 35 16.41  
 




SS Degr. of MS F p
Intercept 84083.23 1 84083.23 9723.884 <0.001
Treatment 4.35 4 1.09 0.126 0.972
Error 302.65 35 8.65  
 
Table CVI: Test results from one-way ANOVA on measured Sampled Fish Weight (g) data from T3 (day 62) 
Sampled fish weight (g) T3
One-way ANOVA
SS Degr. of MS F p
Intercept 314849.5 1 314849.5 466.9436 <0.001
Treatment 2537.3 4 634.3 0.9408 0.452
Error 23599.7 35 674.3  
 
Table CVII: Test results from one-way ANOVA on measured Sampled Fish Weight (g) data from T4 (day 100) 
Sampled fish weight (g) T4
One-way ANOVA
SS Degr. of MS F p
Intercept 819390.6 1 819390.6 338.2744 <0.001
Treatment 2274.1 4 568.5 0.2347 0.917
Error 84779.3 35 2422.3  
 
Table CVIII : Test results from one-way ANOVA on measured Lens Weight (g) data from T3 (day 62) 
Lens weight (g) T3
One-way ANOVA
SS Degr. of MS F p
Intercept 0.085441 1 0.085441 1542.336 <0.001
Treatment 0.001024 4 0.000256 4.620 0.004
Error 0.001884 34 0.000055  
 
Table CIX : Test results from one-way ANOVA on measured Lens Weight (g) data from T4 (day 100) 
Lens weight (g) T4
One-way ANOVA
SS Degr. of MS F p
Intercept 0.154990 1 0.154990 2418.517 <0.001
Treatment 0.000026 4 0.000007 0.103 0.981
Error 0.002243 35 0.000064  
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Two-way Nested ANOVAs 
Table CX : Test results from two-way nested ANOVA on measured Weight data from T0 (day 0). Replicate was 
nested in treatment. 
Weight T0
Nested ANOVA 
SS Degr. of MS F p
Intercept 801664.0 1 801664.0 4611.648 <0.001
Treatment 772.7 4 193.2 1.111 0.351
Replicate(Treatment) 651.7 5 130.3 0.750 0.587
Error 50238.2 289 173.8  
 
Table CXI : Test results from two-way nested ANOVA on measured Weight data from T3 (day 62). Replicate 
was nested in treatment. 
Weight T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 1570721 1 1570721 2335.376 <0.001
Treatment 21443 4 5361 7.970 <0.001
Replicate(Treatment) 7132 5 1426 2.121 0.064
Error 164109 244 673  
 
Table CXII : Test results from two-way nested ANOVA on measured Weight data from T4 (day 100). Replicate 
was nested in treatment. 
Weight T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 3083466 1 3083466 1642.524 <0.001
Treatment 40332 4 10083 5.371 <0.001
Replicate(Treatment) 10494 5 2099 1.118 0.352
Error 399859 213 1877  
 
Table CXIII : Test results from two-way nested ANOVA on calculated SGR data from T0-T3 (day 0-62). 
Replicate was nested in treatment. 
SGR1 (T0-T3)
Nested ANOVA 
SS Degr. of MS F p
Intercept 88.13842 1 88.13842 730.8090 <0.001
Treatment 9.40153 4 2.35038 19.4884 <0.001
Replicate(Treatment) 2.26889 5 0.45378 3.7625 0.003
Error 29.42735 244 0.12060  
 
Table CXIV : Test results from two-way nested ANOVA on calculated SGR data from T3-T4 (day 62-100). 
Replicate was nested in treatment. 
SGR2 (T3-T4)
Nested ANOVA 
SS Degr. of MS F p
Intercept 170.9606 1 170.9606 778.0334 <0.001
Treatment 1.2426 4 0.3106 1.4137 0.230
Replicate(Treatment) 2.1767 5 0.4353 1.9813 0.083
Error 46.8034 213 0.2197  
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Table CXV : Test results from two-way nested ANOVA on calculated SGR data from T0-T4 (day 0-100). 
Replicate was nested in treatment. 
SGR Overall
Nested ANOVA 
SS Degr. of MS F p
Intercept 119.0980 1 119.0980 1289.242 <0.001
Treatment 3.5698 4 0.8924 9.661 <0.001
Replicate(Treatment) 0.4355 5 0.0871 0.943 0.454
Error 19.6766 213 0.0924  
 
Table CXVI : Test results from two-way nested ANOVA on measured Blood Na+ data from T3 (day 62). 





SS Degr. of MS F p
Intercept 1133669 1 1133669 75915.33 <0.001
Treatment 55 4 14 0.93 0.462
Replicate(Treatment) 148 5 30 1.98 0.111
Error 448 30 15  
 
Table CXVII : Test results from two-way nested ANOVA on measured Blood Na+ data from T4 (day 100). 





SS Degr. of MS F p
Intercept 1152263 1 1152263 76015.15 <0.001
Treatment 52 4 13 0.86 0.497
Replicate(Treatment) 163 5 33 2.15 0.087
Error 455 30 15  
 
Table CXVIII : Test results from two-way nested ANOVA on measured Blood K+ data from T3 (day 62). 





SS Degr. of MS F p
Intercept 2066.069 1 2066.069 451648.4 <0.001
Treatment 0.009 4 0.002 0.5 0.725
Replicate(Treatment) 0.043 5 0.009 1.9 0.125
Error 0.133 29 0.005  
 
Table CXIX : Test results from two-way nested ANOVA on measured Blood K+ data from T4 (day 100). 





SS Degr. of MS F p
Intercept 903.0542 1 903.0542 2408.145 <0.001
Treatment 7.5564 4 1.8891 5.038 0.003
Replicate(Treatment) 1.8523 5 0.3705 0.988 0.442
Error 10.8750 29 0.3750  
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Table CXX : Test results from two-way nested ANOVA on blood pH temperature corrected from T3 (day 62). 
Replicate was nested in treatment. 
Blood pHtp T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 2066.069 1 2066.069 451648.4 <0.001
Treatment 0.009 4 0.002 0.5 0.725
Replicate(Treatment) 0.043 5 0.009 1.9 0.125
Error 0.133 29 0.005  
 
Table CXXI : Test results from two-way nested ANOVA on blood pH temperature corrected from T4 (day 
100). Replicate was nested in treatment. 
Blood pHtp T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 2096.548 1 2096.548 694778.6 <0.001
Treatment 0.026 4 0.007 2.2 0.097
Replicate(Treatment) 0.016 5 0.003 1.1 0.391
Error 0.091 30 0.003  
 
Table CXXII : Test results from two-way nested ANOVA on blood pCO2 temperature corrected from T3 (day 
62). Replicate was nested in treatment. 
Blood pCO2 tp T3 
Nested ANOVA 
SS Degr. of MS F p
Intercept 1015.726 1 1015.726 2273.210 <0.001
Treatment 8.768 4 2.192 4.906 0.004
Replicate(Treatment) 0.516 5 0.103 0.231 0.946
Error 12.958 29 0.447  
 
Table CXXIII : Test results from two-way nested ANOVA on blood pCO2 temperature corrected from T4 (day 
100). Replicate was nested in treatment. 
Blood pCO2 tp T4 
Nested ANOVA 
SS Degr. of MS F p
Intercept 1408.850 1 1408.850 3343.542 <0.001
Treatment 7.108 4 1.777 4.217 0.008
Replicate(Treatment) 0.551 5 0.110 0.261 0.931
Error 12.641 30 0.421  
 
Table CXXIV : Test results from two-way nested ANOVA on measured HCO3
- data from T3 (day 62). 





SS Degr. of MS F p
Intercept 505.8668 1 505.8668 1342.804 <0.001
Treatment 3.4296 4 0.8574 2.276 0.085
Replicate(Treatment) 3.1896 5 0.6379 1.693 0.168
Error 10.9250 29 0.3767  
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Table CXXV : Test results from two-way nested ANOVA on measured HCO3
- data from T4 (day 100). 





SS Degr. of MS F p
Intercept 546.8602 1 546.8602 1290.018 <0.001
Treatment 0.3260 4 0.0815 0.192 0.941
Replicate(Treatment) 0.7062 5 0.1413 0.333 0.889
Error 12.7175 30 0.4239  
 
Table CXXVI : Test results from two-way nested ANOVA on measured Lens His data from T3 (day 62). 
Replicate was nested in treatment. 
Lens His T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 55.98297 1 55.98297 1976.219 <0.001
Treatment 1.40949 4 0.35237 12.439 <0.001
Replicate(Treatment) 0.01125 5 0.00225 0.079 0.995
Error 0.82152 29 0.02833  
 
Table CXXVII : Test results from two-way nested ANOVA on measured Lens His data from T4 (day 100). 
Replicate was nested in treatment. 
Lens His T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 58.83535 1 58.83535 3486.013 <0.001
Treatment 0.14426 4 0.03606 2.137 0.101
Replicate(Treatment) 0.48344 5 0.09669 5.729 0.001
Error 0.50633 30 0.01688  
 
Table CXXVIII : Test results from two-way nested ANOVA on measured NAH data from T3 (day 62). 
Replicate was nested in treatment. 
NAH T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 2716.164 1 2716.164 2805.171 <0.001
Treatment 28.019 4 7.005 7.234 <0.001
Replicate(Treatment) 3.306 5 0.661 0.683 0.640
Error 28.080 29 0.968  
 
Table CXXIX : Test results from two-way nested ANOVA on measured NAH data from T4 (day 100). 
Replicate was nested in treatment. 
NAH T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 3195.353 1 3195.353 1679.457 <0.001
Treatment 12.202 4 3.050 1.603 0.199
Replicate(Treatment) 20.404 5 4.081 2.145 0.087
Error 57.078 30 1.903  
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Table CXXX : Test results from two-way nested ANOVA on measured Phser data from T3 (day 62). Replicate 
was nested in treatment. 
Phser T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.006917 1 0.006917 301.8284 <0.001
Treatment 0.000040 4 0.000010 0.4402 0.779
Replicate(Treatment) 0.000051 5 0.000010 0.4473 0.812
Error 0.000688 30 0.000023  
 
Table CXXXI : Test results from two-way nested ANOVA on measured Phser data from T4 (day 100). 
Replicate was nested in treatment. 
Phser T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.006838 1 0.006838 912.7775 <0.001
Treatment 0.000002 4 0.000000 0.0634 0.992
Replicate(Treatment) 0.000138 5 0.000028 3.6874 0.010
Error 0.000225 30 0.000007  
 
Table CXXXII : Test results from two-way nested ANOVA on measured Tau data from T3 (day 62). Replicate 
was nested in treatment. 
Tau T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 5346.893 1 5346.893 686.7664 <0.001
Treatment 11.672 4 2.918 0.3748 0.825
Replicate(Treatment) 29.233 5 5.847 0.7510 0.592
Error 233.568 30 7.786  
 
Table CXXXIII : Test results from two-way nested ANOVA on measured Tau data from T4 (day 100). 
Replicate was nested in treatment. 
Tau T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 7108.836 1 7108.836 1938.166 <0.001
Treatment 17.034 4 4.259 1.161 0.348
Replicate(Treatment) 28.703 5 5.741 1.565 0.200
Error 110.034 30 3.668  
 
Table CXXXIV : Test results from two-way nested ANOVA on measured Pea data from T3 (day 62). Replicate 
was nested in treatment. 
Pea T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.248535 1 0.248535 1373.692 <0.001
Treatment 0.001040 4 0.000260 1.437 0.246
Replicate(Treatment) 0.001686 5 0.000337 1.864 0.130
Error 0.005428 30 0.000181  
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Table CXXXV : Test results from two-way nested ANOVA on measured Pea data from T4 (day 100). Replicate 
was nested in treatment. 
Pea T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.297218 1 0.297218 1105.652 <0.001
Treatment 0.001357 4 0.000339 1.262 0.307
Replicate(Treatment) 0.001927 5 0.000385 1.434 0.241
Error 0.008065 30 0.000269  
 
Table CXXXVI : Test results from two-way nested ANOVA on measured Urea data from T3 (day 62). 
Replicate was nested in treatment. 
Urea T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 2063.604 1 2063.604 1740.104 <0.001
Treatment 2.714 4 0.678 0.572 0.685
Replicate(Treatment) 12.682 5 2.536 2.139 0.088
Error 35.577 30 1.186  
 
Table CXXXVII : Test results from two-way nested ANOVA on measured Urea data from T4 (day 100). 
Replicate was nested in treatment. 
Urea T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 1536.323 1 1536.323 1616.785 <0.001
Treatment 10.473 4 2.618 2.755 0.046
Replicate(Treatment) 1.355 5 0.271 0.285 0.917
Error 28.507 30 0.950  
 
Table CXXXVIII : Test results from two-way nested ANOVA on measured Asp data from T3 (day 62). 
Replicate was nested in treatment. 
Asp T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 13.88509 1 13.88509 689.8779 <0.001
Treatment 0.05937 4 0.01484 0.7374 0.574
Replicate(Treatment) 0.34796 5 0.06959 3.4577 0.014
Error 0.60381 30 0.02013  
 
Table CXXXIX : Test results from two-way nested ANOVA on measured Asp data from T4 (day 100). 
Replicate was nested in treatment. 
Asp T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 14.79142 1 14.79142 803.5630 <0.001
Treatment 0.09903 4 0.02476 1.3449 0.276
Replicate(Treatment) 0.13877 5 0.02775 1.5078 0.217
Error 0.55222 30 0.01841  
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Table CXL : Test results from two-way nested ANOVA on measured Hypro data from T3 (day 62). Replicate 
was nested in treatment. 
Hypro T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 7.965563 1 7.965563 83.49775 <0.001
Treatment 0.236277 4 0.059069 0.61918 0.652
Replicate(Treatment) 0.665032 5 0.133006 1.39422 0.255
Error 2.861956 30 0.095399  
 
Table CXLI : Test results from two-way nested ANOVA on measured Hypro data from T4 (day 100). Replicate 
was nested in treatment. 
Hypro T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 18.35077 1 18.35077 259.0982 <0.001
Treatment 0.46530 4 0.11632 1.6424 0.189
Replicate(Treatment) 0.50256 5 0.10051 1.4191 0.246
Error 2.12477 30 0.07083  
 
Table CXLII : Test results from two-way nested ANOVA on measured Thr data from T3 (day 62). Replicate 
was nested in treatment. 
Thr T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 64.19889 1 64.19889 425.0631 <0.001
Treatment 0.87320 4 0.21830 1.4454 0.243
Replicate(Treatment) 1.71405 5 0.34281 2.2698 0.073
Error 4.53101 30 0.15103  
 
Table CXLIII : Test results from two-way nested ANOVA on measured Thr data from T4 (day 100). Replicate 
was nested in treatment. 
Thr T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 109.4485 1 109.4485 952.5573 <0.001
Treatment 1.1689 4 0.2922 2.5433 0.060
Replicate(Treatment) 0.5642 5 0.1128 0.9821 0.445
Error 3.4470 30 0.1149  
 
Table CXLIV : Test results from two-way nested ANOVA on measured Ser data from T3 (day 62). Replicate 
was nested in treatment. 
Ser T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 100.7682 1 100.7682 501.2716 <0.001
Treatment 1.9159 4 0.4790 2.3827 0.074
Replicate(Treatment) 1.5769 5 0.3154 1.5688 0.199
Error 6.0308 30 0.2010  
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Table CXLV : Test results from two-way nested ANOVA on measured Ser data from T4 (day 100). Replicate 
was nested in treatment. 
Ser T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 46.52002 1 46.52002 634.8569 <0.001
Treatment 0.19750 4 0.04938 0.6738 0.615
Replicate(Treatment) 0.23179 5 0.04636 0.6327 0.676
Error 2.19829 30 0.07328  
 
Table CXLVI : Test results from two-way nested ANOVA on measured Asn data from T3 (day 62). Replicate 
was nested in treatment. 
Asn T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 15.80175 1 15.80175 165.7214 <0.001
Treatment 1.67823 4 0.41956 4.4001 0.006
Replicate(Treatment) 4.60037 5 0.92007 9.6493 <0.001
Error 2.86054 30 0.09535  
 
Table CXLVII : Test results from two-way nested ANOVA on measured Asn data from T4 (day 100). 
Replicate was nested in treatment. 
Asn T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 35.29514 1 35.29514 109.1296 <0.001
Treatment 10.39468 4 2.59867 8.0349 <0.001
Replicate(Treatment) 3.36770 5 0.67354 2.0825 0.095
Error 9.70272 30 0.32342  
 
Table CXLVIII : Test results from two-way nested ANOVA on measured Glu data from T3 (day 62). Replicate 
was nested in treatment. 
Glu T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 18.18048 1 18.18048 1237.535 <0.001
Treatment 0.42648 4 0.10662 7.258 <0.001
Replicate(Treatment) 0.20783 5 0.04157 2.829 0.033
Error 0.44073 30 0.01469  
 
Table CXLIX : Test results from two-way nested ANOVA on measured Glu data from T4 (day 100). Replicate 
was nested in treatment. 
Glu T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 15.68381 1 15.68381 1123.983 <0.001
Treatment 0.28967 4 0.07242 5.190 0.003
Replicate(Treatment) 0.20450 5 0.04090 2.931 0.029
Error 0.41861 30 0.01395  
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Table CL : Test results from two-way nested ANOVA on measured Gln data from T3 (day 62). Replicate was 
nested in treatment. 
Gln T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 31.72317 1 31.72317 1202.116 <0.001
Treatment 0.70969 4 0.17742 6.723 0.001
Replicate(Treatment) 0.39060 5 0.07812 2.960 0.027
Error 0.79168 30 0.02639  
 
Table CLI : Test results from two-way nested ANOVA on measured Gln data from T4 (day 100). Replicate was 
nested in treatment. 
Gln T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 35.14875 1 35.14875 930.3993 <0.001
Treatment 0.65429 4 0.16357 4.3298 0.007
Replicate(Treatment) 0.52166 5 0.10433 2.7617 0.036
Error 1.13334 30 0.03778  
 
Table CLII : Test results from two-way nested ANOVA on measured Sarc data from T3 (day 62). Replicate 
was nested in treatment. 
Sarc T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.042055 1 0.042055 244.0460 <0.001
Treatment 0.000857 4 0.000214 1.2439 0.314
Replicate(Treatment) 0.001289 5 0.000258 1.4956 0.221
Error 0.005170 30 0.000172  
 
Table CLIII : Test results from two-way nested ANOVA on measured Sarc data from T4 (day 100). Replicate 
was nested in treatment. 
Sarc T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.048372 1 0.048372 228.4136 <0.001
Treatment 0.000734 4 0.000184 0.8668 0.496
Replicate(Treatment) 0.000126 5 0.000025 0.1193 0.987
Error 0.006142 29 0.000212  
 
Table CLIV : Test results from two-way nested ANOVA on measured Pro data from T3 (day 62). Replicate 
was nested in treatment. 
Pro T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 74.67649 1 74.67649 74.66790 <0.001
Treatment 3.04299 4 0.76075 0.76066 0.559
Replicate(Treatment) 6.59388 5 1.31878 1.31862 0.283
Error 30.00345 30 1.00012  
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Table CLV : Test results from two-way nested ANOVA on measured Pro data from T4 (day 100). Replicate 
was nested in treatment. 
Pro T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 135.1298 1 135.1298 240.2374 <0.001
Treatment 11.0587 4 2.7647 4.9151 0.004
Replicate(Treatment) 9.8067 5 1.9613 3.4869 0.013
Error 16.8745 30 0.5625  
 
Table CLVI : Test results from two-way nested ANOVA on measured Gly data from T3 (day 62). Replicate 
was nested in treatment. 
Gly T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 2112.691 1 2112.691 4199.269 <0.001
Treatment 4.583 4 1.146 2.277 0.084
Replicate(Treatment) 3.542 5 0.708 1.408 0.250
Error 15.093 30 0.503  
 
Table CLVII : Test results from two-way nested ANOVA on measured Gly data from T4 (day 100). Replicate 
was nested in treatment. 
Gly T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 1407.486 1 1407.486 2125.968 <0.001
Treatment 0.200 4 0.050 0.075 0.989
Replicate(Treatment) 0.694 5 0.139 0.210 0.956
Error 19.861 30 0.662  
 
Table CLVIII : Test results from two-way nested ANOVA on measured Ala data from T3 (day 62). Replicate 
was nested in treatment. 
Ala T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 746.1159 1 746.1159 1564.274 <0.001
Treatment 6.7262 4 1.6815 3.525 0.018
Replicate(Treatment) 0.8373 5 0.1675 0.351 0.877
Error 14.3092 30 0.4770  
 
Table CLIX : Test results from two-way nested ANOVA on measured Ala data from T4 (day 100). Replicate 
was nested in treatment. 
Ala T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 583.9864 1 583.9864 2143.122 <0.001
Treatment 0.7902 4 0.1975 0.725 0.582
Replicate(Treatment) 0.6613 5 0.1323 0.485 0.784
Error 8.1748 30 0.2725  
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Table CLX : Test results from two-way nested ANOVA on measured Citr data from T3 (day 62). Replicate was 
nested in treatment. 
Citr T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.251857 1 0.251857 60.61222 <0.001
Treatment 0.021428 4 0.005357 1.28924 0.296
Replicate(Treatment) 0.029892 5 0.005978 1.43878 0.239
Error 0.124657 30 0.004155  
 
Table CLXI : Test results from two-way nested ANOVA on measured Citr data from T4 (day 100). Replicate 
was nested in treatment. 
Citr T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.633026 1 0.633026 199.3290 <0.001
Treatment 0.026047 4 0.006512 2.0504 0.112
Replicate(Treatment) 0.019402 5 0.003880 1.2219 0.323
Error 0.095274 30 0.003176  
 
Table CLXII : Test results from two-way nested ANOVA on measured Aaba data from T3 (day 62). Replicate 
was nested in treatment. 
Aaba T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.132365 1 0.132365 380.9705 <0.001
Treatment 0.000516 4 0.000129 0.3712 0.827
Replicate(Treatment) 0.002847 5 0.000569 1.6388 0.180
Error 0.010423 30 0.000347  
 
Table CLXIII : Test results from two-way nested ANOVA on measured Aaba data from T4 (day 100). 
Replicate was nested in treatment. 
Aaba T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.180096 1 0.180096 725.8049 <0.001
Treatment 0.002971 4 0.000743 2.9929 0.034
Replicate(Treatment) 0.002725 5 0.000545 2.1964 0.081
Error 0.007444 30 0.000248  
 
Table CLXIV : Test results from two-way nested ANOVA on measured Val data from T3 (day 62). Replicate 
was nested in treatment. 
Val T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.257282 1 0.257282 253.0929 <0.001
Treatment 0.002759 4 0.000690 0.6786 0.612
Replicate(Treatment) 0.008129 5 0.001626 1.5993 0.191
Error 0.030497 30 0.001017  
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Table CLXV : Test results from two-way nested ANOVA on measured Val data from T4 (day 100). Replicate 
was nested in treatment. 
Val T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.111725 1 0.111725 493.3756 <0.001
Treatment 0.000741 4 0.000185 0.8179 0.524
Replicate(Treatment) 0.003409 5 0.000682 3.0106 0.026
Error 0.006794 30 0.000226  
 
Table CLXVI : Test results from two-way nested ANOVA on measured Met data from T3 (day 62). Replicate 
was nested in treatment. 
Met T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.084548 1 0.084548 279.6594 <0.001
Treatment 0.000441 4 0.000110 0.3645 0.832
Replicate(Treatment) 0.003076 5 0.000615 2.0351 0.102
Error 0.009070 30 0.000302  
 
Table CLXVII : Test results from two-way nested ANOVA on measured Met data from T4 (day 100). 
Replicate was nested in treatment. 
Met T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.046104 1 0.046104 744.0145 <0.001
Treatment 0.000526 4 0.000131 2.1207 0.103
Replicate(Treatment) 0.000545 5 0.000109 1.7598 0.152
Error 0.001859 30 0.000062  
 
Table CLXVIII : Test results from two-way nested ANOVA on measured Cysth2 data from T3 (day 62). 
Replicate was nested in treatment. 
Cysth2 T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 26.78951 1 26.78951 171.3955 <0.001
Treatment 0.35475 4 0.08869 0.5674 0.688
Replicate(Treatment) 0.95315 5 0.19063 1.2196 0.324
Error 4.68907 30 0.15630  
 
Table CLXIX : Test results from two-way nested ANOVA on measured Cysth2 data from T4 (day 100). 
Replicate was nested in treatment. 
Cysth2 T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 24.70555 1 24.70555 786.5330 <0.001
Treatment 0.47360 4 0.11840 3.7694 0.013
Replicate(Treatment) 0.20927 5 0.04185 1.3325 0.277
Error 0.94232 30 0.03141  
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Table CLXX : Test results from two-way nested ANOVA on measured Ile data from T3 (day 62). Replicate was 
nested in treatment. 
Ile T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.097713 1 0.097713 243.9223 <0.001
Treatment 0.002701 4 0.000675 1.6857 0.179
Replicate(Treatment) 0.002963 5 0.000593 1.4792 0.226
Error 0.012018 30 0.000401  
 
Table CLXXI : Test results from two-way nested ANOVA on measured Ile data from T4 (day 100). Replicate 
was nested in treatment. 
Ile T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.029322 1 0.029322 281.2009 <0.001
Treatment 0.000744 4 0.000186 1.7847 0.158
Replicate(Treatment) 0.001702 5 0.000340 3.2647 0.018
Error 0.003128 30 0.000104  
 
Table CLXXII : Test results from two-way nested ANOVA on measured Leu data from T3 (day 62). Replicate 
was nested in treatment. 
Leu T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.372683 1 0.372683 243.3623 <0.001
Treatment 0.011086 4 0.002772 1.8098 0.153
Replicate(Treatment) 0.009470 5 0.001894 1.2368 0.317
Error 0.045942 30 0.001531  
 
Table CLXXIII : Test results from two-way nested ANOVA on measured Leu data from T4 (day 100). 
Replicate was nested in treatment. 
Leu T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.145926 1 0.145926 302.2085 <0.001
Treatment 0.003020 4 0.000755 1.5638 0.209
Replicate(Treatment) 0.004859 5 0.000972 2.0127 0.105
Error 0.014486 30 0.000483  
 
Table CLXXIV : Test results from two-way nested ANOVA on measured Tyr data from T3 (day 62). Replicate 
was nested in treatment. 
Tyr T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.125776 1 0.125776 462.6536 <0.001
Treatment 0.003163 4 0.000791 2.9088 0.038
Replicate(Treatment) 0.003388 5 0.000678 2.4924 0.053
Error 0.008156 30 0.000272  
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Table CLXXV : Test results from two-way nested ANOVA on measured Tyr data from T4 (day 100). Replicate 
was nested in treatment. 
Tyr T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.109830 1 0.109830 546.5105 <0.001
Treatment 0.000137 4 0.000034 0.1702 0.952
Replicate(Treatment) 0.001870 5 0.000374 1.8608 0.131
Error 0.006029 30 0.000201  
 
Table CLXXVI : Test results from two-way nested ANOVA on measured Phe data from T3 (day 62). Replicate 
was nested in treatment. 
Phe T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.053876 1 0.053876 445.2529 <0.001
Treatment 0.000664 4 0.000166 1.3717 0.267
Replicate(Treatment) 0.001139 5 0.000228 1.8818 0.127
Error 0.003630 30 0.000121  
 
Table CLXXVII : Test results from two-way nested ANOVA on measured Phe data from T4 (day 100). 
Replicate was nested in treatment. 
Phe T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.050980 1 0.050980 681.5455 <0.001
Treatment 0.000234 4 0.000059 0.7834 0.545
Replicate(Treatment) 0.000286 5 0.000057 0.7647 0.582
Error 0.002244 30 0.000075  
 
Table CLXXVIII : Test results from two-way nested ANOVA on measured Aaiba data from T3 (day 62). 
Replicate was nested in treatment. 
Aaiba T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.029322 1 0.029322 554.9073 <0.001
Treatment 0.001676 4 0.000419 7.9277 <0.001
Replicate(Treatment) 0.000518 5 0.000104 1.9601 0.114
Error 0.001585 30 0.000053  
 
Table CLXXIX : Test results from two-way nested ANOVA on measured Aaiba data from T4 (day 100). 
Replicate was nested in treatment. 
Aaiba T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.078854 1 0.078854 1137.323 <0.001
Treatment 0.000503 4 0.000126 1.815 0.152
Replicate(Treatment) 0.000376 5 0.000075 1.085 0.389
Error 0.002080 30 0.000069  
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Table CLXXX : Test results from two-way nested ANOVA on measured Ethanolamine data from T3 (day 62). 
Replicate was nested in treatment. 
Ethanolamine T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.020319 1 0.020319 194.9596 <0.001
Treatment 0.000656 4 0.000164 1.5742 0.222
Replicate(Treatment) 0.000655 5 0.000131 1.2562 0.323
Error 0.001980 19 0.000104  
 
Table CLXXXI : Test results from two-way nested ANOVA on measured Amm data from T3 (day 62). 
Replicate was nested in treatment. 
Amm T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 614.4208 1 614.4208 10048.28 <0.001
Treatment 0.7834 4 0.1958 3.20 0.026
Replicate(Treatment) 0.8865 5 0.1773 2.90 0.030
Error 1.8344 30 0.0611  
 
Table CLXXXII : Test results from two-way nested ANOVA on measured Amm data from T4 (day 100). 
Replicate was nested in treatment. 
Amm T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 465.8336 1 465.8336 10073.28 <0.001
Treatment 0.5984 4 0.1496 3.23 0.025
Replicate(Treatment) 0.7566 5 0.1513 3.27 0.018
Error 1.3873 30 0.0462  
 
Table CLXXXIII : Test results from two-way nested ANOVA on measured Hylys1 data from T3 (day 62). 
Replicate was nested in treatment. 
Hylys1 T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.076767 1 0.076767 150.0595 <0.001
Treatment 0.001308 4 0.000327 0.6393 0.641
Replicate(Treatment) 0.007189 5 0.001438 2.8104 0.044
Error 0.010232 20 0.000512  
 
Table CLXXXIV : Test results from two-way nested ANOVA on measured Hylys1 data from T4 (day 100). 
Replicate was nested in treatment. 
Hylys1 T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.606144 1 0.606144 295.2457 <0.001
Treatment 0.006554 4 0.001639 0.7981 0.536
Replicate(Treatment) 0.008649 5 0.001730 0.8425 0.530
Error 0.061591 30 0.002053  
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Table CLXXXV : Test results from two-way nested ANOVA on measured Hylys2 data from T3 (day 62). 
Replicate was nested in treatment. 
Hylys2 T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.059272 1 0.059272 148.8033 <0.001
Treatment 0.001498 4 0.000375 0.9405 0.458
Replicate(Treatment) 0.002332 5 0.000466 1.1707 0.352
Error 0.009560 24 0.000398  
 
Table CLXXXVI : Test results from two-way nested ANOVA on measured Hylys2 data from T4 (day 100). 
Replicate was nested in treatment. 
Hylys2 T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.033074 1 0.033074 243.7749 <0.001
Treatment 0.000201 4 0.000050 0.3702 0.828
Replicate(Treatment) 0.000396 5 0.000079 0.5839 0.712
Error 0.004070 30 0.000136  
 
Table CLXXXVII : Test results from two-way nested ANOVA on measured Orn data from T3 (day 62). 
Replicate was nested in treatment. 
Orn T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.021344 1 0.021344 181.9383 <0.001
Treatment 0.001934 4 0.000484 4.1221 0.009
Replicate(Treatment) 0.001492 5 0.000298 2.5431 0.049
Error 0.003520 30 0.000117  
 
Table CLXXXVIII : Test results from two-way nested ANOVA on measured Orn data from T4 (day 100). 
Replicate was nested in treatment. 
Orn T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.035046 1 0.035046 578.8010 <0.001
Treatment 0.001251 4 0.000313 5.1645 0.003
Replicate(Treatment) 0.000252 5 0.000050 0.8332 0.536
Error 0.001817 30 0.000061  
 
Table CLXXXIX : Test results from two-way nested ANOVA on measured Lys data from T3 (day 62). 
Replicate was nested in treatment. 
Lys T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 13.62239 1 13.62239 429.7432 <0.001
Treatment 0.22374 4 0.05593 1.7645 0.162
Replicate(Treatment) 0.04422 5 0.00884 0.2790 0.921
Error 0.95097 30 0.03170  
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Table CXC : Test results from two-way nested ANOVA on measured Lys data from T4 (day 100). Replicate 
was nested in treatment. 
Lys T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 10.47655 1 10.47655 548.0017 <0.001
Treatment 0.05135 4 0.01284 0.6715 0.617
Replicate(Treatment) 0.06584 5 0.01317 0.6887 0.636
Error 0.57353 30 0.01912  
 
Table CXCI : Test results from two-way nested ANOVA on measured Muscle His data from T3 (day 62). 
Replicate was nested in treatment. 
Muscle His T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 60.31690 1 60.31690 193.7861 <0.001
Treatment 0.83607 4 0.20902 0.6715 0.617
Replicate(Treatment) 3.95071 5 0.79014 2.5386 0.050
Error 9.33765 30 0.31126  
 
Table CXCII : Test results from two-way nested ANOVA on measured Muscle His data from T4 (day 100). 
Replicate was nested in treatment. 
Muscle His T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 108.3068 1 108.3068 1899.081 <0.001
Treatment 0.2547 4 0.0637 1.116 0.367
Replicate(Treatment) 0.4429 5 0.0886 1.553 0.203
Error 1.7109 30 0.0570  
 
Table CXCIII : Test results from two-way nested ANOVA on measured Ans data from T3 (day 62). Replicate 
was nested in treatment. 
Ans T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 21.60165 1 21.60165 1635.575 <0.001
Treatment 0.09574 4 0.02393 1.812 0.153
Replicate(Treatment) 0.06478 5 0.01296 0.981 0.445
Error 0.39622 30 0.01321  
 
Table CXCIV : Test results from two-way nested ANOVA on measured Ans data from T4 (day 100). Replicate 
was nested in treatment. 
Ans T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 30.56378 1 30.56378 5467.720 <0.001
Treatment 0.14615 4 0.03654 6.536 0.001
Replicate(Treatment) 0.09303 5 0.01861 3.329 0.016
Error 0.16770 30 0.00559  
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Table CXCV : Test results from two-way nested ANOVA on measured Arg data from T3 (day 62). Replicate 
was nested in treatment. 
Arg T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.581774 1 0.581774 305.7572 <0.001
Treatment 0.009409 4 0.002352 1.2362 0.317
Replicate(Treatment) 0.006381 5 0.001276 0.6707 0.649
Error 0.057082 30 0.001903  
 
Table CXCVI : Test results from two-way nested ANOVA on measured Arg data from T4 (day 100). Replicate 
was nested in treatment. 
Arg T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 0.824551 1 0.824551 258.6658 <0.001
Treatment 0.009806 4 0.002452 0.7691 0.554
Replicate(Treatment) 0.010554 5 0.002111 0.6622 0.655
Error 0.095631 30 0.003188  
 
Table CXCVII : Test results from two-way nested ANOVA on measured SUM free amino acids (FAA) data 
from T3 (day 62). Replicate was nested in treatment. 
SUM FAA T3
Nested ANOVA 
SS Degr. of MS F p
Intercept 84509.50 1 84509.50 4974.870 <0.001
Treatment 24.67 4 6.17 0.363 0.833
Replicate(Treatment) 64.90 5 12.98 0.764 0.583
Error 509.62 30 16.99  
 
Table CXCVIII : Test results from two-way nested ANOVA on measured SUM free amino acids (FAA) data 
from T4 (day 100). Replicate was nested in treatment. 
SUM FAA T4
Nested ANOVA 
SS Degr. of MS F p
Intercept 84083.23 1 84083.23 10717.74 <0.001
Treatment 4.35 4 1.09 0.14 0.967
Replicate(Treatment) 67.29 5 13.46 1.72 0.161
Error 235.36 30 7.85  
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Two-way crossed ANCOVA 
Table CXCIX : : Test results from two-way crossed ANCOVA on measured Blood Na+ data from T3 (day 62). 





SS Degr. of MS F p
Intercept 56203.69 1 56203.69 3708.251 <0.001
W (g) 8.46 1 8.46 0.558 0.461
Treatment 62.64 4 15.66 1.033 0.407
Replicate 88.05 1 88.05 5.810 0.023
Treatment*Replicate 41.88 4 10.47 0.691 0.604
Error 439.54 29 15.16  
 
Table CC : Test results from two-way crossed ANCOVA on measured Blood Na+ data from T4 (day 100). 





SS Degr. of MS F p
Intercept 80532.20 1 80532.20 5256.612 <0.001
W (g) 10.46 1 10.46 0.683 0.415
Treatment 53.53 4 13.38 0.873 0.492
Replicate 33.02 1 33.02 2.156 0.153
Treatment*Replicate 104.45 4 26.11 1.704 0.176
Error 444.29 29 15.32  
 
Table CCI : Test results from two-way crossed ANCOVA on measured Blood K+ data from T3 (day 62). 





SS Degr. of MS F p
Intercept 33.23574 1 33.23574 213.8201 <0.001
W (g) 0.06691 1 0.06691 0.4304 0.517
Treatment 0.19953 4 0.04988 0.3209 0.862
Replicate 0.21461 1 0.21461 1.3807 0.250
Treatment*Replicate 0.24157 4 0.06039 0.3885 0.815
Error 4.35226 28 0.15544  
 
Table CCII : Test results from two-way crossed ANCOVA on measured Blood K+ data from T4 (day 100). 





SS Degr. of MS F p
Intercept 78.44827 1 78.44827 214.6431 <0.001
0.64149 1 0.64149 1.7552 0.196
Treatment 7.49989 4 1.87497 5.1301 0.003
Replicate 0.32634 1 0.32634 0.8929 0.353
Treatment*Replicate 1.43205 4 0.35801 0.9796 0.435
Error 10.23351 28 0.36548  
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Table CCIII : Test results from two-way crossed ANCOVA on measured Blood pH temperature corrected data 
from T3 (day 62). Weight was included as a co-varying factor. 
Blood pHtp T3
Two-way crossed ANCOVA
SS Degr. of MS F p
Intercept 100.6086 1 100.6086 24286.34 <0.001
W (g) 0.0167 1 0.0167 4.02 0.055
Treatment 0.0118 4 0.0030 0.71 0.590
Replicate 0.0200 1 0.0200 4.82 0.037
Treatment*Replicate 0.0142 4 0.0036 0.86 0.502
Error 0.1160 28 0.0041  
 
Table CCIV : Test results from two-way crossed ANCOVA on measured Blood pH temperature corrected data 
from T4 (day 100). Weight was included as a co-varying factor. 
Blood pHtp T4
Two-way crossed ANCOVA
SS Degr. of MS F p
Intercept 152.2478 1 152.2478 55507.39 <0.001
W (g) 0.0110 1 0.0110 4.00 0.055
Treatment 0.0269 4 0.0067 2.45 0.069
Replicate 0.0009 1 0.0009 0.33 0.572
Treatment*Replicate 0.0149 4 0.0037 1.36 0.273
Error 0.0795 29 0.0027  
 
Table CCV : Test results from two-way crossed ANCOVA on measured Blood pCO2 temperature corrected 
data from T3 (day 62). Weight was included as a co-varying factor. 
Blood pCO2 tp T3 
Two-way crossed ANCOVA
SS Degr. of MS F p
Intercept 41.76044 1 41.76044 91.97107 <0.001
W (g) 0.24421 1 0.24421 0.53784 0.469
Treatment 8.22666 4 2.05667 4.52950 0.006
Replicate 0.01062 1 0.01062 0.02340 0.880
Treatment*Replicate 0.69246 4 0.17312 0.38126 0.820
Error 12.71370 28 0.45406  
 
Table CCVI : Test results from two-way crossed ANCOVA on measured Blood pCO2 temperature corrected 
data from T4 (day 100). Weight was included as a co-varying factor. 
Blood pCO2 tp T4 
Two-way crossed ANCOVA
SS Degr. of MS F p
Intercept 113.6737 1 113.6737 269.9038 <0.001
W (g) 0.4272 1 0.4272 1.0143 0.322
Treatment 7.0665 4 1.7666 4.1946 0.008
Replicate 0.0214 1 0.0214 0.0508 0.823
Treatment*Replicate 0.3871 4 0.0968 0.2298 0.919
Error 12.2137 29 0.4212  
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Table CCVII : Test results from two-way crossed ANCOVA on measured HCO3
- data from T3 (day 62). 





SS Degr. of MS F p
Intercept 30.23268 1 30.23268 80.23742 <0.001
W (g) 0.37487 1 0.37487 0.99491 0.327
Treatment 3.73905 4 0.93476 2.48086 0.067
Replicate 1.41547 1 1.41547 3.75666 0.063
Treatment*Replicate 1.33414 4 0.33354 0.88520 0.486
Error 10.55013 28 0.37679  
 
Table CCVIII : Test results from two-way crossed ANCOVA on measured HCO3
- data from T4 (day 100). 





SS Degr. of MS F p
Intercept 54.99264 1 54.99264 141.7018 <0.001
W (g) 1.46297 1 1.46297 3.7697 0.062
Treatment 0.34268 4 0.08567 0.2208 0.925
Replicate 0.18412 1 0.18412 0.4744 0.496
Treatment*Replicate 0.33855 4 0.08464 0.2181 0.926
Error 11.25453 29 0.38809  
 
9.4 Student-Newman-Keuls test 
Table CCIX : p-values from SNK test, testing for differences in Weight at T0 (day 0) between treatments. 
 Weight T0
Treatment {1} {2} {3} {4} {5}
54.108 49.127 52.067 52.190 51.397
1 Control 0.233 0.673 0.425 0.673
2 ChronicLow 0.233 0.440 0.580 0.345
3 ChronicMedium 0.673 0.440 0.959 0.781
4 ChronicHigh 0.425 0.580 0.959 0.942
5 HighPulse 0.673 0.345 0.781 0.942  
 
Table CCX : p-values from SNK test, testing for differences in Weight at T3 (day 62) between treatments. 
 Weight T3
Treatment {1} {2} {3} {4} {5}
89.575 80.020 73.559 65.883 88.506
1 Control 0.160 0.012 <.0.001 0.838
2 ChronicLow 0.160 0.216 0.019 0.104
3 ChronicMedium 0.012 0.216 0.142 0.012
4 ChronicHigh <.0.001 0.019 0.142 <.0.001





Table CCXI : p-values from SNK test, testing for differences in Weight at T4 (day 100) between treatments. 
Weight T4
Treatment {1} {2} {3} {4} {5}
138.41 120.69 109.53 100.04 128.10
1 Control 0.133 0.010 <.0.001 0.264
2 ChronicLow 0.133 0.227 0.065 0.423
3 ChronicMedium 0.010 0.227 0.304 0.110
4 ChronicHigh <.0.001 0.065 0.304 0.013
5 HighPulse 0.264 0.423 0.110 0.013  
 
Table CCXII : p-values from SNK test, testing for differences in SGR at T0-T3 (day 0-62) between treatments. 
SGR1 (T0-T3)
Treatment {1} {2} {3} {4} {5}
.74735 .67575 .47022 .28347 .79259
1 Control 0.313 <0.001 <0.001 0.524
2 ChronicLow 0.313 0.004 <0.001 0.227
3 ChronicMedium <0.001 0.004 0.009 <0.001
4 ChronicHigh <0.001 <0.001 0.009 <0.001
5 HighPulse 0.524 0.227 <0.001 <0.001  
 
Table CCXIII : p-values from SNK test, testing for differences in SGR at T3-T4 (day 62-100) between 
treatments. 
SGR2 (T3-T4)
Treatment {1} {2} {3} {4} {5}
.99702 .92877 .80871 .80067 .89364
1 Control 0.499 0.243 0.293 0.561
2 ChronicLow 0.499 0.459 0.582 0.728
3 ChronicMedium 0.243 0.459 0.937 0.400
4 ChronicHigh 0.293 0.582 0.937 0.627
5 HighPulse 0.561 0.728 0.400 0.627  
 
Table CCXIV : p-values from SNK test, testing for differences in SGR at T0-T4 (day 0-100) between 
treatments. 
SGR Overall
Treatment {1} {2} {3} {4} {5}
.87440 .80007 .65009 .53513 .84580
1 Control 0.483 0.003 0.000 0.658
2 ChronicLow 0.483 0.020 0.000 0.479
3 ChronicMedium 0.003 0.020 0.075 0.007
4 ChronicHigh <0.001 <0.001 0.075 <0.001
5 HighPulse 0.658 0.479 0.007 <0.001  
 
 111 




Treatment {1} {2} {3} {4} {5}
167.88 170.38 168.50 168.25 166.75
1 Control 0.624 0.951 0.857 0.589
2 ChronicLow 0.624 0.370 0.563 0.414
3 ChronicMedium 0.951 0.370 0.904 0.831
4 ChronicHigh 0.857 0.563 0.904 0.749
5 HighPulse 0.589 0.414 0.831 0.749  
 





Treatment {1} {2} {3} {4} {5}
170.38 171.38 168.38 170.00 168.50
1 Control 0.637 0.777 0.859 0.649
2 ChronicLow 0.637 0.614 0.791 0.527
3 ChronicMedium 0.777 0.614 0.722 0.953
4 ChronicHigh 0.859 0.791 0.722 0.480
5 HighPulse 0.649 0.527 0.953 0.480  
 




Treatment {1} {2} {3} {4} {5}
4.2571 4.3125 4.1875 4.4000 4.3250
1 Control 0.778 0.723 0.883 0.936
2 ChronicLow 0.778 0.799 0.895 0.949
3 ChronicMedium 0.723 0.799 0.811 0.894
4 ChronicHigh 0.883 0.895 0.811 0.703
5 HighPulse 0.936 0.949 0.894 0.703  
 





Treatment {1} {2} {3} {4} {5}
4.8250 5.6500 4.5125 4.7143 4.4250
1 Control 0.012 0.578 0.724 0.576
2 ChronicLow 0.012 0.005 0.013 0.003
3 ChronicMedium 0.578 0.005 0.520 0.780
4 ChronicHigh 0.724 0.013 0.520 0.624





Table CCXIX : p-values from SNK test, testing for differences in Blood pH temperature corrected at T3 (day 
62) between treatments. 
Blood pHtp T3
Treatment {1} {2} {3} {4} {5}
7.3054 7.2934 7.2936 7.3337 7.3109
1 Control 0.942 0.749 0.720 0.881
2 ChronicLow 0.942 0.994 0.802 0.963
3 ChronicMedium 0.749 0.994 0.693 0.884
4 ChronicHigh 0.720 0.802 0.693 0.536
5 HighPulse 0.881 0.963 0.884 0.536  
 
Table CCXX : p-values from SNK test, testing for differences in Blood pH temperature corrected at T4 (day 
100) between treatments. 
Blood pHtp T4
Treatment {1} {2} {3} {4} {5}
7.2451 7.1977 7.2259 7.2673 7.2625
1 Control 0.214 0.492 0.703 0.532
2 ChronicLow 0.214 0.315 0.109 0.107
3 ChronicMedium 0.492 0.315 0.449 0.391
4 ChronicHigh 0.703 0.109 0.449 0.863
5 HighPulse 0.532 0.107 0.391 0.863  
 
Table CCXXI : p-values from SNK test, testing for differences in Blood pCO2 temperature corrected at T3 (day 
62) between treatments. 
Blood pCO2 tp T3 
Treatment {1} {2} {3} {4} {5}
5.7853 5.2464 4.9240 4.3336 5.3176
1 Control 0.224 0.050 0.001 0.152
2 ChronicLow 0.224 0.320 0.019 0.825
3 ChronicMedium 0.050 0.320 0.073 0.442
4 ChronicHigh 0.001 0.019 0.073 0.020
5 HighPulse 0.152 0.825 0.442 0.020  
 
Table CCXXII : p-values from SNK test, testing for differences in Blood pCO2 temperature corrected at T4 
(day 100) between treatments. 
Blood pCO2 tp T4 
Treatment {1} {2} {3} {4} {5}
5.6735 6.6658 6.1508 5.5479 5.6358
1 Control 0.007 0.129 0.912 0.903
2 ChronicLow 0.007 0.102 0.007 0.010
3 ChronicMedium 0.129 0.102 0.221 0.228
4 ChronicHigh 0.912 0.007 0.221 0.776




Table CCXXIII : p-values from SNK test, testing for differences in HCO3




Treatment {1} {2} {3} {4} {5}
4.1429 3.6125 3.4000 3.2000 3.7875
1 Control 0.250 0.125 0.049 0.285
2 ChronicLow 0.250 0.520 0.426 0.596
3 ChronicMedium 0.125 0.520 0.545 0.470
4 ChronicHigh 0.049 0.426 0.545 0.292
5 HighPulse 0.285 0.596 0.470 0.292  
 
Table CCXXIV : p-values from SNK test, testing for differences in HCO3




Treatment {1} {2} {3} {4} {5}
3.5625 3.8375 3.7375 3.6625 3.6875
1 Control 0.899 0.942 0.749 0.914
2 ChronicLow 0.899 0.749 0.942 0.879
3 ChronicMedium 0.942 0.749 0.968 0.873
4 ChronicHigh 0.749 0.942 0.968 0.936
5 HighPulse 0.914 0.879 0.873 0.936  
 
Table CCXXV : p-values from SNK test, testing for differences in Lens His at T3 (day 62) between treatments. 
Lens His T3
Treatment {1} {2} {3} {4} {5}
1.2734 .95062 1.0165 1.3263 1.4439
1 Control 0.001 0.003 0.510 0.095
2 ChronicLow 0.001 0.412 <0.001 <0.001
3 ChronicMedium 0.003 0.412 0.001 <0.001
4 ChronicHigh 0.510 <0.001 0.001 0.148
5 HighPulse 0.095 <0.001 <0.001 0.148  
 
Table CCXXVI : p-values from SNK test, testing for differences in Lens His at T4 (day 100) between 
treatments. 
Lens His T4
Treatment {1} {2} {3} {4} {5}
1.2888 1.1251 1.1731 1.2095 1.2675
1 Control 0.313 0.523 0.618 0.802
2 ChronicLow 0.313 0.572 0.580 0.342
3 ChronicMedium 0.523 0.572 0.668 0.507
4 ChronicHigh 0.618 0.580 0.668 0.495





Table CCXXVII : p-values from SNK test, testing for differences in Lens NAH at T3 (day 62) between 
treatments. 
Lens NAH T3
Treatment {1} {2} {3} {4} {5}
9.2829 7.2959 7.6513 8.2454 9.4534
1 Control 0.002 0.006 0.041 0.729
2 ChronicLow 0.002 0.471 0.141 0.001
3 ChronicMedium 0.006 0.471 0.231 0.004
4 ChronicHigh 0.041 0.141 0.231 0.047
5 HighPulse 0.729 0.001 0.004 0.047  
 
Table CCXXVIII : p-values from SNK test, testing for differences in Lens NAH at T4 (day 100) between 
treatments. 
Lens NAH T4
Treatment {1} {2} {3} {4} {5}
8.7799 8.6625 9.2792 8.1762 9.7910
1 Control 0.876 0.507 0.699 0.373
2 ChronicLow 0.876 0.688 0.518 0.439
3 ChronicMedium 0.507 0.688 0.459 0.496
4 ChronicHigh 0.699 0.518 0.459 0.215
5 HighPulse 0.373 0.439 0.496 0.215  
 
Table CCXXIX : p-values from SNK test, testing for differences in Phser at T3 (day 62) between treatments. 
Phser T3
Treatment {1} {2} {3} {4} {5}
.01275 .01313 .01150 .01425 .01412
1 Control 0.871 0.590 0.914 0.822
2 ChronicLow 0.871 0.761 0.877 0.666
3 ChronicMedium 0.590 0.761 0.753 0.666
4 ChronicHigh 0.914 0.877 0.753 0.957
5 HighPulse 0.822 0.666 0.666 0.957  
 
Table CCXXX : p-values from SNK test, testing for differences in Phser at T4 (day 100) between treatments. 
Phser T4
Treatment {1} {2} {3} {4} {5}
.01300 .01300 .01350 .01288 .01300
1 Control 1.000 0.758 1.000 1.000
2 ChronicLow 1.000 0.948 0.997 1.000
3 ChronicMedium 0.758 0.948 0.995 0.990
4 ChronicHigh 1.000 0.997 0.995 0.939




Table CCXXXI : p-values from SNK test, testing for differences in Tau at T3 (day 62) between treatments. 
Tau T3
Treatment {1} {2} {3} {4} {5}
12.286 10.927 11.360 11.125 12.110
1 Control 0.857 0.779 0.832 0.899
2 ChronicLow 0.857 0.947 0.886 0.824
3 ChronicMedium 0.779 0.947 0.865 0.588
4 ChronicHigh 0.832 0.886 0.865 0.754
5 HighPulse 0.899 0.824 0.588 0.754  
 
Table CCXXXII : p-values from SNK test, testing for differences in Tau at T4 (day 100) between treatments. 
Tau T4
Treatment {1} {2} {3} {4} {5}
13.402 13.118 13.145 12.497 14.493
1 Control 0.956 0.798 0.800 0.281
2 ChronicLow 0.956 0.979 0.537 0.520
3 ChronicMedium 0.798 0.979 0.793 0.376
4 ChronicHigh 0.800 0.537 0.793 0.285
5 HighPulse 0.281 0.520 0.376 0.285  
 
Table CCXXXIII : p-values from SNK test, testing for differences in Pea at T3 (day 62) between treatments. 
 Pea T3
Treatment {1} {2} {3} {4} {5}
.08362 .08487 .07950 .07175 .07437
1 Control 0.862 0.567 0.357 0.406
2 ChronicLow 0.862 0.733 0.367 0.464
3 ChronicMedium 0.567 0.733 0.528 0.477
4 ChronicHigh 0.357 0.367 0.528 0.715
5 HighPulse 0.406 0.464 0.477 0.715  
 
Table CCXXXIV : p-values from SNK test, testing for differences in Pea at T4 (day 100) between treatments. 
Pea T4
Treatment {1} {2} {3} {4} {5}
.08150 .09450 .09187 .08025 .08288
1 Control 0.426 0.445 0.883 0.872
2 ChronicLow 0.426 0.758 0.455 0.364
3 ChronicMedium 0.445 0.758 0.522 0.294
4 ChronicHigh 0.883 0.455 0.522 0.948





Table CCXXXV : p-values from SNK test, testing for differences in Urea at T3 (day 62) between treatments. 
Urea T3
Treatment {1} {2} {3} {4} {5}
1 Control 0.736 0.682 0.607 0.385
2 ChronicLow 0.736 0.772 0.947 0.989
3 ChronicMedium 0.682 0.772 0.932 0.972
4 ChronicHigh 0.607 0.947 0.932 0.938
5 HighPulse 0.385 0.989 0.972 0.938  
 
Table CCXXXVI : p-values from SNK test, testing for differences in Urea at T4 (day 100) between treatments. 
Urea T4
Treatment {1} {2} {3} {4} {5}
6.3755 6.2877 6.2670 5.2515 6.8054
1 Control 0.851 0.970 0.089 0.358
2 ChronicLow 0.851 0.965 0.078 0.508
3 ChronicMedium 0.970 0.965 0.035 0.652
4 ChronicHigh 0.089 0.078 0.035 0.015
5 HighPulse 0.358 0.508 0.652 0.015  
 
Table CCXXXVII : p-values from SNK test, testing for differences in Asp at T3 (day 62) between treatments. 
Asp T3
Treatment {1} {2} {3} {4} {5}
.57650 .60438 .54288 .56675 .65538
1 Control 0.737 0.913 0.907 0.609
2 ChronicLow 0.737 0.878 0.892 0.540
3 ChronicMedium 0.913 0.878 0.774 0.654
4 ChronicHigh 0.907 0.892 0.774 0.707
5 HighPulse 0.609 0.540 0.654 0.707  
 
Table CCXXXVIII : p-values from SNK test, testing for differences in Asp at T4 (day 100) between 
treatments. 
Asp T4
Treatment {1} {2} {3} {4} {5}
.66112 .66738 .56900 .54113 .60187
1 Control 0.930 0.399 0.335 0.405
2 ChronicLow 0.930 0.508 0.391 0.624
3 ChronicMedium 0.399 0.508 0.694 0.643
4 ChronicHigh 0.335 0.391 0.694 0.666





Table CCXXXIX : p-values from SNK test, testing for differences in Hypro at T3 (day 62) between treatments. 
Hypro T3
Treatment {1} {2} {3} {4} {5}
.43913 .53538 .45750 .30725 .49200
1 Control 0.929 0.909 0.412 0.941
2 ChronicLow 0.929 0.876 0.609 0.786
3 ChronicMedium 0.909 0.876 0.615 0.829
4 ChronicHigh 0.412 0.609 0.615 0.653
5 HighPulse 0.941 0.786 0.829 0.653  
 
Table CCXL : p-values from SNK test, testing for differences in Hypro at T4 (day 100) between treatments. 
Hypro T4
Treatment {1} {2} {3} {4} {5}
.63038 .82450 .64125 .76962 .52088
1 Control 0.498 0.937 0.572 0.430
2 ChronicLow 0.498 0.384 0.691 0.198
3 ChronicMedium 0.937 0.384 0.355 0.657
4 ChronicHigh 0.572 0.691 0.355 0.283
5 HighPulse 0.430 0.198 0.657 0.283  
 
Table CCXLI : p-values from SNK test, testing for differences in Thr at T3 (day 62) between treatments. 
Thr T3
Treatment {1} {2} {3} {4} {5}
1.4575 1.3544 1.1915 1.0260 1.3050
1 Control 0.629 0.594 0.268 0.752
2 ChronicLow 0.629 0.723 0.417 0.817
3 ChronicMedium 0.594 0.723 0.439 0.595
4 ChronicHigh 0.268 0.417 0.439 0.393
5 HighPulse 0.752 0.817 0.595 0.393  
 
Table CCXLII : p-values from SNK test, testing for differences in Thr at T4 (day 100) between treatments. 
Thr T4
Treatment {1} {2} {3} {4} {5}
1.6176 1.7265 1.4974 1.9466 1.4826
1 Control 0.524 0.482 0.142 0.707
2 ChronicLow 0.524 0.376 0.202 0.483
3 ChronicMedium 0.482 0.376 0.055 0.931
4 ChronicHigh 0.142 0.202 0.055 0.068





Table CCXLIII : p-values from SNK test, testing for differences in Ser at T3 (day 62) between treatments. 
Ser T3
Treatment {1} {2} {3} {4} {5}
1.7137 1.9093 1.2540 1.5618 1.4973
1 Control 0.408 0.218 0.519 0.626
2 ChronicLow 0.408 0.058 0.308 0.306
3 ChronicMedium 0.218 0.058 0.394 0.304
4 ChronicHigh 0.519 0.308 0.394 0.784
5 HighPulse 0.626 0.306 0.304 0.784  
 
Table CCXLIV : p-values from SNK test, testing for differences in Ser at T4 (day 100) between treatments. 
Ser T4
Treatment {1} {2} {3} {4} {5}
.99838 1.1181 1.1956 1.0373 1.0428
1 Control 0.800 0.571 0.770 0.940
2 ChronicLow 0.800 0.560 0.814 0.571
3 ChronicMedium 0.571 0.560 0.630 0.484
4 ChronicHigh 0.770 0.814 0.630 0.967
5 HighPulse 0.940 0.571 0.484 0.967  
 
Table CCXLV : p-values from SNK test, testing for differences in Asn at T3 (day 62) between treatments. 
Asn T3
Treatment {1} {2} {3} {4} {5}
.67462 .33063 .93600 .70750 .49388
1 Control 0.308 0.501 0.888 0.439
2 ChronicLow 0.308 0.088 0.374 0.484
3 ChronicMedium 0.501 0.088 0.329 0.240
4 ChronicHigh 0.888 0.374 0.329 0.628
5 HighPulse 0.439 0.484 0.240 0.628  
 
Table CCXLVI : p-values from SNK test, testing for differences in Asn at T4 (day 100) between treatments. 
Asn T4
Treatment {1} {2} {3} {4} {5}
.71162 .45150 1.1916 1.8185 .52350
1 Control 0.674 0.125 0.003 0.542
2 ChronicLow 0.674 0.091 0.001 0.815
3 ChronicMedium 0.125 0.091 0.048 0.088
4 ChronicHigh 0.003 0.001 0.048 0.001





Table CCXLVII : p-values from SNK test, testing for differences in Glu at T3 (day 62) between treatments. 
Glu T3
Treatment {1} {2} {3} {4} {5}
.59625 .87313 .64337 .59275 .66538
1 Control 0.002 0.493 0.959 0.572
2 ChronicLow 0.002 0.005 0.002 0.004
3 ChronicMedium 0.493 0.005 0.739 0.749
4 ChronicHigh 0.959 0.002 0.739 0.712
5 HighPulse 0.572 0.004 0.749 0.712  
 
Table CCXLVIII : p-values from SNK test, testing for differences in Glu at T4 (day 100) between treatments. 
Glu T4
Treatment {1} {2} {3} {4} {5}
.65387 .75275 .62262 .48738 .61425
1 Control 0.147 0.643 0.078 0.824
2 ChronicLow 0.147 0.140 0.003 0.181
3 ChronicMedium 0.643 0.140 0.121 0.901
4 ChronicHigh 0.078 0.003 0.121 0.066
5 HighPulse 0.824 0.181 0.901 0.066  
 
Table CCXLIX : p-values from SNK test, testing for differences in Gln at T3 (day 62) between treatments. 
Gln T3
Treatment {1} {2} {3} {4} {5}
.85350 .79575 1.0489 1.0400 .71462
1 Control 0.534 0.099 0.050 0.298
2 ChronicLow 0.534 0.044 0.031 0.384
3 ChronicMedium 0.099 0.044 0.924 0.007
4 ChronicHigh 0.050 0.031 0.924 0.006
5 HighPulse 0.298 0.384 0.007 0.006  
 
Table CCL : p-values from SNK test, testing for differences in Gln at T4 (day 100) between treatments. 
Gln T4
Treatment {1} {2} {3} {4} {5}
1.0010 .93063 1.1178 .91113 .72650
1 Control 0.522 0.290 0.689 0.073
2 ChronicLow 0.522 0.212 0.859 0.160
3 ChronicMedium 0.290 0.212 0.246 0.008
4 ChronicHigh 0.689 0.859 0.246 0.099





Table CCLI : p-values from SNK test, testing for differences in Sarc at T3 (day 62) between treatments. 
Sarc T3
Treatment {1} {2} {3} {4} {5}
.04100 .02988 .02950 .02825 .03350
1 Control 0.244 0.343 0.348 0.277
2 ChronicLow 0.244 0.956 0.969 0.597
3 ChronicMedium 0.343 0.956 0.855 0.827
4 ChronicHigh 0.348 0.969 0.855 0.866
5 HighPulse 0.277 0.597 0.827 0.866  
 
Table CCLII : p-values from SNK test, testing for differences in Sarc at T4 (day 100) between treatments. 
Sarc T4
Treatment {1} {2} {3} {4} {5}
.02875 .03812 .03537 .03343 .04138
1 Control 0.531 0.605 0.502 0.372
2 ChronicLow 0.531 0.692 0.776 0.640
3 ChronicMedium 0.605 0.692 0.779 0.662
4 ChronicHigh 0.502 0.776 0.779 0.659
5 HighPulse 0.372 0.640 0.662 0.659  
 
Table CCLIII : p-values from SNK test, testing for differences in Pro at T3 (day 62) between treatments. 
Pro T3
Treatment {1} {2} {3} {4} {5}
1.3169 1.7616 1.5345 .93425 1.2845
1 Control 0.663 0.673 0.737 0.950
2 ChronicLow 0.663 0.660 0.496 0.787
3 ChronicMedium 0.673 0.660 0.647 0.877
4 ChronicHigh 0.737 0.496 0.647 0.498
5 HighPulse 0.950 0.787 0.877 0.498  
 
Table CCLIV : p-values from SNK test, testing for differences in Pro at T4 (day 100) between treatments. 
Pro T4
Treatment {1} {2} {3} {4} {5}
2.2963 1.7634 1.7135 2.4560 .96088
1 Control 0.230 0.386 0.717 0.021
2 ChronicLow 0.230 0.910 0.265 0.172
3 ChronicMedium 0.386 0.910 0.339 0.094
4 ChronicHigh 0.717 0.265 0.339 0.013





Table CCLV : p-values from SNK test, testing for differences in Gly at T3 (day 62) between treatments. 
Gly T3
Treatment {1} {2} {3} {4} {5}
7.1339 7.3550 6.6997 7.7095 7.4396
1 Control 0.549 0.242 0.404 0.682
2 ChronicLow 0.549 0.186 0.599 0.818
3 ChronicMedium 0.242 0.186 0.064 0.197
4 ChronicHigh 0.404 0.599 0.064 0.465
5 HighPulse 0.682 0.818 0.197 0.465  
 
Table CCLVI : p-values from SNK test, testing for differences in Gly at T4 (day 100) between treatments. 
Gly T4
Treatment {1} {2} {3} {4} {5}
5.9399 5.8955 6.0371 5.8244 5.9625
1 Control 0.909 0.965 0.951 0.953
2 ChronicLow 0.909 0.983 0.854 0.983
3 ChronicMedium 0.965 0.983 0.981 0.847
4 ChronicHigh 0.951 0.854 0.981 0.984
5 HighPulse 0.953 0.983 0.847 0.984  
 
Table CCLVII : p-values from SNK test, testing for differences in Ala at T3 (day 62) between treatments. 
Ala T3
Treatment {1} {2} {3} {4} {5}
4.0570 4.5297 4.8790 4.4415 3.6873
1 Control 0.333 0.078 0.250 0.269
2 ChronicLow 0.333 0.296 0.790 0.068
3 ChronicMedium 0.078 0.296 0.388 0.008
4 ChronicHigh 0.250 0.790 0.388 0.070
5 HighPulse 0.269 0.068 0.008 0.070  
 
Table CCLVIII : p-values from SNK test, testing for differences in Ala at T4 (day 100) between treatments. 
Ala T4
Treatment {1} {2} {3} {4} {5}
3.8754 3.8558 4.0374 3.6910 3.6452
1 Control 0.938 0.523 0.745 0.797
2 ChronicLow 0.938 0.752 0.516 0.682
3 ChronicMedium 0.523 0.752 0.521 0.532
4 ChronicHigh 0.745 0.516 0.521 0.857





Table CCLIX : p-values from SNK test, testing for differences in Citr at T3 (day 62) between treatments. 
Citr T3
Treatment {1} {2} {3} {4} {5}
.08325 .07888 .06175 .05287 .12000
1 Control 0.896 0.795 0.797 0.276
2 ChronicLow 0.896 0.610 0.716 0.439
3 ChronicMedium 0.795 0.610 0.791 0.313
4 ChronicHigh 0.797 0.716 0.791 0.278
5 HighPulse 0.276 0.439 0.313 0.278  
 
Table CCLX : p-values from SNK test, testing for differences in Citr at T4 (day 100) between treatments. 
Citr T4
Treatment {1} {2} {3} {4} {5}
.13925 .16412 .12750 .08975 .10838
1 Control 0.391 0.684 0.324 0.533
2 ChronicLow 0.391 0.416 0.093 0.227
3 ChronicMedium 0.684 0.416 0.394 0.509
4 ChronicHigh 0.324 0.093 0.394 0.520
5 HighPulse 0.533 0.227 0.509 0.520  
 
Table CCLXI : p-values from SNK test, testing for differences in Aaba at T3 (day 62) between treatments. 
Aaba T3
Treatment {1} {2} {3} {4} {5}
.06388 .05775 .05713 .05287 .05600
1 Control 0.533 0.769 0.790 0.850
2 ChronicLow 0.533 0.949 0.958 0.982
3 ChronicMedium 0.769 0.949 0.901 0.909
4 ChronicHigh 0.790 0.958 0.901 0.750
5 HighPulse 0.850 0.982 0.909 0.750  
 
Table CCLXII : p-values from SNK test, testing for differences in Aaba at T4 (day 100) between treatments. 
Aaba T4
Treatment {1} {2} {3} {4} {5}
.06813 .06687 .06875 .07938 .05238
1 Control 0.884 0.942 0.394 0.169
2 ChronicLow 0.884 0.974 0.468 0.098
3 ChronicMedium 0.942 0.974 0.221 0.238
4 ChronicHigh 0.394 0.468 0.221 0.025
5 HighPulse 0.169 0.098 0.238 0.025  
 
Table CCLXIII : p-values from SNK test, testing for differences in Val at T3 (day 62) between treatments. 
Val T3
Treatment {1} {2} {3} {4} {5}
.07212 .06900 .08875 .08900 .08213
1 Control 0.852 0.581 0.741 0.551
2 ChronicLow 0.852 0.638 0.749 0.712
3 ChronicMedium 0.581 0.638 0.988 0.693
4 ChronicHigh 0.741 0.749 0.988 0.910
5 HighPulse 0.551 0.712 0.693 0.910  
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Table CCLXIV : p-values from SNK test, testing for differences in Val at T4 (day 100) between treatments. 
Val T4
Treatment {1} {2} {3} {4} {5}
Treatment .05450 .05375 .04938 .04713 .05950
1 Control 0.931 0.821 0.823 0.562
2 ChronicLow 0.931 0.612 0.720 0.780
3 ChronicMedium 0.821 0.612 0.794 0.640
4 ChronicHigh 0.823 0.720 0.794 0.601
5 HighPulse 0.562 0.780 0.640 0.601  
 
Table CCLXV : p-values from SNK test, testing for differences in Met at T3 (day 62) between treatments. 
Met T3
Treatment {1} {2} {3} {4} {5}
.04312 .04137 .04625 .04963 .04950
1 Control 0.852 0.739 0.897 0.774
2 ChronicLow 0.852 0.861 0.900 0.819
3 ChronicMedium 0.739 0.861 0.930 0.729
4 ChronicHigh 0.897 0.900 0.930 0.989
5 HighPulse 0.774 0.819 0.729 0.989  
 
Table CCLXVI : p-values from SNK test, testing for differences in Met at T4 (day 100) between treatments. 
Met T4
Treatment {1} {2} {3} {4} {5}
.03700 .03338 .03025 .03000 .03913
1 Control 0.388 0.247 0.345 0.611
2 ChronicLow 0.388 0.456 0.697 0.358
3 ChronicMedium 0.247 0.456 0.952 0.160
4 ChronicHigh 0.345 0.697 0.952 0.203
5 HighPulse 0.611 0.358 0.160 0.203  
 
Table CCLXVII : p-values from SNK test, testing for differences in Cysth2 at T3 (day 62) between treatments. 
Cysth2 T3
Treatment {1} {2} {3} {4} {5}
.96338 .88187 .78200 .69263 .77200
1 Control 0.687 0.642 0.663 0.776
2 ChronicLow 0.687 0.622 0.782 0.849
3 ChronicMedium 0.642 0.622 0.897 0.961
4 ChronicHigh 0.663 0.782 0.897 0.695
5 HighPulse 0.776 0.849 0.961 0.695  
 
Table CCLXVIII : p-values from SNK test, testing for differences in Cysth2 at T4 (day 100) between 
treatments. 
Cysth2 T4
Treatment {1} {2} {3} {4} {5}
.77287 .79600 .83050 .93250 .59762
1 Control 0.800 0.802 0.309 0.062
2 ChronicLow 0.800 0.706 0.301 0.088
3 ChronicMedium 0.802 0.706 0.269 0.067
4 ChronicHigh 0.309 0.301 0.269 0.006
5 HighPulse 0.062 0.088 0.067 0.006  
 
 124 
Table CCLXIX : p-values from SNK test, testing for differences in Ile at T3 (day 62) between treatments. 
Ile T3
Treatment {1} {2} {3} {4} {5}
.03925 .04025 .05462 .05987 .05312
1 Control 0.924 0.456 0.290 0.382
2 ChronicLow 0.924 0.357 0.248 0.222
3 ChronicMedium 0.456 0.357 0.615 0.886
4 ChronicHigh 0.290 0.248 0.615 0.792
5 HighPulse 0.382 0.222 0.886 0.792  
 
Table CCLXX : p-values from SNK test, testing for differences in Ile at T4 (day 100) between treatments. 
Ile  T4
Treatment {1} {2} {3} {4} {5}
.02800 .02800 .02425 .02112 .03400
1 Control 1.000 0.800 0.649 0.314
2 ChronicLow 1.000 0.527 0.478 0.569
3 ChronicMedium 0.800 0.527 0.598 0.360
4 ChronicHigh 0.649 0.478 0.598 0.207
5 HighPulse 0.314 0.569 0.360 0.207  
 
Table CCLXXI : p-values from SNK test, testing for differences in Leu at T3 (day 62) between treatments. 
Leu T3
Treatment {1} {2} {3} {4} {5}
.07287 .08300 .10888 .11850 .09937
1 Control 0.614 0.286 0.171 0.387
2 ChronicLow 0.614 0.404 0.298 0.416
3 ChronicMedium 0.286 0.404 0.632 0.636
4 ChronicHigh 0.171 0.298 0.632 0.606
5 HighPulse 0.387 0.416 0.636 0.606  
 
Table CCLXXII : p-values from SNK test, testing for differences in Leu at T4 (day 100) between treatments. 
Leu T4
Treatment {1} {2} {3} {4} {5}
.06187 .06600 .05525 .04688 .07200
1 Control 0.728 0.577 0.418 0.668
2 ChronicLow 0.728 0.635 0.377 0.613
3 ChronicMedium 0.577 0.635 0.481 0.493
4 ChronicHigh 0.418 0.377 0.481 0.228
5 HighPulse 0.668 0.613 0.493 0.228  
 
Table CCLXXIII : p-values from SNK test, testing for differences in Tyr at T3 (day 62) between treatments. 
Tyr T3
Treatment {1} {2} {3} {4} {5}
.05875 .05475 .04213 .05488 .06987
1 Control 0.899 0.276 0.672 0.229
2 ChronicLow 0.899 0.173 0.989 0.357
3 ChronicMedium 0.276 0.173 0.350 0.033
4 ChronicHigh 0.672 0.989 0.350 0.238
5 HighPulse 0.229 0.357 0.033 0.238  
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Table CCLXXIV : p-values from SNK test, testing for differences in Tyr at T4 (day 100) between treatments. 
Tyr T4
Treatment {1} {2} {3} {4} {5}
.05425 .05300 .04913 .05388 .05175
1 Control 0.985 0.959 0.961 0.987
2 ChronicLow 0.985 0.864 0.908 0.869
3 ChronicMedium 0.959 0.864 0.921 0.729
4 ChronicHigh 0.961 0.908 0.921 0.957
5 HighPulse 0.987 0.869 0.729 0.957  
 
Table CCLXXV : p-values from SNK test, testing for differences in Phe at T3 (day 62) between treatments. 
Phe T3
Treatment {1} {2} {3} {4} {5}
.03563 .03487 .03062 .04038 .04200
1 Control 0.899 0.671 0.421 0.525
2 ChronicLow 0.899 0.471 0.618 0.618
3 ChronicMedium 0.671 0.471 0.354 0.312
4 ChronicHigh 0.421 0.618 0.354 0.782
5 HighPulse 0.525 0.618 0.312 0.782  
 
Table CCLXXVI : p-values from SNK test, testing for differences in Phe at T4 (day 100) between treatments. 
Phe T4
Treatment {1} {2} {3} {4} {5}
.03712 .03737 .03388 .03187 .03825
1 Control 0.954 0.450 0.441 0.962
2 ChronicLow 0.954 0.691 0.573 0.838
3 ChronicMedium 0.450 0.691 0.641 0.734
4 ChronicHigh 0.441 0.573 0.641 0.570
5 HighPulse 0.962 0.838 0.734 0.570  
 
Table CCLXXVII : p-values from SNK test, testing for differences in Aaiba at T3 (day 62) between treatments. 
Aaiba T3
Treatment {1} {2} {3} {4} {5}
.03112 .02663 .01487 .02950 .03325
1 Control 0.484 0.001 0.678 0.587
2 ChronicLow 0.484 0.005 0.463 0.334
3 ChronicMedium 0.001 0.005 0.002 <.0.001
4 ChronicHigh 0.678 0.463 0.002 0.602
5 HighPulse 0.587 0.334 <.0.001 0.602  
 
Table CCLXXVIII : p-values from SNK test, testing for differences in Aaiba at T4 (day 100) between 
treatments. 
Aaiba T4
Treatment {1} {2} {3} {4} {5}
.03975 .05038 .04537 .04425 .04225
1 Control 0.106 0.543 0.536 0.555
2 ChronicLow 0.106 0.241 0.321 0.231
3 ChronicMedium 0.543 0.241 0.790 0.738
4 ChronicHigh 0.536 0.321 0.790 0.636
5 HighPulse 0.555 0.231 0.738 0.636  
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Table CCLXXIX : p-values from SNK test, testing for differences in Ethanolamine at T3 (day 62) between 
treatments. 
Ethanolamine T3
Treatment {1} {2} {3} {4} {5}
.02257 .04133 .02900 .02975 .03213
1 Control 0.076 0.355 0.552 0.511
2 ChronicLow 0.076 0.294 0.227 0.190
3 ChronicMedium 0.355 0.294 0.913 0.891
4 ChronicHigh 0.552 0.227 0.913 0.731
5 HighPulse 0.511 0.190 0.891 0.731  
 
Table CCLXXX : p-values from SNK test, testing for differences in Amm at T3 (day 62) between treatments. 
Amm T3
Treatment {1} {2} {3} {4} {5}
3.7805 3.9579 3.9092 4.1627 3.7859
1 Control 0.586 0.629 0.068 0.970
2 ChronicLow 0.586 0.729 0.151 0.442
3 ChronicMedium 0.629 0.729 0.179 0.382
4 ChronicHigh 0.068 0.151 0.179 0.049
5 HighPulse 0.970 0.442 0.382 0.049  
 
Table CCLXXXI : p-values from SNK test, testing for differences in Amm at T4 (day 100) between treatments. 
Amm T4
Treatment {1} {2} {3} {4} {5}
3.4411 3.5698 3.3021 3.2441 3.5059
1 Control 0.558 0.269 0.263 0.604
2 ChronicLow 0.558 0.154 0.086 0.609
3 ChronicMedium 0.269 0.154 0.642 0.240
4 ChronicHigh 0.263 0.086 0.642 0.168
5 HighPulse 0.604 0.609 0.240 0.168  
 
Table CCLXXXII : p-values from SNK test, testing for differences in Hylys1 at T3 (day 62) between 
treatments. 
Hylys1 T3
Treatment {1} {2} {3} {4} {5}
.06743 .05883 .05567 .04820 .05250
1 Control 0.580 0.726 0.720 0.765
2 ChronicLow 0.580 0.838 0.899 0.911
3 ChronicMedium 0.726 0.838 0.878 0.838
4 ChronicHigh 0.720 0.899 0.878 0.781
5 HighPulse 0.765 0.911 0.838 0.781  
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Table CCLXXXIII : p-values from SNK test, testing for differences in Hylys1 at T4 (day 100) between 
treatments. 
Hylys1 T4
Treatment {1} {2} {3} {4} {5}
.12550 .12463 .12700 .13875 .09962
1 Control 0.969 0.947 0.826 0.487
2 ChronicLow 0.969 0.994 0.922 0.272
3 ChronicMedium 0.947 0.994 0.603 0.617
4 ChronicHigh 0.826 0.922 0.603 0.420
5 HighPulse 0.487 0.272 0.617 0.420  
 
Table CCLXXXIV : p-values from SNK test, testing for differences in Hylys1 at T3 (day 62) between 
treatments. 
Hylys2 T3
Treatment {1} {2} {3} {4} {5}
.04975 .03188 .04267 .04583 .04783
1 Control 0.502 0.919 0.934 0.864
2 ChronicLow 0.502 0.339 0.430 0.486
3 ChronicMedium 0.919 0.339 0.777 0.888
4 ChronicHigh 0.934 0.430 0.777 0.858
5 HighPulse 0.864 0.486 0.888 0.858  
 
Table CCLXXXV : p-values from SNK test, testing for differences in Hylys2 at T4 (day 100) between 
treatments. 
Hylys2 T4
Treatment {1} {2} {3} {4} {5}
.02712 .02925 .02775 .03290 .02675
1 Control 0.925 0.913 0.738 0.948
2 ChronicLow 0.925 0.792 0.522 0.971
3 ChronicMedium 0.913 0.792 0.637 0.983
4 ChronicHigh 0.738 0.522 0.637 0.811
5 HighPulse 0.948 0.971 0.983 0.811  
 
Table CCLXXXVI : p-values from SNK test, testing for differences in Orn at T3 (day 62) between treatments. 
Orn T3
Treatment {1} {2} {3} {4} {5}
.03025 .02375 .01575 .01462 .03113
1 Control 0.285 0.053 0.061 0.885
2 ChronicLow 0.285 0.190 0.292 0.442
3 ChronicMedium 0.053 0.190 0.852 0.067
4 ChronicHigh 0.061 0.292 0.852 0.065
5 HighPulse 0.885 0.442 0.067 0.065  
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Table CCLXXXVII : p-values from SNK test, testing for differences in Orn at T4 (day 100) between 
treatments. 
Orn T4
Treatment {1} {2} {3} {4} {5}
.03200 .03913 .02438 .02400 .02850
1 Control 0.072 0.131 0.179 0.369
2 ChronicLow 0.072 0.003 0.003 0.024
3 ChronicMedium 0.131 0.003 0.923 0.291
4 ChronicHigh 0.179 0.003 0.923 0.478
5 HighPulse 0.369 0.024 0.291 0.478  
 
Table CCLXXXVIII : p-values from SNK test, testing for differences in Lys at T3 (day 62) between 
treatments. 
Lys T3
Treatment {1} {2} {3} {4} {5}
.60325 .62825 .65037 .59713 .43888
1 Control 0.769 0.843 0.943 0.140
2 ChronicLow 0.769 0.795 0.928 0.131
3 ChronicMedium 0.843 0.795 0.921 0.112
4 ChronicHigh 0.943 0.928 0.921 0.069
5 HighPulse 0.140 0.131 0.112 0.069  
 
Table CCLXXXIX : p-values from SNK test, testing for differences in Lys at T4 (day 100) between treatments. 
Lys T4
Treatment {1} {2} {3} {4} {5}
.53587 .48738 .48563 .57087 .47913
1 Control 0.478 0.740 0.608 0.835
2 ChronicLow 0.478 0.980 0.441 0.992
3 ChronicMedium 0.740 0.980 0.593 0.924
4 ChronicHigh 0.608 0.441 0.593 0.658
5 HighPulse 0.835 0.992 0.924 0.658  
 
Table CCXC : p-values from SNK test, testing for differences in Muscle His at T3 (day 62) between treatments. 
Muscle His T3
Treatment {1} {2} {3} {4} {5}
1.4449 1.2395 1.0690 1.0715 1.3150
1 Control 0.784 0.740 0.624 0.676
2 ChronicLow 0.784 0.845 0.589 0.808
3 ChronicMedium 0.740 0.845 0.994 0.855
4 ChronicHigh 0.624 0.589 0.994 0.711
5 HighPulse 0.676 0.808 0.855 0.711  
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Table CCXCI : p-values from SNK test, testing for differences in Muscle His at T4 (day 100) between 
treatments. 
Muscle His T4
Treatment {1} {2} {3} {4} {5}
1.6645 1.7154 1.5041 1.7229 1.6206
1 Control 0.684 0.409 0.886 0.726
2 ChronicLow 0.684 0.337 0.952 0.727
3 ChronicMedium 0.409 0.337 0.410 0.354
4 ChronicHigh 0.886 0.952 0.410 0.843
5 HighPulse 0.726 0.727 0.354 0.843  
 
Table CCXCII : p-values from SNK test, testing for differences in Ans at T3 (day 62) between treatments. 
Ans T3
Treatment {1} {2} {3} {4} {5}
.81950 .71650 .74687 .67063 .72088
1 Control 0.293 0.214 0.093 0.213
2 ChronicLow 0.293 0.858 0.430 0.940
3 ChronicMedium 0.214 0.858 0.551 0.653
4 ChronicHigh 0.093 0.430 0.551 0.659
5 HighPulse 0.213 0.940 0.653 0.659  
 
Table CCXCIII : p-values from SNK test, testing for differences in Ans at T4 (day 100) between treatments. 
 Ans T4
Treatment {1} {2} {3} {4} {5}
.84000 .83613 .80688 .91712 .97050
1 Control 0.929 0.725 0.083 0.013
2 ChronicLow 0.929 0.503 0.161 0.018
3 ChronicMedium 0.725 0.503 0.069 0.005
4 ChronicHigh 0.083 0.161 0.069 0.225
5 HighPulse 0.013 0.018 0.005 0.225  
 
Table CCXCIV : p-values from SNK test, testing for differences in Arg at T3 (day 62) between treatments. 
Arg T3
Treatment {1} {2} {3} {4} {5}
.14913 .12338 .11425 .10688 .10937
1 Control 0.235 0.244 0.295 0.261
2 ChronicLow 0.235 0.671 0.865 0.789
3 ChronicMedium 0.244 0.671 0.936 0.820
4 ChronicHigh 0.295 0.865 0.936 0.907
5 HighPulse 0.261 0.789 0.820 0.907  
 
Table CCXCV : p-values from SNK test, testing for differences in Arg at T4 (day 100) between treatments. 
Arg T4
Treatment {1} {2} {3} {4} {5}
.14775 .13863 .13775 .17062 .12313
1 Control 0.742 0.930 0.412 0.808
2 ChronicLow 0.742 0.975 0.483 0.841
3 ChronicMedium 0.930 0.975 0.635 0.599
4 ChronicHigh 0.412 0.483 0.635 0.433
5 HighPulse 0.808 0.841 0.599 0.433  
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Table CCXCVI : p-values from SNK test, testing for differences in SUM free amino acids (FAA) at T3 (day 
62) between treatments. 
SUM FAA T3
Treatment {1} {2} {3} {4} {5}
47.340 46.326 45.450 45.195 45.512
1 Control 0.620 0.787 0.826 0.643
2 ChronicLow 0.620 0.902 0.944 0.690
3 ChronicMedium 0.787 0.902 0.901 0.976
4 ChronicHigh 0.826 0.944 0.901 0.987
5 HighPulse 0.643 0.690 0.976 0.987  
 
Table CCXCVII : p-values from SNK test, testing for differences in SUM free amino acids (FAA) at T4 (day 
100) between treatments. 
SUM FAA T4
Treatment {1} {2} {3} {4} {5}
46.415 45.852 45.933 45.552 45.490
1 Control 0.923 0.745 0.935 0.969
2 ChronicLow 0.923 0.957 0.840 0.967
3 ChronicMedium 0.745 0.957 0.964 0.990
4 ChronicHigh 0.935 0.840 0.964 0.967
5 HighPulse 0.969 0.967 0.990 0.967  
 
Table CCXCVIII : p-values from SNK test, testing for differences in Sampled Fish Weight at T3 (day 62) 
between treatments. 
Sampled Fish weight T3
Treatment {1} {2} {3} {4} {5}
90.375 86.625 82.650 80.750 103.20
1 Control 0.775 0.824 0.880 0.330
2 ChronicLow 0.775 0.761 0.894 0.418
3 ChronicMedium 0.824 0.761 0.885 0.401
4 ChronicHigh 0.880 0.894 0.885 0.430
5 HighPulse 0.330 0.418 0.401 0.430  
 
Table CCXCIX : p-values from SNK test, testing for differences in Sampled Fish Weight at T4 (day 100) 
between treatments. 
Sampled Fish weight T4
Treatment {1} {2} {3} {4} {5}
146.75 144.15 136.97 133.13 154.63
1 Control 0.917 0.917 0.945 0.751
2 ChronicLow 0.917 0.772 0.896 0.905
3 ChronicMedium 0.917 0.772 0.877 0.890
4 ChronicHigh 0.945 0.896 0.877 0.905
5 HighPulse 0.751 0.905 0.890 0.905  
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Table CCC : p-values from SNK test, testing for differences in Lens Weight at T3 (day 62) between treatments. 
Lens weight T3
Treatment {1} {2} {3} {4} {5}
.04501 .05349 .04737 .03845 .05004
1 Control 0.132 0.536 0.091 0.388
2 ChronicLow 0.132 0.251 0.003 0.367
3 ChronicMedium 0.536 0.251 0.060 0.485
4 ChronicHigh 0.091 0.003 0.060 0.021
5 HighPulse 0.388 0.367 0.485 0.021  
 
Table CCCI : p-values from SNK test, testing for differences in Lens Weight at T4 (day 100) between 
treatments. 
Lens weight T4
Treatment {1} {2} {3} {4} {5}
.06146 .06205 .06284 .06139 .06350
1 Control 0.884 0.937 0.985 0.956
2 ChronicLow 0.884 0.845 0.985 0.930
3 ChronicMedium 0.937 0.845 0.984 0.870
4 ChronicHigh 0.985 0.985 0.984 0.984
5 HighPulse 0.956 0.930 0.870 0.984  
 
9.5 Kolmorogov smirnof test for normality 
Table CCCII : Test result from Kolmogorov-Smirnov test for normality. The distributions of measured Weight 
were analyzed at T0 (day 0), T3 (day 62) and T4 (day 100). 
Treatment Weight T0 Weight T3 Wieght T4
N d P N d P N d P
Control 59 0.118 n.s 56 0.172 <0.10 52 0.209 <0.05
ChronicLow 60 0.195 <0.05 45 0.124 n.s 42 0.107 n.s
ChronicMedium 60 0.114 n.s 54 0.218 <0.05 48 0.257 <0.01
ChronicHigh 60 0.086 n.s 52 0.258 <0.01 40 0.283 <0.05
HighPulse 60 0.091 n.s 47 0.194 <0.10 41 0.128 n.s  
 
Table CCCIII : Test result from Kolmogorov-Smirnov test for normality. The distributions of measured SGR 
were analyzed at T0-T3 (day 0-62), T3-T4 (day 62-100) and T0-T4 (day 0-100). 
Treatment SGR1 SGR2 SGR Overall
N d P N d P N d P
Control 56 0.216 <0.05 52 0.215 <0.05 52 0.281 <0.01
ChronicLow 45 0.164 <0.20 42 0.133 n.s 42 0.174 <0.20
ChronicMedium 54 0.147 <0.20 48 0.140 n.s 48 0.144 n.s
ChronicHigh 52 0.340 <0.01 40 0.122 n.s 40 0.256 <0.05






Table CCCIV : Test result from Kolmogorov-Smirnov test for normality. The distributions of measured blood 
parameters were analyzed at T0 (day 0), T3 (day 62) and T4 (day 100). 
Variable T0 T3 T4
N d P N d P N d P
Blood Na+ 19 0.132 n.s 40 0.109 n.s 40 0.169 <0.20
Blood K+ 19 0.156 n.s 39 0.118 n.s 39 0.185 <0.15
Blood pHtp 19 0.103 n.s 39 0.131 n.s 40 0.091 n.s
Blood pCO2 tp 19 0.243 <0.20 39 0.142 n.s 40 0.173 <0.20
Blood HCO3
- 19 0.097 n.s 39 0.160 n.s 40 0.140 n.s
Sampled fish weight 20 0.162 n.s 40 0.091 n.s 40 0.113 n.s
Lens weight 20 0.266 <0.10 39 0.221 <0.05 40 0.177 <0.20
Lense His 20 0.222 n.s 39 0.118 n.s 40 0.114 n.s
NAH 20 0.124 n.s 39 0.070 n.s 40 0.100 n.s
Phser 20 0.109 n.s 40 0.263 <0.01 40 0.126 n.s
Tau 20 0.183 n.s 40 0.106 n.s 40 0.078 n.s
Pea 20 0.190 n.s 40 0.075 n.s 40 0.185 <0.15
Urea 20 0.166 n.s 40 0.098 n.s 40 0.069 n.s
Asp 20 0.138 n.s 40 0.120 n.s 40 0.111 n.s
Hypro 20 0.171 n.s 40 0.825 n.s 40 0.112 n.s
Thr 20 0.139 n.s 40 0.094 n.s 40 0.099 n.s
Ser 20 0.170 n.s 40 0.087 n.s 40 0.102 n.s
Asn 20 0.177 n.s 40 0.141 n.s 40 0.177 <0.20
Glu 20 0.234 <0.20 40 0.136 n.s 40 0.140 n.s
Gln 20 0.142 n.s 40 0.735 n.s 40 0.108 n.s
Sarc 5 0.240 n.s 40 0.142 n.s 39 0.120 n.s
Pro 20 0.331 <0.05 40 0.140 n.s 40 0.124 n.s
Gly 20 0.102 n.s 40 0.085 n.s 40 0.086 n.s
Ala 20 0.130 n.s 40 0.086 n.s 40 0.065 n.s
Citr 20 0.234 <.020 40 0.177 <0.20 40 0.116 n.s
Aaba 20 0.084 n.s 40 0.098 n.s 40 0.149 n.s
Val 20 0.168 n.s 40 0.177 <0.20 40 0.126 n.s
Met 20 0.238 <0.20 40 0.205 <0.10 40 0.120 n.s
Cysth2 20 0.151 n.s 40 0.082 n.s 40 0.086 n.s
Ile 20 0.133 n.s 40 0.171 <0.20 40 0.089 n.s
Leu 20 0.153 n.s 40 0.175 <0.20 40 0.090 n.s
Tyr 20 0.165 n.s 40 0.152 n.s 40 0.061 n.s
B-ala 5 0.183 n.s
Phe 20 0.134 n.s 40 0.206 <0.10 40 0.086 n.s
Aaiba 20 0.141 n.s 40 0.097 n.s 40 0.102 n.s
Ethanolamine 29 0.147 n.s 28 0.284 <0.05
Amm 20 0.216 n.s 40 0.157 n.s 40 0.113 n.s
Hylys1 10 0.256 n.s 30 0.115 n.s 40 0.108 n.s
Hylys2 20 0.128 n.s 34 0.096 n.s 40 0.011 n.s
Orn 20 0.191 n.s 40 0.108 n.s 40 0.144 n.s
Lys 20 0.198 n.s 40 0.060 n.s 40 0.104 n.s
Muscle His 20 0.175 n.s 40 0.074 n.s 40 0.110 n.s
Ans 20 0.158 n.s 40 0.114 n.s 40 0.094 n.s
Arg 20 0.245 <0.20 40 0.113 n.s 40 0.154 n.s








9.6 Levene’s test 
Table CCCV : Test results from Levene’s test performed on observations of all response variables, for each 
sampling date, or period. 
Levene's test for homogenity of variance
Variable MS Effect MS Error F p
Weight T0 116.352 61.900 1.880 0.114
Weight T3 261.016 263.198 0.992 0.413
Weight T4 913.722 642.660 1.422 0.228
SGR1 0.062 0.045 1.386 0.239
SGR2 0.257 0.080 3.224 0.013
SGR Overall 0.042 0.032 1.314 0.266
Blood Na+ T3 3.733 7.025 0.531 0.713
Blood Na+ T4 5.162 6.250 0.826 0.518
Blood K+ T3 0.054 0.064 0.841 0.509
Blood K+ T4 0.341 0.112 3.043 0.030
Blood pHtp T3 0.002 0.002 1.170 0.341
Blood pHtp T4 0.000 0.001 0.656 0.627
Blood pCO2 tp T3 0.257 0.129 1.991 0.118
Blood pCO2 tp T4 0.359 0.107 3.357 0.020
Blood HCO3
- T3 0.298 0.172 1.726 0.167
Blood HCO3
- T4 0.047 0.136 0.347 0.844
Sampled Fish Weight T3 377.809 228.080 1.656 0.182
Sampled Fish Weight T4 1302.547 618.772 2.105 0.101
Sampled Lens Weight T3 <0.001 <0.001 2.753 0.044
Sampled Lens Weight T4 <0.001 <0.001 3.299 0.021
Lens His T3 0.034 0.008 4.440 0.005
Lens His T4 0.038 0.008 4.741 0.004
NAH T3 0.358 0.325 1.100 0.372
NAH T4 1.458 0.738 1.974 0.121
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Table CCCVI: Test results from Levene’s test performed on observations of all response variables, for each 
sampling date, or period. 
Levene's test for homogenity of variance
Variable MS Effect MS Error F p
Phser T3 <0.001 <0.001 2.620 0.051
Phser T4 <0.001 <0.001 0.823 0.520
Tau T3 0.927 1.919 0.483 0.748
Tau T4 1.602 1.309 1.224 0.319
Pea T3 <0.001 <0.001 1.179 0.337
Pea T4 <0.001 <0.001 0.858 0.499
Urea T3 0.135 0.332 0.407 0.802
Urea T4 0.644 0.247 2.609 0.053
Asp T3 0.011 0.008 1.512 0.220
Asp T4 0.000 0.007 0.039 0.997
Hypro T3 0.041 0.024 1.749 0.161
Hypro T4 0.010 0.029 0.338 0.850
Thr T3 0.037 0.050 0.729 0.578
Thr T4 0.089 0.038 2.366 0.072
Ser T3 0.087 0.060 1.461 0.235
Ser T4 0.032 0.027 1.207 0.326
Asn T3 0.296 0.055 5.431 0.002
Asn T4 0.241 0.112 2.159 0.095
Glu T3 0.014 0.007 2.187 0.091
Glu T4 0.009 0.005 1.742 0.164
Gln T3 0.004 0.011 0.377 0.823
Gln T4 0.015 0.016 0.914 0.467
Sarc T3 <0.001 <0.001 0.877 0.487
Sarc T4 <0.001 <0.001 0.941 0.452
Pro T3 0.458 0.290 1.579 0.202
Pro T4 0.550 0.185 2.966 0.033
Gly T3 0.502 0.149 3.360 0.020
Gly T4 0.179 0.196 0.916 0.466
Ala T3 0.219 0.116 1.889 0.134
Ala T4 0.027 0.089 0.305 0.873
Citr T3 0.002 0.002 1.092 0.376
Citr T4 0.001 0.001 0.782 0.544
Aaba T3 <0.001 <0.001 1.234 0.314
Aaba T4 <0.001 <0.001 1.684 0.176
Val T3 <0.001 <0.001 0.118 0.975
Val T4 <0.001 <0.001 1.377 0.262
Met T3 <0.001 <0.001 1.131 0.358
Met T4 <0.001 <0.001 0.747 0.567
Cysth2 T3 0.081 0.052 1.556 0.208
Cysth2 T4 0.013 0.009 1.476 0.230
Ile T3 <0.001 <0.001 0.233 0.918
Ile T4 <0.001 <0.001 0.345 0.846
Leu T3 <0.001 0.001 0.201 0.936
Leu T4 <0.001 <0.001 0.261 0.901
Tyr T3 <0.001 <0.001 1.513 0.220
Tyr T4 <0.001 <0.001 0.582 0.678
Phe T3 <0.001 <0.001 0.796 0.536
Phe T4 <0.001 <0.001 1.497 0.224
Aaiba T3 <0.001 <0.001 1.738 0.164
Aaiba T4 <0.001 <0.001 0.287 0.884
Ethanolamine T3 <0.001 <0.001 1.500 0.255
Amm T3 0.035 0.017 2.127 0.131
Amm T4 0.086 0.026 3.353 0.020
Hylys1 T3 <0.001 <0.001 1.213 0.349
Hylys1 T4 0.001 0.001 1.833 0.145
Hylys2 T3 <0.001 <0.001 2.139 0.130
Hylys2 T4 <0.001 <0.001 0.743 0.569
Orn T3 <0.001 <0.001 1.107 0.392
Orn T4 <0.001 <0.001 3.269 0.022
Lys T3 0.004 0.004 1.071 0.407
Lys T4 0.003 0.007 0.385 0.818
His T3 0.014 0.090 0.158 0.958
His T4 0.048 0.021 2.276 0.081
Ans T3 0.008 0.003 2.771 0.042
Ans T4 0.001 0.003 0.336 0.852
Arg T3 0.001 0.001 2.660 0.049
Arg T4 0.001 0.002 0.978 0.432
SUM FAA T3 4.143 6.378 0.650 0.631
SUM FAA T4 0.425 2.241 0.190 0.942  
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Figur I: Lens weight mean regression for each treatment. Each datapoint from individually sampled fish n=8 per 
treatment. (a) day 62: Lens Weight=0.038+0.0001*x, p=0.0193, (b) Lens Weight=0.411+0.0001*x, p=0.0000.  
 

























Figur II: Measured mean values of UIA—N (mg l-1) in HighPulse group during the experimental days.  
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Table I: Results calculated growth coefficient V=S.D/Mean (Zar, 1984) for each treatment and sampling date. 
Calculated from all fish, tagged and untagged, between all treatment groups.  
Growth coefficient V=S.D/Mean
Treatment W 21/10 W 11/11 W 2/12 W 22/12 W 29/01
Control 0 0 0 0 0
ChronicLow 0.3236 0.3330 0.3315 0.3300 0.3662
ChronicMedium 0.33475 0.32701 0.36071 0.38175 0.39154
ChronicHigh 0.318959 0.340282 0.354139 0.353037 0.398113
HighPulse 0.329559438 0.324211443 0.321384285 0.333219813 0.349176696  
 
 
 
